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systems (such as found in the US), where economic evaluations are used less formally or 
at a limited scope [9].  
There are a number of international and country-specific guidelines defining how 
to conduct and report health economic studies and how to assess their components [10, 
11]. At the same time the requirements for full economic evaluations, that is, evaluations 
including outcomes besides costs, are very diverse and may ask to include information on 
baseline risk, treatment effect, resource utilization, health state preferences, associated 
costs and studies transferability from other countries [12]. The topic of improving 
economic data transferability between jurisdictions is frequently addressed in economic 
policy research [9, 11, 12].  
 
Transferability of economic evaluations  
This dissertation uses the definition of transferability given by the International 
Society For Pharmacoeconomics and Outcomes Research (ISPOR) Task Force Report on 
Transferability [13]. That is to say, economic evaluations are considered to be 
generalizable if their results can be applied without additional adaptation to other 
countries, and they are considered to be transferable if adaptation (adjustments based on 
local parameters) is necessary in order for evidence to be transferred [13]. Specific 
elements of economic evaluations can be considered to have a high or a low 
transferability [12]. To the highly transferable elements belong parameters of economic 
evaluations from other countries that can be used in local studies [12]. Elements such as 
treatment effect and utility parameters are often seen as generalizable, even though 
several recent studies have concluded that adjustment to the local population may be 
needed in view of possible differences in general health between the populations in the 
countries involved [12, 14,15]. Low transferable elements are data that are accepted as 
valid only when collected in the local jurisdiction (for example unit prices, clinical practice, 
baseline risk) [11,12]. Besides those indicated above, other factors may impact the 
acceptability of data from other countries, such as level of expert knowledge in economic 
evaluations and general development of economic study methods in the country, as well 
as date of issue of guidelines [12]. 
To simplify transferability of economic evaluations between different countries, 
various approaches have been developed over time [11,14]�� ���������� ����������
generalizability criteria (1996) [16]�� �������� ���������������� ����������� ������� [17]����������
transferability decision chart (2004) [18]����������������������������������������������������
(2005) [190]��������������������������������������������[20]�������������������������������������
(2009) [21], and Anto�������� ���������������� ������ ������� [22]. While these approaches 
differ substantially in terms of complexity – primarily in the number of criteria included in 
the assessment, structure, cut-off points, and primary aim of application [11,14] – a 
6 
 
Economic studies in health care decision making 
Healthcare technology is defined as prevention and rehabilitation, vaccines, 
pharmaceuticals and devices, medical and surgical procedures and the systems within 
which health is protected and maintained. The medical, social, ethical and economic 
implications of development, diffusion and use of health technology are studied by health 
technology assessment (HTA) to provide for a transparent decision on creating health care 
policy [1]. HTA is a multidisciplinary process, the last part of which – i.e. economic 
evaluations – allows state authorities to decide on rationality of resource allocation.  
Economic studies that unite research on costs (such as cost-of-illness analysis and 
budget impact studies) with comparative economic evaluations are widely used in 
healthcare decision making. The general purpose of an economic evaluation is to serve as 
input which will help decision makers choose from a wide range of treatment alternatives 
and use resources more efficiently. To provide a rationale for the decisions, thresholds are 
set defining the additional cost that governments are ready to pay for the additional 
therapeutic value.  
Comparative economic evaluation is generally seen as a type of analysis which 
involves the identification, measurement and valuation of interventions, and then 
compares costs and consequences of two or more alternative interventions [3-5]. There 
are many methods of comparative economic evaluations, of which cost-minimization 
analysis, cost-effectiveness analysis, and cost-utility analysis are most commonly used. 
Cost-minimization analysis assumes close to equal effectiveness of alternatives and so 
compares only the related costs. In cost-effectiveness analysis, clinical parameters serve 
as a measure of effectiveness, while cost-utility analysis accounts for quality of life after an 
intervention, usually expressed in quality adjusted life years (QALYs) [2-5]. Because many 
countries currently include in their decisions the additional costs spent per QALY, cost-
utility analysis has now become the most preferred method [3, 6]. Countries which have 
set thresholds defining the additional cost they are ready to pay for the additional 
therapeutic value use these in determining whether an intervention is cost-effective or 
not [3]; developing countries which have not yet done so may use the World Health 
Organization recommendations to consider a technology highly cost-effective, cost-
effective or not cost-effective by comparing incremental cost per QALY to gross domestic 
product per capita [7,8]. Using economic evaluations in the healthcare decision making 
process is important for a number of reasons, including resource scarcity, a continual rise 
in healthcare expenditures due to the introduction of innovative treatments and the aging 
of populations. At the same time, application of economic evaluations in the healthcare 
decision making process varies from country to country. For example, in countries with 
centralized healthcare systems -- as is the case in many Western European countries -- the 
results of economic evaluations carry more weight than in countries with decentralized 
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Healthcare background in Ukraine 
Despite current attempts to address population health needs, the crude adult 
death rates in Ukraine are higher than in the European Union [37]. Non-communicable 
diseases (cardio-vascular diseases and cancer) are responsible for nearly 70% of all deaths 
in Ukraine, followed by injuries and poisoning (14%), and communicable diseases (7%) 
[38,39]. The present donor funding is heavily focused on supporting human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV) prevention, care, treatment and 
support programs, followed by maternal health and family planning [40-42]. 
Besides the current focus of healthcare policy on improving health indicators, 
reforming the healthcare system has been a continuous process since Ukraine achieved 
independence in 1991. This process does not come without challenges; among the current 
challenges are: inefficiency of health care financing, inequitable access to resources, high 
prevalence of out-of-pocket payments, and a free generic-oriented drug market without 
mandatory prescription. At the same time, free access to healthcare for all people in 
Ukraine is formally ensured by the Constitution [43].  
The Ministry of Health is the central body that coordinates and controls a number 
of relevant health departments and policies in Ukraine [44]. In addition to general 
financing, the government addresses programs to urgent public health problems that are 
approved by resolution of the Cabinet of Ministers. The most urgent public health 
problems in Ukraine are: infectious diseases (vaccination of children), HIV/HCV, 
tuberculosis, cancer, diabetes and cardio-vascular diseases [45]. As a step toward a 
planned healthcare system, several reforms were proposed: giving greater autonomy to 
health facilities, switching from historical budgeting to budgets based on cost estimates, 
reimbursement implementation, and rationalization of hospital services to facilitate better 
resource allocation [46,47].  
Currently there is no central HTA agency in Ukraine. Nonetheless, some HTA-
related procedures are applied for the development of a State Drug formulary and the 
development of national treatment protocols. The State Formulary, maintained by the 
State expert center of the Ministry of Health, can be updated in two ways: 1) revision by 
experts of the Formulary committee; 2) by submissions from the drug manufacturers, who 
are required to provide an evidence dossier together with an official request [48]. The 
national treatment protocols are developed by the Department of Standardization for 
medical services of the State expert center of the Ministry of Health. Evidence for 
development of protocols is sought by the expert group of the department of 
Standardization and usually includes HTA guidance from other countries [49]. Both bodies 
may consider economic evidence, although officially or publicly available requirements for 
methodology and input parameters are lacking.  
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common element of most approaches is the use of critical and noncritical criteria for 
defining transferability of economic evaluations between jurisdictions.  
The need for simple transferability of results of health economic studies is 
potentially more important in countries that have limited scientific and financial resources 
for conducting economic evaluations, as in many countries of the Central and Eastern 
European (CEE) region and the former Soviet Union.  
 
Healthcare background for economic evaluations use in Central and Eastern 
European and Central Asian countries 
Except for the Russian Federation, Turkey, Ukraine, Romania and Kazakhstan, 
most countries of the CEE region and the former Soviet Union have relatively small 
populations of fewer than 10 million people [23]. Excluding the Baltic countries (Estonia, 
Latvia and Lithuania) and Georgia, eleven of these countries (Russian Federation, Ukraine, 
Belarus, Moldova, Kazakhstan, Kyrgyz Republic, Tajikistan, Turkmenistan, Uzbekistan, 
Armenia and Azerbaijan) are currently organized under the heading of the Commonwealth 
of Independent States. Except for Estonia, Latvia, Lithuania, Russian Federation and 
Slovenia, all of which have gross domestic products (GDPs) per capita above 12 475 US$, 
and low-income Tajikistan [24], countries in this region belong to the middle-income 
countries (Appendix 1.1). 
Despite the common historical background for many of the aforementioned 
countries, after gaining their independence, not only did their general political 
developments diverge, but also the reform of their inherited Semashko health care model 
went separate ways. While Bulgaria, Estonia, Latvia, Lithuania, Macedonia, Moldova, 
Romania, Serbia and Slovenia implemented a societal health insurance and 
reimbursement system [25-33], the other post-Soviet countries are applying different 
mixed models or are still in transition (Appendix 1.1). For example, a mixed financing 
scheme of general taxation and insurance contributions is applied in the Russian 
Federation [34], and in Kazakhstan a unified national healthcare system now substitutes 
for an unsuccessful earlier attempt at implementing societal health insurance [35]. As a 
result of these implemented changes, both expenditure on health per capita (highest in 
Estonia, Lithuania, Russian Federation, Slovenia) and expenditure on health as a 
percentage of GDP (highest in Georgia, Serbia, Slovenia) [23] vary and, as can be seen in 
Appendix 1.1, these variables are not directly related to each other. Except for a number 
of low-income countries (such as Armenia, Azerbaijan, Georgia, Moldova and Tajik 
Republic) state coverage for healthcare expenses in the region exceeds 50% [36].  
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The transferability of cost of illness methods regarding the analysis of treatment 
cost for chronic lymphocytic leukemia in Ukraine is addressed in chapter 4. Next, the net 
present values for future populations conceived via in-vitro fertilization technologies in 
Belarus, Kazakhstan and Ukraine are analyzed in chapter 5. Chapter 6 provides an analysis 
of transferability of comparative cost studies and their elements to Ukraine, pertaining to 
the use of pegylated interferons as treatment of chronic hepatitis C. Chapter 7 analyzes 
the transferability of treatment outcomes in a qualitative study on the preferences and 
perceptions of type 2 diabetes patients in Ukraine who suffer from hypoglycemia. Chapter 
8 reviews the transferability of comparative cost-effectiveness studies with regard to the 
use of rituximab for the treatment of chronic lymphocytic leukemia in both previously 
non-treated and relapsed/refractory patients in Ukraine.  
In chapter 9 the main findings and conclusions of both part 1 and part 2 are 
presented together with their implications for the healthcare policy decision making 
process, organizational changes, and future research.  
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Still, non-governmental organizations and patient associations are calling for 
setting up a central HTA agency. Looking at the present state of affairs, however, it will not 
be easy to achieve good functioning of such an organizational structure. Critical factors are 
ƚŚĞ ƵŶĂǀĂŝůĂďŝůŝƚǇ ŽĨ ƉĂƚŝĞŶƚƐ͛ ƌĞŐŝƐƚĞƌƐ ;ĞǆĐĞƉƚ ŝŶ Ɛelected clinical areas, such as HIV or 
cancer), standardization and tariffing of medical services, insufficient number of experts in 
the field of HTA and economic evaluations, and a very limited state share in total 
healthcare expenditures, particularly in treatment spending.  
The above issues highlight the difficulties in applying economic evaluations in the 
decision making processes in Ukraine and other CEE and former Soviet countries with a 
similar healthcare structure. It is argued, however, that opportunities to incorporate 
evidence from neighboring countries could significantly economize financial resources and 
optimize healthcare decision making in those countries.  
 
Aim, objectives and outline of the thesis 
The aim of this thesis, which is in two parts, is to explore transferability of health 
economic studies in CEE and former Soviet countries, using Ukraine as the primary 
example.  
To reach this aim, the following objectives were addressed: 
1. To assess the use of health economic studies and need for transferability in CEE 
and former Soviet countries (part 1); 
2. To assess the practical applicability of transferability principles, transferability of 
health economic studies in general, and input parameters more specifically (part 
2). 
In part 1, chapter 2 analyses the current use and acceptability of economic 
evaluations in the CEE and former Soviet countries, factors that may have an impact on 
transferability of foreign economic studies to these countries, and the weighted 
importance of each factor. Chapter 3 presents characteristics of published economic 
evaluations from CEE and former Soviet countries that may require only simple adaptation 
to be used in countries with similar socio-economic and geographic characteristics, and 
specific transferability issues addressed in these studies. 
In part 2, a number of case studies explore the transferability of input parameters 
and the impact of their variation on economic evaluations, and compare the results with 
those of studies carried out in other countries. As such, the impact of population 
differences is studied in chapters 5, 6 and 8, healthcare practice variations are investigated 
in chapters 4, 6, 7 and 8 and differences in unit costs are evaluated in chapters 4, 5, 6 and 
8.  
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Introduction 
Currently not only jurisdictions in Western European, Northern America, Australia 
and New Zealand, but regulatory establishments all around the world require submission 
of economic evidence of medical technologies for state purchase purposes or for price 
negotiations [1]. Because of the growing requirements of such submissions, the producer 
of a medical technology is expected to develop multiple country-specific dossiers in which 
the local context of economic studies is required. The methodology of economic 
evaluations is standardized by country guidelines or other relevant local normative 
documents [1-4], defining data requirements.  
 In the current article we used the definition of transferability by the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR) Task Force Report on 
Transferability [2] stating that economic studies can be considered as generalizable, if 
their results can be applied without additional adaptations to other jurisdictions. When 
adaptation to the local parameters is required, economic evaluations can be considered as 
transferable [2]. Elements of economic evaluations from other jurisdictions that can be 
used in local cost-effectiveness studies are considered highly transferable input 
parameters [1]. The analysis of twenty-seven guidelines [1] has shown that baseline risk, 
ƵŶŝƚ ĐŽƐƚƐ͕ ĂŶĚ ƌĞƐŽƵƌĐĞƐ͛ ƵƐĞǁĞƌĞ ĐŽŶƐŝĚĞƌĞĚ ƚŽ ŚĂǀĞ Ă ůŽǁ ŐĞŶĞƌĂůŝǌĂďŝůŝƚǇ ĂŶĚ ŶĞĞĚ
adaptation to be transferable. Meanwhile, the ISPOR Task Force Report [2] suggests a 
necessity for justifying the need for local data or methods because this increases the 
burden on those undertaking studies in multiple jurisdictions, and simple model 
adaptation (price substitution) should be carried out when it is possible.  
To systematically assess transferability of economic evaluations between 
different jurisdictions, a number of different approaches were developed over time [4,5]; 
ĨŝƌƐƚ ĂŵŽŶŐ ƚŚĞ ŽƚŚĞƌƐ ǁĞƌĞ ,ĞǇůĂŶĚ͛Ɛ ŐĞŶĞƌĂůŝǌĂďŝůŝƚǇ ĐƌŝƚĞƌŝĂ ;ϭϵϵϲͿ ΀ϲ΁͕ ^ƉćƚŚ͛Ɛ
transferability indicators (1999) [7], and WeltĞ͛Ɛ ƚƌĂŶƐĨĞƌĂďŝůŝƚǇĚĞĐŝƐŝŽŶĐŚĂƌƚ ;ϮϬϬϰͿ [8]. 
While the developed approaches differ substantially by complexity and structure, cut-off 
points, and primary aim of application (empirical or method-based economic evaluations) 
[4,5], the common element among a majority of the methods is using critical and 
noncritical criteria for defining transferability of economic evaluations between 
ũƵƌŝƐĚŝĐƚŝŽŶƐ͘ tĞůƚĞ͛Ɛ ĚĞĐŝƐŝŽŶ ŵŽĚĞů ĚĞĨŝŶĞƐ ƚŚƌĞĞ ŐĞŶĞƌĂů ŬŶŽĐŬ-out transferability 
criteria: the comparability of evaluated technologies and alternatives, acceptable quality 
of the study and, additionally, specific transferability criteria (see Appendix 2.1). This 
approach can be applied for both trial- and model-based economic evaluations and is one 
of the few that have been validated explicitly [9]. Furthermore, this instrument is easy 
usable in a qualitative manner without claiming to show a quantitative transferability 
results [10].  
  
22 
 
Abstract 
We aimed to assess use of economic evaluations, geographic preferences, and major 
transferability factors in Central and Eastern European (CEE) and former Soviet countries. 
Eleven experts on technology reimbursement from eight countries were interviewed on 
their expertise and practice of using economic evaluations, transferability of economic 
evidence and importance of transferability factors (Welte͛Ɛ criteria).  
In the countries studied, economic evidence is acceptable for decision making depending 
upon the perspective of the study, quality or methodology, costs source and assessment 
method, reliability of the study and population characteristics. Five experts from four 
countries confirmed direct use of foreign studies in local decision making. All except one 
respondent agreed that results of economic studies are not generalizable between CEE 
countries, but transferability is simpler than between different international regions. For 
transferring economic evidence, similar health care system and practices were named 
ďĞŝŶŐ ŵŽƐƚ ŝŵƉŽƌƚĂŶƚ͕ ĂůŽŶŐ ǁŝƚŚ ĐŽƐƚƐ ĂŶĚ ĐŽƵŶƚƌŝĞƐ͛ ĐŽŵƉĂƌĂƚŝǀĞ ĞĐŽŶŽŵŝĐ
development, perspective of the study, and disease epidemiology. Meanwhile, such 
factors as compliance, health status preferences, and case-mix are considered to be less 
important.  
Despite experts acknowledging the limited relevance of foreign studies in local decision 
making, transferability principles are rarely applied in practice.  
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development, perspective of the study, and disease epidemiology. Meanwhile, such 
factors as compliance, health status preferences, and case-mix are considered to be less 
important.  
Despite experts acknowledging the limited relevance of foreign studies in local decision 
making, transferability principles are rarely applied in practice.  
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experience in economic evaluations and transferability, their opinion on current practice 
of using economic evaluations in healthcare decision making and acceptance of economic 
studies, overall transferability of economic evaluations and their personal judgment on 
the ŝŵƉŽƌƚĂŶĐĞŽĨŝŶĚŝǀŝĚƵĂůtĞůƚĞ͛Ɛ criteria. Besides this, experts were proposed to read 
a one-page extract from publications (Appendix 2.3), give a preference to one of the 
country-blinded economic evaluations in which the application of rituximab in treatment 
of chronic lymphocytic leukemia (CLL) was assessed and to provide their reasoning for 
case selection. After completion of the assessment the information on the origin of the 
studies (the USA and Ukraine) was disclosed, and the respondents were asked to 
reconsider their opinion on the study preferences for the decision-making process in their 
country. 
All questions were addressed to the experts verbally. Description of the Welte͛Ɛ
criteria [8] and methodological brief of two economic evaluations of the use of rituximab 
in treatment of CLL were presented in written form. The respondents interviewed by 
Skype were provided with the written materials before the interview and instructed not to 
open until instructions to do so were given. All interviews were transcribed by the 
interviewer. The interviews conducted in the Russian or Ukrainian language were double-
back translated into English by two interpreters independently. The transcripts were 
analyzed by one researcher (OM) with an independent validity check of two interviews by 
SK, and one more by SK and JS (>20%). An inductive approach of the content analysis was 
used. This process included open coding, creating categories and their grouping under 
higher order headings and abstraction (or formulating a general description of the 
research topic) [11]. The headings of the categories corresponded to the objectives of the 
study identified above.  
In the assessment of acceptance of economic evaluations by the decision makers, 
ǁĞ ĚĞĐŝĚĞĚ ƚŽ ƐĞƉĂƌĂƚĞ ƚǁŽ ŐƌŽƵƉƐ ŽĨ ĨĂĐƚŽƌƐ͗ ͞ƋƵĂůŝƚǇ͟ ĂŶĚ ͞ƌĞůŝĂďŝůŝƚǇ͘͟ Ǉ ĚĞĨŝŶŝƚŝŽŶ
(Collins dictionary, http://www.collinsdictionary.com), quality is a ͞ĚĞŐƌĞĞŽƌƐƚĂŶĚĂƌĚŽĨ
ĞǆĐĞůůĞŶĐĞ͕͟ ĂŶĚ ƐŽ ƐƵƉƉŽƐĞƐ ĂĐĐeptance of economic evaluation basing on objective 
judgment (such as, for example, correspondence of the study methodology to the 
ĂĐĐĞƉƚĞĚůŽĐĂůƐƚĂŶĚĂƌĚƐͿ͘DĞĂŶǁŚŝůĞ͕ƌĞůŝĂďŝůŝƚǇŝƐ͞the ability (of a person or thing) to be 
trusted to work well or to behave in the way that you want them ƚŽ͟, which includes a 
subjective judgment. Thus, under reliability we united factors that may have a subjective 
impact on the quality or its perception: references to the data sources, conflict of interests 
for authors of the study and the decision makers, perceived quality of the study by the 
autŚŽƌƐ͛ǁŽrkplace or publication origin.  
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The need to have a simple adaptation of economic evaluations is potentially 
more important in the countries where the human resource and budget capacity for 
conducting economic studies is limited. Such countries may be low- and middle-income 
countries of Central and Eastern European (CEE) and former Soviet Union regions with no 
centralized HTA agency. In this case there is less interest by the producer of a medical 
ƚĞĐŚŶŽůŽŐǇƚŽŝŶǀĞƐƚŝŶƚŚĞƉƌŽĚƵĐƚ͛ƐĞĐŽŶŽŵŝĐĂŶĂůǇƐŝƐďĞĐĂƵƐĞŽĨƌĂŶĚŽŵŽƌƐŚŽƌƚ-term 
finance allocation. Nevertheless, it can be expected that similar to other countries [1], the 
decision makers in this region will prefer economic evaluations that are applicable to their 
own jurisdiction.  
The objectives of this qualitative descriptive study were to explore the opinion of 
experts in technology reimbursement from CEE and former Soviet countries with no 
existing single HTA agency or with a recently created agency on 1) use and acceptance of 
economic evaluations; 2) geographic preferences for transferring HTA / health economic 
evidence; and 3) factors that have an impact on transferability of economic studies.  
 
Methods  
In order to reach the listed objectives, interviews with reimbursement experts 
from CEE and former Soviet countries where a formal HTA review is not implemented, 
were conducted. Potential respondents were selected by convenience method. Enrolment 
of the reimbursement experts was through personal connections or during specialized 
congresses (ISPOR or Society of Medical Decision Making - SMDM). The interviews were 
conducted either in person (nine interviews) or by Skype (two interviews). All involved 
respondents fulfilled the following criteria: residence in a country of interest; formal or 
advisory role in the national decision making process on health technology 
reimbursement; and agreement to hold an interview on the research topic in either the 
English, Russian, or Ukrainian language. In total, fourteen experts corresponding to the 
inclusion criteria were asked to participate in the study, from whom eleven experts from 
the following countries agreed to participate: Ukraine (3), Romania (2), Armenia (1), 
Estonia (1), Kazakhstan (1), the former Yugoslav Republic of Macedonia (1), Russian 
&ĞĚĞƌĂƚŝŽŶ;ϭͿ͕ĂŶĚdƵƌŬĞǇ;ϭͿ͘tŝƚŚĞǆƉĞƌƚƐ͛ƉĞƌŵŝƐƐŝŽŶĂůůŝŶƚĞƌǀŝĞǁƐǁĞƌĞƌĞĐŽƌĚĞĚ͘^ŝǆ
from the interviewed respondents are employees of the Ministry of Health in the country 
of residence, while the remaining experts are members of advisory committees or execute 
governmental consulting services on pricing and/or reimbursement. The interviews were 
conducted on a personal basis on the conditions of identity confidentiality.  
For the purposes of the study an interview guide (Appendix 2.2) with a semi-rigid 
structure (questions could be excluded or included depending on the responses of the 
interviewee) was used. The minimum interview time needed was 15 minutes, and the 
maximum was 46 minutes. Questions covered the following topics: respondents 
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Criteria took into account when reviewing submitted economic evaluations, N of experts 
 
Quality/methodology applied 
 
 
4 
Reliability (data source, assumptions,  experts involvement) 
 
4 
Study perspective 
 
3 
Local costs 
 
3 
Population characteristics 
 
2 
Reasoning for selection a country-blinded economic evaluation a, N of experts 
 
Selected Case A (Case B) 
 
 
5 (5) 
Perspective (specified use of indirect costs) 
 
8 (5) 
Cost assessment method 
 
4 
Methodology  
 
2 
Would have a general preference to Ukraine 
 
8 
Acceptance of economic evaluations (summarized values), N of experts 
 
Perspective 
 
 
9 
Quality/methodology 
 
8 
Costs 
 
5 
Reliability (data source, assumptions,  experts involvement) 
 
5 
Population characteristics 
 
2 
a Experts were proposed to give a preference to one of the Cases (Appendix 2.3) in which the 
application of rituximab in treatment of chronic lymphocytic leukemia was assessed and to provide a reasoning 
for case selection. 
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Results 
Eleven experts in technology reimbursement in total (representing Ukraine, 
Romania, Armenia, Estonia, Kazakhstan, the former Yugoslav Republic of Macedonia, 
Russian Federation, and Turkey) were interviewed on their education, current use of 
economic evaluations in the decision making processes and transferability of economic 
studies. All reimbursement experts except one had at least some training in HTA and/or 
economic evaluations, and the majority of study programs in which experts took part were 
organized by international teams either abroad (short-course programs) or in the country 
of residence. It was also typical for one educational program to combine several 
methodology aspects: five out of eight HTA courses included economic evaluations, and 
four of them also presented material on transferability.  
Use and acceptance of economic evaluations  
The parameters focused on use and acceptance of economic evaluations in the 
study countries are summarized in Table 2.1. We distinguish four main issues regarding 
use and acceptance of economic evaluation: country of evidence and budget analysis, 
criteria taken into account when reviewing submitted economic evaluations, and barriers 
for economic evaluation use. 
Table 2.1 Use and acceptance of economic evaluations: frequencies report (in total 11 
respondents from 8 countries) 
Use of economic evaluation studies and health technology assessment (HTA) reports 
HTA (or HTA elements) use in state healthcare decision making  All countries except Armenia 
 
Account economic evidence from the other countries 
 
Ukraine, Turkey, Estonia, 
and Kazakhstan (5 experts) 
 
Use other countries reimbursement as example 
 
 Ukraine, Turkey 
Report underestimation of economic evidence importance by healthcare 
decision makers 
Ukraine and Romania  (3 
experts) 
Report difference in personal preferences and current acceptance criteria  
 
4 experts 
Report preference for local data studies in decision making 
 
3 experts for, 1 oppose 
Significantly rely on budget impact  
 
Romania, Estonia, Turkey 
Recognize limited  capacity for HTA review 2 experts 
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acceptance criteria were accounted in the assessment of important factors for accepting 
economic evaluations, the most frequently named were perspective, 
quality/methodology, costs assessment and study reliability. 
Barriers for economic evaluation use 
Despite the current level of economic studies use, some barriers in application of 
evidence in the decision making process may be observed. Experts from Ukraine and 
Romania noted that the decision makers either do not recognize or they underestimate 
the importance of economic evaluations in the health care resource allocation processes. 
Among the weaknesses in the currently applied HTA systems and use of economic 
evaluation the experts named the following: insufficient transparency of the 
governmental bodies, insufficient or low quality data for health economic studies and/or 
significant share of assumptions in the model inputs (especially if the societal perspective 
is required), insufficient resources to provide financing to all required innovative 
treatments even when economic evaluations show that the innovative treatment is cost-
effective, insufficient labor capacity to conduct HTA studies and possible conflict of 
interest for the experts involved in HTA assessment and/or appraisal processes: ������� 
������������ ���� �� ��� ������ ������������͖͟�������� �� ���� �������� – authors] 
are called to evaluate studies on medicines where they participated as clinical 
investigators. So, they participated in the study themselves and then they are called to 
�������� �������� ������������� �� ���� �����͖͟ ͞when you look on economic evaluations 
������ ��� ������ ���� �� ����������� � ������ �� ����� ��� ���� ������ �������� ���� 
with some level of uncertainty you know that it will be even more robust when you transfer 
the results from one country to the other͖͟ ͞Currently, it is not included [into state 
purchases – auth.] only because it is a very costly methodology for effective treatment of 
��������� ����� ��� �� ��������� �� ����� ��� ��� ���� ���� ���� ����������͘͟ 
The need for plans to establish more profound education for the experts involved 
in evidence evaluation was expressed by the respondents from Kazakhstan, Romania, and 
dƵƌŬĞǇ͗ ͞Now economic evaluations in our country are far from being perfect. This is a 
trend of Commonwealth of Independent States countries in general because when 
someone speaks about pharmacoeconomics, for some reasons these are doctors or 
��������������� ���� ����� �� ��� �������� ��� �� ���������� ��������� �� �� considered 
that anyone can do it. It is ���� �� � ������� �� ������� ��� ��� ����������� � � �������� 
that economists should do economic evaluations, ��� ��� ��������͖͟ ͞most of the 
pr�������� �������� ���� ��� ����� have a training necessary to do systematic review or 
���������� �������� �� �������� ���� ����� ���� � �������� �� �������� ����������͖͟���� ��� 
planning to educate, we are planning to use a Master degree course which will use 
�������� ���� ��� ������ ��� ���� ��� ��� �����������͘͟ 
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Experts from all the countries except Armenia declared use of economic 
evaluations in their decision making processes. The state bodies using HTA evidence may 
accept the economic evidence from other countries, as it was mentioned by the experts 
from Ukraine, Turkey, Estonia, and Kazakhstan. In Turkey not only evidence itself, but also 
the impact of the presented evidence on reimbursement decision in the country of the 
study origin may also have a potential impact on a governmental health supply or 
ƌĞŝŵďƵƌƐĞŵĞŶƚĚĞĐŝƐŝŽŶ͗͙͞ǁĞůŽŽŬŽŶƌĞƐƚƌŝĐƚŝŽŶƐ΀ĨŽƌƌĞŝŵďƵƌƐĞŵĞŶƚʹ author]. If we see 
the economic evaluation was done in another country, we look how it is used in that 
country, how they use the results of economic evaluation there, and are there any 
ƌĞƐƚƌŝĐƚŝŽŶƐŽŶƚŚĞĚƌƵŐƵƐĂŐĞ͙tĞůŽŽŬŽŶƌĞŝŵďƵƌƐĞŵĞŶƚŽĨƚŚĞŽƌŝŐŝŶĂůŵŽůĞĐƵůĞŽŶƚŚĞ
European market. After that we review for Turkey, because Turkey is a developing 
ĐŽƵŶƚƌǇ͙͟  
Experts from Romania, Turkey, and Estonia mentioned that in the decision 
making process a preference to studies on local population is given by the members of 
relevant HTA committees, while another expert from Kazakhstan indicated that local 
origin and authorship of the study may have a negative context because of the lower 
perceived reliability of studies conducted in countries of the former Soviet Union and 
perceived high methodological quality of studies from specific western countries: 
͙͞ĞĐĂƵƐĞŚĞƌĞĂůƐŽĂ ůŽƚĚĞƉĞŶĚs on from which place this came from. For example, if 
you came and said that this was made by NICE, this would be accepted perfectly, if by 
Singapore - then not.  The brand is important. Who did, which journal, - depends on this 
factor. In our country the foreign studies are loved. I mean they respect the level of studies 
ƚŚĂƚĞǆŝƐƚƐĂďƌŽĂĚ͘ ^ŽŵĞƚŝŵĞƐ ŝƚĐĂŶďĞƐƚĞƌĞŽƚǇƉĞǁŚĞŶǁĞĚŽŶ͛ƚĂĐĐĞƉƚŽƵƌƐĂŶĚůŽŽŬ
abroad, but this is a specificity of our mentality͖͟͞if I account the country, despite some 
similarities between our countries, I would select case B [study done in US -authors]. Even if 
ŝƚŝƐĨĂƌĂǁĂǇ͕ĞǀĞŶŝĨŝƚ͛ƐŵĞƌŝĐĂŶƐƚƵĚǇ͕/ĚŽŶ͛ƚƌĞůǇŽŶƋƵĂůŝƚǇŽĨƚŚĞƐƚƵĚŝĞƐĐŽŶĚƵĐƚĞĚŝŶ
hŬƌĂŝŶĞ͙ ďĞĐĂƵƐĞ ŝŶ ƚŚĞ ƉŽƐƚ-Soviet space we have big problems with the high quality 
ƐƚƵĚǇ ĚĞƐŝŐŶ͕ ƚŚĂƚ͛Ɛ Ă ǁĞůů-known problem. Maybe, this is not related to this particular 
ƐƚƵĚǇ͕ďƵƚ/ĚŽŶ͛ƚŬŶŽǁƚŚŝƐ͟.  
Besides impact of the other factors, in Romania and Estonia, budget-impact has a 
recognized impact in the reimbursement decision, while in Turkey such analysis is 
ĚĞĐŝƐŝǀĞ͗͞/ƚ͛ƐŵŽƐƚůǇĐŽƐƚƐ͘tĞůŽŽŬŽŶĐŽŵƉĂƌĂƚŽƌƐ͕ŚŽǁŵƵĐŚ͕ƚŚĞŶĞǁĚƌƵŐƉƌŝĐŝŶŐ͕ĂŶĚ
how many people are required to treat. So, mostly we review costs, budget impact. 
ǀĞƌǇƚŚŝŶŐĞůƐĞŝƐŵŽƐƚůǇŶŽƚŝŵƉŽƌƚĂŶƚ͘͙ Its importance is 80-90%...͟ 
During the interview experts named conditions for acceptance of economic 
studies in the decision making process: reliability of the study (data source, assumptions) 
and its quality, use of the appropriate perspective and local costs, and relevant population 
characteristics. While using a practical case, eight of the experts accepted the evidence 
based on the perspective of the study, and five of them also specified problems especially 
in assessing indirect costs in their country. When both case argumentation and named 
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acceptance criteria were accounted in the assessment of important factors for accepting 
economic evaluations, the most frequently named were perspective, 
quality/methodology, costs assessment and study reliability. 
Barriers for economic evaluation use 
Despite the current level of economic studies use, some barriers in application of 
evidence in the decision making process may be observed. Experts from Ukraine and 
Romania noted that the decision makers either do not recognize or they underestimate 
the importance of economic evaluations in the health care resource allocation processes. 
Among the weaknesses in the currently applied HTA systems and use of economic 
evaluation the experts named the following: insufficient transparency of the 
governmental bodies, insufficient or low quality data for health economic studies and/or 
significant share of assumptions in the model inputs (especially if the societal perspective 
is required), insufficient resources to provide financing to all required innovative 
treatments even when economic evaluations show that the innovative treatment is cost-
effective, insufficient labor capacity to conduct HTA studies and possible conflict of 
interest for the experts involved in HTA assessment and/or appraisal processes: ������� 
������������ ���� �� ��� ������ ������������͖͟�������� �� ���� �������� – authors] 
are called to evaluate studies on medicines where they participated as clinical 
investigators. So, they participated in the study themselves and then they are called to 
�������� �������� ������������� �� ���� �����͖͟ ͞when you look on economic evaluations 
������ ��� ������ ���� �� ����������� � ������ �� ����� ��� ���� ������ �������� ���� 
with some level of uncertainty you know that it will be even more robust when you transfer 
the results from one country to the other͖͟ ͞Currently, it is not included [into state 
purchases – auth.] only because it is a very costly methodology for effective treatment of 
��������� ����� ��� �� ��������� �� ����� ��� ��� ���� ���� ���� ����������͘͟ 
The need for plans to establish more profound education for the experts involved 
in evidence evaluation was expressed by the respondents from Kazakhstan, Romania, and 
dƵƌŬĞǇ͗ ͞Now economic evaluations in our country are far from being perfect. This is a 
trend of Commonwealth of Independent States countries in general because when 
someone speaks about pharmacoeconomics, for some reasons these are doctors or 
��������������� ���� ����� �� ��� �������� ��� �� ���������� ��������� �� �� considered 
that anyone can do it. It is ���� �� � ������� �� ������� ��� ��� ����������� � � �������� 
that economists should do economic evaluations, ��� ��� ��������͖͟ ͞most of the 
pr�������� �������� ���� ��� ����� have a training necessary to do systematic review or 
���������� �������� �� �������� ���� ����� ���� � �������� �� �������� ����������͖͟���� ��� 
planning to educate, we are planning to use a Master degree course which will use 
�������� ���� ��� ������ ��� ���� ��� ��� �����������͘͟ 
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Experts from all the countries except Armenia declared use of economic 
evaluations in their decision making processes. The state bodies using HTA evidence may 
accept the economic evidence from other countries, as it was mentioned by the experts 
from Ukraine, Turkey, Estonia, and Kazakhstan. In Turkey not only evidence itself, but also 
the impact of the presented evidence on reimbursement decision in the country of the 
study origin may also have a potential impact on a governmental health supply or 
ƌĞŝŵďƵƌƐĞŵĞŶƚĚĞĐŝƐŝŽŶ͗͙͞ǁĞůŽŽŬŽŶƌĞƐƚƌŝĐƚŝŽŶƐ΀ĨŽƌƌĞŝŵďƵƌƐĞŵĞŶƚʹ author]. If we see 
the economic evaluation was done in another country, we look how it is used in that 
country, how they use the results of economic evaluation there, and are there any 
ƌĞƐƚƌŝĐƚŝŽŶƐŽŶƚŚĞĚƌƵŐƵƐĂŐĞ͙tĞůŽŽŬŽŶƌĞŝŵďƵƌƐĞŵĞŶƚŽĨƚŚĞŽƌŝŐŝŶĂůŵŽůĞĐƵůĞŽŶƚŚĞ
European market. After that we review for Turkey, because Turkey is a developing 
ĐŽƵŶƚƌǇ͙͟  
Experts from Romania, Turkey, and Estonia mentioned that in the decision 
making process a preference to studies on local population is given by the members of 
relevant HTA committees, while another expert from Kazakhstan indicated that local 
origin and authorship of the study may have a negative context because of the lower 
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perceived high methodological quality of studies from specific western countries: 
͙͞ĞĐĂƵƐĞŚĞƌĞĂůƐŽĂ ůŽƚĚĞƉĞŶĚs on from which place this came from. For example, if 
you came and said that this was made by NICE, this would be accepted perfectly, if by 
Singapore - then not.  The brand is important. Who did, which journal, - depends on this 
factor. In our country the foreign studies are loved. I mean they respect the level of studies 
ƚŚĂƚĞǆŝƐƚƐĂďƌŽĂĚ͘ ^ŽŵĞƚŝŵĞƐ ŝƚĐĂŶďĞƐƚĞƌĞŽƚǇƉĞǁŚĞŶǁĞĚŽŶ͛ƚĂĐĐĞƉƚŽƵƌƐĂŶĚůŽŽŬ
abroad, but this is a specificity of our mentality͖͟͞if I account the country, despite some 
similarities between our countries, I would select case B [study done in US -authors]. Even if 
ŝƚŝƐĨĂƌĂǁĂǇ͕ĞǀĞŶŝĨŝƚ͛ƐŵĞƌŝĐĂŶƐƚƵĚǇ͕/ĚŽŶ͛ƚƌĞůǇŽŶƋƵĂůŝƚǇŽĨƚŚĞƐƚƵĚŝĞƐĐŽŶĚƵĐƚĞĚŝŶ
hŬƌĂŝŶĞ͙ ďĞĐĂƵƐĞ ŝŶ ƚŚĞ ƉŽƐƚ-Soviet space we have big problems with the high quality 
ƐƚƵĚǇ ĚĞƐŝŐŶ͕ ƚŚĂƚ͛Ɛ Ă ǁĞůů-known problem. Maybe, this is not related to this particular 
ƐƚƵĚǇ͕ďƵƚ/ĚŽŶ͛ƚŬŶŽǁƚŚŝƐ͟.  
Besides impact of the other factors, in Romania and Estonia, budget-impact has a 
recognized impact in the reimbursement decision, while in Turkey such analysis is 
ĚĞĐŝƐŝǀĞ͗͞/ƚ͛ƐŵŽƐƚůǇĐŽƐƚƐ͘tĞůŽŽŬŽŶĐŽŵƉĂƌĂƚŽƌƐ͕ŚŽǁŵƵĐŚ͕ƚŚĞŶĞǁĚƌƵŐƉƌŝĐŝŶŐ͕ĂŶĚ
how many people are required to treat. So, mostly we review costs, budget impact. 
ǀĞƌǇƚŚŝŶŐĞůƐĞŝƐŵŽƐƚůǇŶŽƚŝŵƉŽƌƚĂŶƚ͘͙ Its importance is 80-90%...͟ 
During the interview experts named conditions for acceptance of economic 
studies in the decision making process: reliability of the study (data source, assumptions) 
and its quality, use of the appropriate perspective and local costs, and relevant population 
characteristics. While using a practical case, eight of the experts accepted the evidence 
based on the perspective of the study, and five of them also specified problems especially 
in assessing indirect costs in their country. When both case argumentation and named 
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Geographical preferences for transferability  
Almost all experts consider the results of economic evaluations are not 
generalizable, neither between different regions nor within one geographic region, and 
they agree that transferability within one region is easier (Table 2.2).  
Seven respondents consider that transferability within one geographic region 
(including CEE and former Soviet countries) should be easy to conduct even though local 
cost calculations are required and some other adaptations may be needed. 
When the country origins of the presented case-studies were disclosed to the 
experts, the majority confirmed that knowing the country of origin of the study has an 
impact on their decision. They would give a general preference to use the case from 
Ukraine rather than the USA as it requires less adaptation, while several respondents 
indicated that closeness of methodological and input parameters to local requirements is 
ŵŽƌĞ ŝŵƉŽƌƚĂŶƚ ƚŚĂŶ ƚŚĞ ƐƚƵĚǇ ĐŽƵŶƚƌǇ ŝƚƐĞůĨ͗ ͞I would give more attention to the case 
made in this area, but not on 100%. The level of patient involvement, practice variation 
ŵĂǇďĞĚŝĨĨĞƌĞŶƚ͕ďƵƚŵĂǇďĞĐůŽƐĞƌŝŶhŬƌĂŝŶĞĂŶĚZŽŵĂŶŝĂƚŚĂŶtĞƐƚĞƌŶĐŽƵŶƚƌǇ͖͟͙͞tĞ
ĐĂŶ͛ƚ ƵƐĞ ĐĂƐĞƐ ǁŝƚŚŽƵƚ ĂĚĂƉƚĂƚŝŽŶ͕ ŽƵƌ ŵĞƚŚŽĚƐ ĂƌĞ ƐŽ ĚŝĨĨĞƌĞŶƚ͙ ĞĐĂƵƐĞ ƚŚĞ h^ ŝƐ
completely different, private insurance, and we are covered by the government, I would 
definitely prefer to have case from hŬƌĂŝŶĞ͕ ďƵƚ ǁŝƚŚ ĂĚĂƉƚĂƚŝŽŶ͙͟  Some other 
respondents also stated that as any case requires use of the local context and 
generalizability is not possible, the country of the study has no impact on their choice of 
the model for transferability:  ͞&Žƌ ĞĐŽŶŽŵŝĐ ĞǀĂůƵĂƚŝŽŶ ǁĞ ŵĂǇ ƵƐĞ Ă ĨƌĂŵĞǁŽƌŬ͕
ƚĞŵƉůĂƚĞ͕ďƵƚŶŽƚƚŚĞƐƚƵĚǇ͙ĞĂĐŚĐŽƵŶƚƌǇŚĂƐƐƉĞĐŝĨŝĐĞůĞŵĞŶƚƐ͕ĞƐƉĞĐŝĂůůǇĨƌŽŵƚŚĞƐŝĚĞŽĨ
ŚĞĂůƚŚĐĂƌĞĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͘^Ž͕ǁĞĐĂŶ͛ƚ ũƵƐƚĂĐĐĞƉƚƚŚĞ/Z͙͟ 
Factors that have an impact on transferability of economic studies  
ĞĨŽƌĞtĞůƚĞ͛Ɛ criteria were presented and described to the respondents, the 
most frequently named transferability factors were healthcare system characteristics  and 
comparators (including actual clinical practice, patients pathways and guidelines), as well 
as correspondence of costs, financial characteristics of the country or healthcare (such as 
gross domestic product - GDP or spending of healthcare as a percentage of GDP), 
perspective, incidence/prevalence, and attitude among society or medical circles.  
DŽƐƚŽĨƚŚĞĞǆƉĞƌƚƐǁĞƌĞŶŽƚĨĂŵŝůŝĂƌǁŝƚŚtĞůƚĞ͛ƐƚƌĂŶƐĨĞƌĂďŝůŝƚǇĐƌŝƚĞƌŝĂďĞĨŽƌĞ
the inteƌǀŝĞǁ͘&ƌŽŵƚŚĞƉƌĞƐĞŶƚĞĚtĞůƚĞ͛Ɛcriteria, the most important named were the 
following: cost approach, absolute and relative prices and practice variation, technology 
availability and incidence and prevalence, while the least important were compliance, 
health status preferences, and case-mix (Table 2.2).  
The majorŝƚǇŽĨĞǆƉĞƌƚƐŶŽƚĞĚƚŚĂƚtĞůƚĞ͛Ɛcriteria fully describe all transferability 
issues; two experts also considered it important to have reliability of economic evaluations 
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Table 2.2 Transferability and generalizability of economic evaluations 
Consideration regarding transferability and generalizability of economic evaluations, N of experts 
 
Results are not generalizable within one region 
 
10 (1 -partly) 
Results are easily transferable 7 
Transferability is more difficult between the regions 
 
10 
Factors that should be first addressed when transferring economic evaluations a, N of experts 
 
Healthcare system characteristics 
 
8 
Comparators (guidelines, practice) 7 
Costs 5 
Financial system characteristics 4 
Perspective 3 
Attitude (societal, physicians) 2 
Incidence/prevalence 
 
2 
dŚĞŵŽƐƚŝŵƉŽƌƚĂŶƚtĞůƚĞ͛Ɛcriteria, N of experts 
 
Cost approach 
 
7 
Absolute and  relative prices 5 
Practice variation 5 
Technology availability 4 
Incidence and prevalence 
 
4 
dŚĞůĞĂƐƚŝŵƉŽƌƚĂŶƚtĞůƚĞ͛Ɛcriteria b, N of experts 
 
Compliance 
 
5 
Health status preferences 3 
Case-mix 
 
3 
a Named by experts beforĞďĞŝŶŐĨĂŵŝůŝĂƌŝǌĞĚǁŝƚŚtĞůƚĞ͛Ɛcriteria (Appendix 2.1) 
b Five experts did not rank the least important transferability criteria. 
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Almost all experts consider the results of economic evaluations are not 
generalizable, neither between different regions nor within one geographic region, and 
they agree that transferability within one region is easier (Table 2.2).  
Seven respondents consider that transferability within one geographic region 
(including CEE and former Soviet countries) should be easy to conduct even though local 
cost calculations are required and some other adaptations may be needed. 
When the country origins of the presented case-studies were disclosed to the 
experts, the majority confirmed that knowing the country of origin of the study has an 
impact on their decision. They would give a general preference to use the case from 
Ukraine rather than the USA as it requires less adaptation, while several respondents 
indicated that closeness of methodological and input parameters to local requirements is 
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definitely prefer to have case from hŬƌĂŝŶĞ͕ ďƵƚ ǁŝƚŚ ĂĚĂƉƚĂƚŝŽŶ͙͟  Some other 
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Results are not generalizable within one region 
 
10 (1 -partly) 
Results are easily transferable 7 
Transferability is more difficult between the regions 
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perspective, population characteristics, costs assessment), study quality and a subjective 
ƉĞƌĐĞƉƚŝŽŶ ŽĨ ƚŚĞ ƐƚƵĚǇ͛Ɛ ƌĞůŝĂďŝůŝƚǇ͘ ĂƌƌŝĞƌƐ ƚŽ ƚŚĞ ƵƐĞ ŽĨ ĞĐŽŶŽŵŝĐ ĞǀĂůƵĂƚŝŽŶƐ ŝŶ ƚŚĞ
USA, Canada and the UK identified by Erntoft [3] were similar to factors identified in our 
analysis.  
Geographic preferences for transferring HTA evidence 
In contradiction to current practice, there is a unified agreement between the 
respondents that economic evaluations cannot be generalized between countries. 
Independently of similarities between jurisdictions, differences in healthcare structures 
and costs differences will have an impact on the results of economic studies and so make 
it impossible to apply the evidence without adaptation. This conclusion corresponds to 
ISPOR Task Force Report [2] and a systematic review on generalizability of economic 
evaluations by Goeree et al. [14], indicating simple adaptation as a minimum need for 
transferring economic evaluations between countries. Meanwhile, our results suggest that 
transferability of studies should be simpler within one region, as the similar political and 
structural background of the countries may result in more similarities in methodology and 
input parameters of the models, and so will require less adaptation.   
Factors that have an impact on transferability of economic studies 
For transferring economic evidence, the healthcare system model and similarity 
of clinical practice (correct comparators) were named as the most important, together 
ǁŝƚŚ ĐŽƐƚƐ ĂŶĚ ƚŚĞ ĐŽƵŶƚƌŝĞƐ͛ ĐŽŵƉĂƌĂƚŝǀĞ ĞĐŽŶŽŵŝĐ ĚĞǀĞůopment, perspective of the 
study and disease incidence/prevalence. Each of the indicated factors can be placed under 
the five broad characteristics defined by Goeree et al. [14] as important for geographical 
transferability, namely: patients, disease, provider, health care system, methodology. 
  The Welte͛Ɛ criteria [8] can be considered as an appropriate and complete 
instrument for transferability assessment, though such parameters as compliance, health 
status preferences and case-mix are considered to be less important for transferability of 
economic evaluations in CEE and former Soviet countries. While compliance is considered 
both less influential and difficult to assess, the reasons for leaving aside health status 
preferences are connected with the information gap on quality of life data in CEE and 
former Soviet countries and lack of its understanding and acceptance in some 
jurisdictions. Similar to Sculpher et al. [15] and Barbieri et al. [1], we observed greater 
attention paid by the technology reimbursement experts to ensure use of country-specific 
cost inputs in submitted economic evaluations, rather than clinical parameters or patient 
preference characteristics. Thus we conclude that outcome parameters are considered to 
be more generalizable between jurisdictions. 
Despite each respondent naming at least one factor important for the 
transferability of economic evidence, it can be observed from the current study that 
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and availability of priority assessment from the governmental perspective to be analyzed 
before transferring the economic studies across countries. 
 
Discussion 
Independently of the geographic location of the jurisdiction, we observed a 
consistency in the replies of the experts from the studied CEE and former Soviet countries 
regarding use and transferability of economic evaluations in healthcare decision making. 
The difference between known and applied transferability observed in this study and 
outlined below may be an issue of future policy application and development. 
Use and acceptance of economic evaluations 
While some countries, such as Kazakhstan, Turkey, Estonia and Romania have 
newly established HTA agencies, in the Russian Federation, the former Yugoslav Republic 
of Macedonia and Ukraine economic evaluations and/or HTA dossiers are taken into 
account to support the inclusion of medical products into the formularies, state purchase 
list, or therapeutic guidelines.  
Having significantly less experience than Poland or Hungary, which implemented 
HTA almost a decade ago, the other CEE countries may require similar critical factors for 
HTA development, such as a mandatory role of HTA within an independent agency, 
explicit cost-effectiveness thresholds, and budget-impact importance [12], as the latter is 
a requirement for decisions in a number of CEE jurisdictions according to our study. While 
in many study countries economic evaluations are used more informally than on an 
obligatory or regular basis, this practice is not different from countries in Western Europe 
[3]. At the same time, Western European countries generally possess larger financial and 
labor resources [13] and may have less barriers for appropriate HTA system functioning. 
Identically to Poland and Hungary [12], some other CEE and former Soviet countries, while 
being on different stages of standardizing HTA approach, face human resource constraint, 
and may potentially face budget constraints as well if obligatory HTA is planned to be 
implemented. Lack of education was indicated as one of the major barriers for the use of 
economic evaluations in the study of Erntoft [3], something also observed within our 
study. In our study as well as in others, missing and insufficient data are considered to be 
a significant obstacle for using the preferred methodology of economic evaluations. At the 
same time, similar to other studies, we noticed a limited acceptability of sponsored 
studies [3]. 
Despite evidence from other countries being frequently taken into account in 
healthcare decision making of CEE and former Soviet countries, state committees 
generally prefer studies conducted in their local setting. The major factors that experts 
pay attention to in their decision to accept the evidence were methodology (study 
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perspective, population characteristics, costs assessment), study quality and a subjective 
ƉĞƌĐĞƉƚŝŽŶ ŽĨ ƚŚĞ ƐƚƵĚǇ͛Ɛ ƌĞůŝĂďŝůŝƚǇ͘ ĂƌƌŝĞƌƐ ƚŽ ƚŚĞ ƵƐĞ ŽĨ ĞĐŽŶŽŵŝĐ ĞǀĂůƵĂƚŝŽŶƐ ŝŶ ƚŚĞ
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jurisdictions. Similar to Sculpher et al. [15] and Barbieri et al. [1], we observed greater 
attention paid by the technology reimbursement experts to ensure use of country-specific 
cost inputs in submitted economic evaluations, rather than clinical parameters or patient 
preference characteristics. Thus we conclude that outcome parameters are considered to 
be more generalizable between jurisdictions. 
Despite each respondent naming at least one factor important for the 
transferability of economic evidence, it can be observed from the current study that 
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Conclusions 
Despite reimbursement experts acknowledging the limited relevance of 
international studies in local jurisdiction, transferability principles are rarely applied in 
practice. We suggest that an explicit transferability assessment may help to improve the 
use of economic evaluations within CEE and former Soviet countries which have a purpose 
of single HTA agency implementation. 
  
  
34 
 
transferability principles are rarely used in the decision making process of the countries 
studied. Knowing the limitations of generalizability, experts may be skeptical about using 
foreign studies in a local decision making process while nonetheless applying this 
evidence.  
As indicated by Drummond et al. [2], the approach for dealing with aspects of 
transferability is based on data availability and the attributes of various analytic methods. 
Limited data availability was an important factor for study perspective preferences (i.e., 
limited use of societal perspective) and so for study transferability, as it was observed in 
the current study.  
When the model from the reference country is of appropriate quality and 
includes relevant study technology and comparators, and at the same time both 
jurisdictions have similar health care structures and disease incidence/prevalence, simple 
adaptation (or costs substitution) should be possible for countries of CEE and former 
Soviet Union region. The focus towards simple transferability is especially urged by the 
data insufficiency and lack of HTA education for technology reimbursement experts and 
decision makers, as indicated by study respondents.   
Policy implication  
Governmental bodies of countries wishing to enhance the use of HTA in health 
care decision making should, at a minimum, address the following barriers: non-
transparency of the decision making process and lack of value of economic evaluations 
among the decision makers, limited capacity of HTA bodies and insufficient education of 
experts, insufficient or low quality input data and significant share of assumptions in 
����������������� ����������� ����������� ��������� ����������� – that is primarily based on 
education – potentially may have significant impact on both acceptability and 
transferability judgments.  
Although guidelines in many countries recommend using the societal perspective 
[16], this approach should be reconsidered in countries of CEE and former Soviet Union 
region which are in the process of implementing or have recently implemented single HTA 
agencies, because of data constraint issues.  
The centralized or governmental HTA bodies of CEE and former Soviet countries 
should focus on a standardized approach for simple transferability of economic 
evaluations in order to avoid budget and labor constraints and provide rational decisions. 
Limitations 
A limitation of this study is its qualitative design. The sample of respondents 
included only a limited number of experts. Because experts were enrolled in the study by 
convenience, their background and expressed personal opinion may differ from other 
experts or decision makers of the countries studied. Moreover, observations obtained 
from the study countries may differ from other jurisdictions of the region. 
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Appendix 2.1 Specific knock-out Welte’s criteria presented to the respondents 
Methodological 
characteristics 
Healthcare characteristics Population characteristics 
Perspective 
 
Absolute and Relative prices Disease incidence/prevalence 
Discount rate 
 
 
Practice variation Case-mix (age, sex, race, etcetera) 
Medical cost approach (tariffs, 
prices) 
 
Technology availability Life expectancy 
Productivity cost approach (US 
panel approach, human capital 
approach, friction cost method) 
 Health-status preferences 
  Acceptance, compliance, incentives 
to patients 
 
  Productivity and work-loss time 
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6. Do you consider the results of economic evaluation generalizable between the regions (for 
example, from Western European countries, US to your country)? Why or why not?  (Please explain or clarify 
your opinion.) 
7. What in your opinion is important for transferability of economic studies from one country 
to another? Which factors influence the transferability of economic evaluations?  
 
Experts are provided with two cases on use of rituximab in healthcare decision making process, 
ĐŽŶĚƵĐƚĞĚŝŶƚǁŽƵŶŝĚĞŶƚŝĨŝĞĚĐŽƵŶƚƌŝĞƐ;ŵĂƌŬĞĚĂƐ͞^͟ĂŶĚ͞^͟Ϳ͘ 
8. Please, read both of the provided cases of economic evaluations of rituximab use in 
treating chronic lymphocytic leukemia.  
a) Can you use Case A in the decision making process in your country? Can you use Case B in 
the decision making process in your country? What are your thoughts about using the results of Case A or Case B 
in the decision making process in your country? 
b) Which case is more applicable to your country? Why? 
 
Experts are provided with the written description of Welte͛Ɛcriteria and, if needed, have the criteria 
explained to them. 
 
9. tŚŝĐŚƚŚƌĞĞĨĂĐƚŽƌƐ ĨƌŽŵtĞůƚĞ͛Ɛcriteria do you consider the most influential/important 
for transferability of the results to your country and which three factors do you consider the least 
influential/important? Why?  
10. Please, look once more at the cases provided. How might your decision on transferability 
and applicability of these studies to the decision making process in your country change if you were to use 
tĞůƚĞ͛Ɛcriteria? Which of these criteria would you say is the most influential in your decision regarding these 
cases? Which criteria are the least influential?  
11. Do you see any other factors that might make the results of these studies more applicable/ 
trustable in your country? 
 
Now, let me tell you that in Case B, country Y actually was the USA, in Case A, country X actually was 
Ukraine, and country Z actually was the UK. 
12. Please tell me now, would you be able to use Case A in the decision making in your 
country? Case B? Which case would you tell now is more applicable and reliable? Which case you can use 
more/better? Why? 
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Appendix 2.2 Interview guide 
ĞĂƌ͙ 
This research aims to study current use of economic evaluations in the different countries of Eastern 
European and Asian region, as well as possible perspectives on their applications in the healthcare decision 
making process. The answers you provide will be analyzed together with the answers of other experts. The 
manuscript presenting the results of this survey will be published afterwards. Your identity will be kept 
anonymous, and no relation between you and any information provided by you will be presented. If any 
ƌĞĨĞƌĞŶĐĞƐĨƌŽŵǇŽƵƌŝŶƚĞƌǀŝĞǁǁŝůůďĞŝŶĐůƵĚĞĚŝŶƚŚĞŵĂŶƵƐĐƌŝƉƚ͕ǇŽƵǁŝůůďĞƌĞĨĞƌƌĞĚƚŽƐŝŵƉůǇ͗͞ZĞƐƉŽŶĚĞŶƚy͕
ŽƵŶƚƌǇ͟ 
If the information indicated below is not available, all of the experts are asked general questions prior 
to the interview: 
Country__________________________ 
Place of work of the decision maker______________________________ 
Level of the decision maker:            country level            /        regional level 
Have an impact on the decisions in:   
a) State purchases; 
b) Reimbursement; 
c) Protocols/Formulary/State purchase list; 
d) National programs creation/execution. 
 
1. A) Did you have any training on health technology assessment in the past? If yes, what kind 
and when? 
B) Did you have any training on economic evaluations or pharmacoeconomics in the past? If yes, what 
kind and when? 
Ϳ ;ƐŬĞĚ ŝĨ ƚŚĞƉƌĞǀŝŽƵƐĂŶƐǁĞƌ ŝƐ͞ǇĞƐ͟Ϳ͘ŝĚǇŽƵŚĂǀĞĂŶǇƚƌĂŝŶŝŶŐŽŶ ƚƌĂŶƐĨĞƌĂďŝůŝƚǇŽĨĞĐŽŶŽŵŝĐ
studies in the past? If yes, what kind and when? 
2. Do you use economic evaluations in decision making process of drugs/devices 
reimbursement? Please explain or clarify your opinion. 
3. How important to you is it to use economic evaluations in decision making? Please discuss. 
4. How should an economic evaluation be performed (what criteria correspond) for you to 
accept the results of the study? 
 
As you might know, conducting a full economic evaluation requires significant labor, time and 
financial resources. It is considered that in certain cases the results of the studies, conducted in one country can 
ďĞƵƐĞĚŝŶƚŚĞĚĞĐŝƐŝŽŶŵĂŬŝŶŐƉƌŽĐĞƐƐŽĨĂŶŽƚŚĞƌĐŽƵŶƚƌǇ;ĂŶĚƐŽĐĂůůĞĚ͞ŐĞŶĞƌĂůŝǌĂďůĞ͟Ϳ͘/ŶƚŚĞŽƚŚĞƌĐĂƐĞƐ͕ƚŚĞ
results of an economic evaluation cannot be transferred directly to the other country, but with changes of some 
input parameters in the economic model it is possible to get results that fit to the decision making needs. In 
other cases, it is not possible either to use or to transfer results of the model, nor to apply the model itself. In 
these cases there is a need to develop a new model and, therefore, a new economic evaluation, specific to this 
country. The possibility to transfer results of economic evaluations from one country to another is called 
͞ƚƌĂŶƐĨĞƌĂďŝůŝƚǇ͘͟dŚĞƉŽƐƐŝďůĞůĞǀĞůŽĨƚƌĂŶƐĨĞƌĂďŝůŝƚǇŵĂǇďĞĚĞĨŝŶĞĚďǇassessing different aspects of healthcare 
systems on various factors in each of the comparison countries. 
 
5. Do you consider the results of economic evaluation generalizable within one region (for 
example, from a developing country of Central and Eastern Europe/Central Asia to your country)? Why or why 
not? (Please explain or clarify your opinion.) 
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your opinion.) 
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Appendix 2.2 Interview guide 
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European and Asian region, as well as possible perspectives on their applications in the healthcare decision 
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ƌĞĨĞƌĞŶĐĞƐĨƌŽŵǇŽƵƌŝŶƚĞƌǀŝĞǁǁŝůůďĞŝŶĐůƵĚĞĚŝŶƚŚĞŵĂŶƵƐĐƌŝƉƚ͕ǇŽƵǁŝůůďĞƌĞĨĞƌƌĞĚƚŽƐŝŵƉůǇ͗͞ZĞƐƉŽŶĚĞŶƚy͕
ŽƵŶƚƌǇ͟ 
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Level of the decision maker:            country level            /        regional level 
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a) State purchases; 
b) Reimbursement; 
c) Protocols/Formulary/State purchase list; 
d) National programs creation/execution. 
 
1. A) Did you have any training on health technology assessment in the past? If yes, what kind 
and when? 
B) Did you have any training on economic evaluations or pharmacoeconomics in the past? If yes, what 
kind and when? 
Ϳ ;ƐŬĞĚ ŝĨ ƚŚĞƉƌĞǀŝŽƵƐĂŶƐǁĞƌ ŝƐ͞ǇĞƐ͟Ϳ͘ŝĚǇŽƵŚĂǀĞĂŶǇƚƌĂŝŶŝŶŐŽŶ ƚƌĂŶƐĨĞƌĂďŝůŝƚǇŽĨĞĐŽŶŽŵŝĐ
studies in the past? If yes, what kind and when? 
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4. How should an economic evaluation be performed (what criteria correspond) for you to 
accept the results of the study? 
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ďĞƵƐĞĚŝŶƚŚĞĚĞĐŝƐŝŽŶŵĂŬŝŶŐƉƌŽĐĞƐƐŽĨĂŶŽƚŚĞƌĐŽƵŶƚƌǇ;ĂŶĚƐŽĐĂůůĞĚ͞ŐĞŶĞƌĂůŝǌĂďůĞ͟Ϳ͘/ŶƚŚĞŽƚŚĞƌĐĂƐĞƐ͕ƚŚĞ
results of an economic evaluation cannot be transferred directly to the other country, but with changes of some 
input parameters in the economic model it is possible to get results that fit to the decision making needs. In 
other cases, it is not possible either to use or to transfer results of the model, nor to apply the model itself. In 
these cases there is a need to develop a new model and, therefore, a new economic evaluation, specific to this 
country. The possibility to transfer results of economic evaluations from one country to another is called 
͞ƚƌĂŶƐĨĞƌĂďŝůŝƚǇ͘͟dŚĞƉŽƐƐŝďůĞůĞǀĞůŽĨƚƌĂŶƐĨĞƌĂďŝůŝƚǇŵĂǇďĞĚĞĨŝŶĞĚďǇassessing different aspects of healthcare 
systems on various factors in each of the comparison countries. 
 
5. Do you consider the results of economic evaluation generalizable within one region (for 
example, from a developing country of Central and Eastern Europe/Central Asia to your country)? Why or why 
not? (Please explain or clarify your opinion.) 
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considered to be a part of the costs 
of hospitalization. From healthcare 
perspective these costs are not 
different for the treatment schemes 
as the duration of hospitalization 
during the six cycles of initial 
therapy is the same.  
based on the number of hours spent 
administering the drug as well as the 
amount and number of drugs 
administered. These costs were based 
on the corresponding reimbursement 
rates. 
Adverse event costs 
 
 
 
No adverse events costs were 
included due to the difficulty of 
their assessment. 
Neutropenia and leukocytopenia 
costs were calculated by DRG rates. 
Indirect costs (caregiver 
resources) 
 
 
 
 
 
 
 
 
 
 
 
 
No indirect costs were included as 
the healthcare perspective was 
used.  
The cost for an informal caregiver was 
assessed from the literature ($275 
per week for a patient with 
continuing cancer care and $385 per 
week for a patient with advanced, 
terminal cancer). Participation rate 
for persons aged 60 – 64 is 
approximately 55%, declining linearly 
to 15% by age 70. Expected costs of 
lost work productivity due to severe 
adverse events from the treatment 
were also included, taking into 
consideration the length of a full 
course of therapy and incidence of 
the adverse events. 
Salvage therapy costs The costs for salvage therapy were 
calculated from the results of the 
previously conducted retrospective 
analysis of hospital cards in the 
country X with the account of tariffs 
applied in the state purchases.  
The costs for salvage therapy were 
calculated from the total price of the 
six most common regimens used in 
the treatment of patients with CLL in 
country Y after progression based on 
market tracking data. The insurance 
data on salvage therapies showed 
that approximately 22% of the 
patients who relapsed or were 
refractory were not treated with any 
therapy. 
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Appendix 2.3 Description of the provided case studies 
A recent phase III trial demonstrated improved progression free survival (PFS) and overall survival (OS) 
associated with adding rituximab to fludarabine and cyclophosphamide (R-FC) compared to FC in treatment of 
previously untreated chronic lymphocytic leukemia (CLL). A cost-effectiveness analysis of R-FC over FC was 
performed 
Methodological 
parameters 
Case A (rituximab in the 
country X) 
Case B (rituximab in the country 
Y) 
Perspective 1) Healthcare perspective 1) Third-party payer perspective; 
2) Societal perspective 
Horizon 
 
Life-time Life-time 
Model description 
 
 
 
Cost-effectiveness models calculate the incremental cost of a given technology 
per unit of benefit gained. Markov model with three-states (no disease progress, 
relapse, and death) was run using one month cycle time. 
Discount rate 
 
3% 
Mortality data 
 
 
Data from randomized controlled trial with vital mortality statistics for study 
country population 
Utilities included Utility values for health states 
associated with CLL treatment 
based on the general population in 
the Z. A utility value of 0.78 for the 
progression-free or stable disease 
state and a value of 0.68 for the 
progressed disease state have been 
reported. 
 
The decrement in utilities for 
spouses /caregivers was not 
accounted in the model, neither for 
a period of caregiving nor in case of 
death of the patient.  
 
 
Utility values for health states 
associated with CLL treatment based 
on the general population in the  Z. A 
utility value of 0.78 for the 
progression-free or stable disease 
state and a value of 0.68 for the 
progressed disease state have been 
reported. 
 
It was assumed a 0.18 decrement to 
the spouse/partner for the patient 
having progression-free CLL and a 
0.40 decrement if the patient 
progressed. Also included is a 0.60 
decrement in the utility if the patient 
died, assuming a 1-year bereavement 
period. 
 
Medical costs included 
 
 
 
Drug and hospitalization costs for 
initial and salvage therapies. 
Drug and administration costs for 
initial therapy, costs related to 
adverse events and salvage therapy 
costs. 
Drug costs 
 
 
 
 
A body surface area (BSA) of 1.72 
m2 was assumed for drug dose 
calculation. Adjustment to the real-
consumed dose was conducted  
A body surface area (BSA) of 1.84 m2 
was assumed for drug dose 
calculation. Adjustment to the real-
consumed dose was conducted 
Administration costs The cost of administration was The costs of drug administration are 
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Introduction 
The application of Health Technology Assessment (HTA), a policy analysis that 
examines short- and long-term consequences of the use of a health technology in decision 
making [1], has significantly sped up during the past years all around the world [2, 3]. At 
the same time, middle income countries, classified by the World Bank as countries with a 
gross national income per capita between $1,036 US and $12,475 US [4], face common 
problems in establishing HTA paradigms [2]. Most countries of the Central and Eastern 
European (CEE) and former Soviet Union regions are middle income countries, while many 
others from the same regions (for example, the Russian Federation), being nominally high-
ŝŶĐŽŵĞŵĂƌŬĞƚƐ͕ƐƚŝůůƉŽƐƐĞƐƐ͚ŵŝĚĚůĞ-ŝŶĐŽŵĞĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͛[2].  
Among countries of the CEE region, Poland, the Czech Republic, Slovakia and 
Hungary have introduced HTA principles and so can be considered countries with an 
established HTA process [5, 6]. The other CEE and former Soviet countries, being in 
different stages of HTA implementation, frequently incorporate some HTA elements or 
emerge with an idea for HTA use in their healthcare decision making. Frequently, such 
countries have no well-defined structural plan for the implementation of HTA results in 
their healthcare decision-making process. Some of them express initiation for full or 
partial HTA implementation, while not being able to allocate significant financial or 
qualified scientific resources for substantiating policy decisions with evidence [6, 7]. In 
many countries (e.g., Hungary and Poland), HTA capacity building is a first mandatory step 
for HTA implementation, followed by the development and approval of methodological 
guidelines and, after having an appropriately organized scientific environment, approval of 
compulsory HTA in policy decisions [7,8]. In other countries (e.g., Slovakia) mandating HTA 
evidence prior to pricing and reimbursement decisions of pharmaceuticals is the first step 
of HTA implementation, which eventually creates the need for HTA training. However, 
insufficient or low-quality HTA capacity may lead to speculations and corruption rather 
than the benefits from early HTA implementations.  
The other challenge for CEE and former Soviet countries with no central HTA 
agency is that when voluntary HTA dossier submissions exist, HTA may become a 
commercial promotional product rather than a decision-making tool. Although 
pharmaceutical companies, consulting firms, or private HTA agencies may become 
interested in this particular topic, the actual need for such an assessment is not always 
expressed by the government. For example, while health authorities may be equally 
interested in HTA for expensive medical services and procedures, most of the online 
Russian-language literature on HTA studies, which we acquired via an Internet search, is 
focused on pharmaceuticals. 
  
44 
 
Abstract 
The aim of this study is to analyze the quality and transferability issues reported in 
published peer-reviewed English-language economic evaluations based in healthcare 
settings of the Central and Eastern European (CEE) and former Soviet countries. 
A systematic search of economic evaluations conducted for healthcare was performed for 
Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Turkmenistan, Kazakhstan, 
Lithuania, the former Yugoslav Republic of Macedonia, Republic of Moldova, Romania, the 
Russian Federation, Serbia, Slovenia, and Ukraine. The included studies were assessed 
ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŝƌĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͕ƋƵĂůŝƚǇ;ƵƐŝŶŐƌƵŵŵŽŶĚ͛ƐĐŚĞĐŬůŝƐƚͿ͕ƵƐĞŽĨůŽĐĂůĚĂƚĂ͕
and the transferability of inputs and results, if addressed.  
Most of the 34 economic evaluations identified were conducted from a healthcare or 
payor perspective (74%), with 47% of studies focusing on infectious diseases. The least 
frequently and transparently addressed parameters were ƚŚĞ ŝƚĞŵƐ͛ƐƚĂƚĞĚƉĞƌƐƉĞĐƚŝǀĞƐ͕
relevant costs included, accurately measured costs in appropriate units, outcomes and 
costs credibly valued, and the uncertainties addressed. Local data were often used to 
assess unit costs, baseline risk and resource utilization, while jurisdiction-specific utilities 
were included in only one study. Only 32% of relevant studies discussed the limitations of 
using foreign data, and 36% of studies discussed the transferability of their own study 
results to other jurisdictions. 
Transferability of the results is not sufficiently discussed in published economic 
evaluations. To simplify the transferability of studies to other jurisdictions, the following 
should be comprehensively addressed: uncertainty, the impact of influential parameters, 
and data transferability. Transparency reporting should be improved. 
44 Chapter 3
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Slovenia, and Ukraine). The methodology applied in this review was based on the 
���������������� ��� ���� ������ ��������� ���� ������������ �������� ��� ����������� ��� ����
University of York [9]. 
 
Figure 3.1 Flowchart outlining paper selection process for the systematic review 
Scopus (946 abstracts): 12 full-text articles included 
Inclusion based on: 
- Country of interest 
- English language publication; 
- Full-text article 
- Economic evaluation 
- Comparative study 
934 abstracts excluded 
From which 7 because of 
the repetition 
Pubmed (1878 abstracts): 30 full-text articles included 
Inclusion based on: 
- Country of interest 
- English language publication; 
- Full-text article 
- Economic evaluation 
- Comparative study 
 
1848 abstracts 
excluded 
34 articles included in the review  
13 articles from 47 excluded: 
1) No economic evaluation included – 2 
2) Not a comparative study -  6 
3) Does not include country of interest -1 
4) No full text available - 4 
 
Science Direct (175 abstracts): 5 full-text article included 
Inclusion based on: 
- Country of interest 
- English language publication; 
- Full-text article 
- Economic evaluation 
- Comparative study 
170 abstracts excluded 
From which 3 because 
of the repetition 
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Although HTA capacity is already considered to be very limited [2], the 
implementation of HTA research and the critical appraisal of completed studies in CEE and 
former Soviet countries with no single public HTA agency may involve a number of 
additional problems [6]. When the appropriate training in HTA methodologies and 
concepts (and more specifically economic evaluations, being the core concept within HTA) 
is provided to experts from national institutions with no formal education in HTA or 
related sciences, there is no guarantee that the training will be successful. Language 
barriers limit the impact of international training courses in English. Language limitations, 
together with quality considerations, are factors that influence the potential 
transferability and generalizability of local-language studies, which are frequently not 
referenced in the international databases.  
The potential solution while operating in a narrow pool of high-quality economic 
studies can be generalizability or simplified transferability of economic evaluations across 
countries with defined similarities in healthcare systems and economic development [6]. 
The need for simple transferability of health economic studies is potentially more 
important in countries with limited scientific and financial resources for conducting 
economic evaluations, as it is in many countries of the CEE and former Soviet Union 
[2,5,7]. In this study we analyzed the scope of transferability issues that are addressed in 
published peer-reviewed English-language economic evaluations based in healthcare 
settings of the CEE and former Soviet countries with a recently formed or no centralized 
HTA agency. The research aim was operationalized by the following research questions: 
1) What are the background characteristics of economic evaluations conducted in 
healthcare settings of CEE and former Soviet countries and published in English-
language peer-review journals? 
2) What is the quality of the retrieved studies based on Drummond's check-list for 
assessing economic evaluations?  
3) To what extent is the transferability of economic evaluations addressed in the 
retrieved studies? 
a) In what respect were local and foreign inputs used in economic evaluations?  
b) Are the transferability of the inputs and the results of the study frequently 
discussed in these publications? 
 
Methods 
In September 2013, a systematic search for scientific literature on cost-
effectiveness studies conducted in the selected CEE and former Soviet countries was 
performed (Armenia, Azerbaijan, Belarus, Bulgaria, Estonia, Georgia, Turkmenistan, 
Kazakhstan, Lithuania, Macedonia, Moldova, Romania, Russian Federation, Serbia, 
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Slovenia, and Ukraine). The methodology applied in this review was based on the 
���������������� ��� ���� ������ ��������� ���� ������������ �������� ��� ����������� ��� ����
University of York [9]. 
 
Figure 3.1 Flowchart outlining paper selection process for the systematic review 
Scopus (946 abstracts): 12 full-text articles included 
Inclusion based on: 
- Country of interest 
- English language publication; 
- Full-text article 
- Economic evaluation 
- Comparative study 
934 abstracts excluded 
From which 7 because of 
the repetition 
Pubmed (1878 abstracts): 30 full-text articles included 
Inclusion based on: 
- Country of interest 
- English language publication; 
- Full-text article 
- Economic evaluation 
- Comparative study 
 
1848 abstracts 
excluded 
34 articles included in the review  
13 articles from 47 excluded: 
1) No economic evaluation included – 2 
2) Not a comparative study -  6 
3) Does not include country of interest -1 
4) No full text available - 4 
 
Science Direct (175 abstracts): 5 full-text article included 
Inclusion based on: 
- Country of interest 
- English language publication; 
- Full-text article 
- Economic evaluation 
- Comparative study 
170 abstracts excluded 
From which 3 because 
of the repetition 
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Although HTA capacity is already considered to be very limited [2], the 
implementation of HTA research and the critical appraisal of completed studies in CEE and 
former Soviet countries with no single public HTA agency may involve a number of 
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2) What is the quality of the retrieved studies based on Drummond's check-list for 
assessing economic evaluations?  
3) To what extent is the transferability of economic evaluations addressed in the 
retrieved studies? 
a) In what respect were local and foreign inputs used in economic evaluations?  
b) Are the transferability of the inputs and the results of the study frequently 
discussed in these publications? 
 
Methods 
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effectiveness studies conducted in the selected CEE and former Soviet countries was 
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3) Quality assessment using Drummond's check-list for assessing economic 
evaluations [11]. 
4) Use of local inputs for the main data categories according to Barbieri et al. 
[12]: baseline risk, treatment effect, health state preference values (utilities), resource 
utilization, unit costs (prices). 
5) Addressed limitations regarding foreign data use and transferability of the 
received results to other jurisdictions.  
The articles were assessed independently by two researchers (OM and either SK, 
ZK or JLS). The results of the two independent assessments during the third step were 
compared, and any disagreements were discussed. If no consensus was reached, a third 
researcher was involved in the final decision making. 
 
Results 
Out of the 47 full-text publications, 34 articles [13-46] were included in the 
systematic review. Fifteen of the studies (44%) had a main author (and corresponding 
authors, if different) not from a study country (Western European countries, the UK, or 
the USA). An academic establishment was the most common affiliation of the main author 
;ϮϱŽƌϳϰйŽĨƚŚĞƐƚƵĚŝĞƐͿ͘dŚĞƐƚƵĚǇ͛ƐƐƉŽŶƐŽƌƐŚŝƉǁĂƐŝŶĚŝĐĂƚĞĚŝŶϮϮ;ϲ5%) publications; 
of these, pharmaceutical companies sponsored 5 and conducted 2 more studies. 
Background characteristics of economic evaluations 
Some background characteristics of the studies are described in Table 3.1. In 
short, the majority of the retrieved studies were conducted in healthcare settings of 
Bulgaria, the Russian Federation, Slovenia, Lithuania, and Ukraine. The retrieved studies 
also included six cross-country studies, which additionally analyzed the application of a 
technology in Croatia, Tajikistan and Uzbekistan. Infectious diseases were the most 
frequently addressed topics in publications (16 or 47% of all studies), and the most 
frequently funded (87% of infectious disease studies were funded in comparison to 44% of 
all the other evaluations). Besides pharmaceutical companies, the other sponsors of 
studies on infectious diseases were international organizations, European and the USA 
grant committees, Ministries of Health or universities. In studies considering chronic 
disease topics, different cardiologic interventions and diabetes drugs were the most 
frequently addressed. Medicines were the most frequently researched interventions, 
among which vaccines had a significant share. Healthcare, governmental, or healthcare 
payor perspectives were predominant in the analyzed publications. Models were applied 
in two-third of the studies (Markov model was frequently used). Cost-utility analysis, with 
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Data search 
The search, selection, and analysis of the relevant articles were performed in a 
three-step procedure (Figure 3.1): initial assessment of the title, abstract, and keywords 
(Step 1); a full-text assessment of the selected references (Step 2); and analysis of the 
articles that fully corresponded to the inclusion criteria (Step 3). The search terms applied 
ƚŽ ĨƵůů ƚĞǆƚƐ ŽĨ ƉƵďůŝĐĂƚŝŽŶƐ ŝŶ ƚŚĞ WƵďDĞĚ ĚĂƚĂďĂƐĞ ǁĞƌĞ ĂƐ ĨŽůůŽǁƐ͗ ͞ĞĐŽŶŽŵŝĐ
ĞǀĂůƵĂƚŝŽŶ͟ н ͞ĐŽƵŶƚƌǇ͟ ;ŽŶĞ ĨƌŽŵ ƚŚŽƐĞ ŝŶĚŝĐĂƚĞĚ ĂďŽǀĞͿ͖ ͞ĐŽƐƚ͟ н ͞ĐŽƵŶƚƌǇ͘͟ dŚĞ
extended searcŚ ĨŽƌ ŬĞǇ ǁŽƌĚƐ ǁŝƚŚŝŶ ĂďƐƚƌĂĐƚƐ ;͞ĞĐŽŶŽŵŝĐ ĞǀĂůƵĂƚŝŽŶ͟ н ͞ĐŽƵŶƚƌǇ͕͟
͞ĐŽƐƚΎ͟ н͟ĐŽƵŶƚƌǇ͟Ϳ ǁĂƐ ĐŽŶĚƵĐƚĞĚ ŝŶ ƚŚĞ ^ĐŝĞŶĐĞ ŝƌĞĐƚ ĂŶĚ ^ĐŽƉƵƐ ĚĂƚĂďĂƐĞƐ͘ dŚĞ
difference in search conditions among databases was highlighted by the unlimited number 
of word combinatiŽŶƐĂƉƉĞĂƌŝŶŐŝĨƚŚĞƚĞƌŵ͞ĐŽƐƚΎ͟ǁĂƐƐĞĂƌĐŚĞĚŝŶWƵďDĞĚ͘ 
The following exclusion criteria were applied for Step 1: study older than 5 years (<2008) 
based on the publication-date of the ISPOR task force report on transferability in 2009 
[10]; abstract not available, study written in a language other than English.  
The inclusion criteria for Step 1 were the following: study includes at least one 
country of interest, study includes an economic evaluation, study published as a peer-
reviewed article (abstract only, or congress report excluded) in the English language.  
 Full texts of the publications were analyzed on correspondence to the inclusion 
criteria during the second step: study includes comparative economic evaluation, 
conducted in healthcare setting of at least one country of interest, full text of the study 
available. Both trial-based and model-based economic evaluations were eligible for 
inclusion. All references included in the second step were summarized in the dataset with 
the following information: main author and year of publication, whether it is an economic 
evaluation or not, inclusion of a direct comparison of two or more technologies, countries 
included in the assessment, full text availability, decision on inclusion in the systematic 
review. Hard copies of potentially relevant full-text articles were received. Authors of the 
articles which corresponded to all inclusion criteria except full-text availability were 
contacted. If no full text of the article was received, the publication was withdrawn from 
the analysis, and the reason for this was recorded. 
Data extraction and reporting 
The following information was summarized from the included studies:  
1) Technical characteristics of the publications: country and affiliation of the main 
and corresponding author (if differ), study sponsorship and type of sponsorship indicated. 
2) Study characteristics: countries of analysis, clinical area, study technology and 
comparators, type of analysis and methods used, perspective, application of discounting, 
costs assessment (technology, medical, and productivity costs), outcome measure, type of 
sensitivity analysis applied. 
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payor perspectives were predominant in the analyzed publications. Models were applied 
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Data search 
The search, selection, and analysis of the relevant articles were performed in a 
three-step procedure (Figure 3.1): initial assessment of the title, abstract, and keywords 
(Step 1); a full-text assessment of the selected references (Step 2); and analysis of the 
articles that fully corresponded to the inclusion criteria (Step 3). The search terms applied 
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The following exclusion criteria were applied for Step 1: study older than 5 years (<2008) 
based on the publication-date of the ISPOR task force report on transferability in 2009 
[10]; abstract not available, study written in a language other than English.  
The inclusion criteria for Step 1 were the following: study includes at least one 
country of interest, study includes an economic evaluation, study published as a peer-
reviewed article (abstract only, or congress report excluded) in the English language.  
 Full texts of the publications were analyzed on correspondence to the inclusion 
criteria during the second step: study includes comparative economic evaluation, 
conducted in healthcare setting of at least one country of interest, full text of the study 
available. Both trial-based and model-based economic evaluations were eligible for 
inclusion. All references included in the second step were summarized in the dataset with 
the following information: main author and year of publication, whether it is an economic 
evaluation or not, inclusion of a direct comparison of two or more technologies, countries 
included in the assessment, full text availability, decision on inclusion in the systematic 
review. Hard copies of potentially relevant full-text articles were received. Authors of the 
articles which corresponded to all inclusion criteria except full-text availability were 
contacted. If no full text of the article was received, the publication was withdrawn from 
the analysis, and the reason for this was recorded. 
Data extraction and reporting 
The following information was summarized from the included studies:  
1) Technical characteristics of the publications: country and affiliation of the main 
and corresponding author (if differ), study sponsorship and type of sponsorship indicated. 
2) Study characteristics: countries of analysis, clinical area, study technology and 
comparators, type of analysis and methods used, perspective, application of discounting, 
costs assessment (technology, medical, and productivity costs), outcome measure, type of 
sensitivity analysis applied. 
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dĂďůĞ ϯ͘Ϯ &ƌĞƋƵĞŶĐŝĞƐ ŽĨ ƚŚĞ ƐƚƵĚŝĞƐ͛ ƌĂŶŬŝŶŐƐ ďǇ ƌƵŵŵŽŶĚΖƐ ĐŚĞĐŬ-list for assessing 
economic evaluations, use of local data and transferability addressed (34 articles in 
total) 
Parameters Yes Partially No Unclear 
 
Comprehensive description of alternatives given 
 
 
27 (79%) 
 
0 
 
6 (18%) 
 
1 (3%) 
Effectiveness is established 
 
22 (65%) 3 (9%) 2 (6%) 7 (20%) 
All relevant costs included 
 
18 (53%) 0 6 (18%) 10 (29%) 
All relevant outcomes included 
 
29 (85%) 2 (6%) 3 (9%) 0 
Costs measured accurately in appropriate units 
 
17 (50%) 0 1 (3%) 16 (47%) 
Outcomes measured accurately in appropriate units 
 
26 (76%) 5 (15%) 1 (3%) 2 (6%) 
Outcomes and costs valued credibly 
 
13 (38%) 5 (15%) 3 (9%) 13 (38%) 
Incremental analysis performed  
 
27 (79%) 1 (3%) 4 (12%) 1 (3%) 
Uncertainty addressed 
 
12 (35%) 11 (32%) 9 (26%) 2 (6%) 
Results include issues of purchasers concern 
 
18 (53%) 7 (21%) 5 (15%) 4 (12%) 
Conclusions justified by the evidence presented 
 
25 (74%) 4 (12%) 5 (15%) 0 
Results can be applied to the local population  
 
31 (91%) 1 (3%) 1 (3)% 1 (3%) 
Unit costs retrieved from local data  
 
28 (82%) 4 (12%) 1 (3%) 1 (3%) 
Resource utilization retrieved from local data  
 
23 (68%) 2 (6%) 1 (3%) 8 (24%) 
Utility parameters retrieved from local data  
 
1 (3%) 0 0 0 
Baseline risk received from local data  
 
23 (68%) 2 (6%) 0 0 
Treatment effect received from local data  
 
15 (44%) 2 (6%) 16 (47%) 1 (3%) 
Transferability of study to other jurisdiction was discussed  
 
4 (12%) 8 (24%) 22 (65%) - 
Limitations of the results regarding foreign data used 2 
 
 
4 (16%) 4 (16%)a 17 (68%) 9 (26%) 
1 Rounding is applied; 2 from applicable 
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quality-adjusted life years (QALY) at the effect side, was applied in more than half of the 
evaluations.  
 
Table 3.1 Frequencies of the studies rankings by characteristics (34 articles in total) 
Parameters N (%)1 
 
Perspective of the study is stated2 
 
23 (68%) 
 Health care, state, or health care payer 25 (74%) 
 Societal 5 (15%) 
 Provider 3 (9%) 
 Employer  1 (3%) 
 Patient 
 
1 (3%) 
Discounting applied  21 (62%) 
 Both costs and outcomes are discounted at 3% (% from model studies) 10 (43%) 
 Both costs and outcomes are discounted at 5% (% from model studies) 4 (17%) 
 Unequal discounting for costs and effects  (% from model studies) 
 
4 (17%) 
Productivity costs included  
 
5 (15%) 
Outcomes used   
 Quality adjusted life years 3 18 (53%) 
 Life-years gained 13 (38%) 
 N of cases/deaths averted 6 (18%) 
 Disability adjusted life years 
 
5 (15%) 
Sensitivity assessed4 27 (79%) 
 Probabilistic sensitivity analysis reported (% from model studies) 11 (47%) 
 Only univariate analysis  11 (32%) 
 Only univariate with multivariate analyses 4 (12%) 
 Bootstrap 
 
1 (3%) 
1 Rounding is applied; 2 Number of studies used several perspectives; 3 One study assessed quality of life using 
WHOQOL-BREF instrument; 4 Two studies indicated that sensitivity analysis was applied, but did not report the 
results 
 
Quality of economic evaluations 
The summary of the assessment of the articles is presented in Table 3.2.  
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 Health care, state, or health care payer 25 (74%) 
 Societal 5 (15%) 
 Provider 3 (9%) 
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 Patient 
 
1 (3%) 
Discounting applied  21 (62%) 
 Both costs and outcomes are discounted at 3% (% from model studies) 10 (43%) 
 Both costs and outcomes are discounted at 5% (% from model studies) 4 (17%) 
 Unequal discounting for costs and effects  (% from model studies) 
 
4 (17%) 
Productivity costs included  
 
5 (15%) 
Outcomes used   
 Quality adjusted life years 3 18 (53%) 
 Life-years gained 13 (38%) 
 N of cases/deaths averted 6 (18%) 
 Disability adjusted life years 
 
5 (15%) 
Sensitivity assessed4 27 (79%) 
 Probabilistic sensitivity analysis reported (% from model studies) 11 (47%) 
 Only univariate analysis  11 (32%) 
 Only univariate with multivariate analyses 4 (12%) 
 Bootstrap 
 
1 (3%) 
1 Rounding is applied; 2 Number of studies used several perspectives; 3 One study assessed quality of life using 
WHOQOL-BREF instrument; 4 Two studies indicated that sensitivity analysis was applied, but did not report the 
results 
 
Quality of economic evaluations 
The summary of the assessment of the articles is presented in Table 3.2.  
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supported by the observation that in the countries with a relatively high number of 
publications (such as Bulgaria and Lithuania) the articles are frequently published by the 
same research teams. Additionally, we observed a trend for sponsored studies and for 
studies conducted under international co-authorship (either the first author or the 
corresponding author is not affiliated with the study country) to be of higher quality as 
ĂƐƐĞƐƐĞĚ ďǇ ƌƵŵŵŽŶĚ͛Ɛ ĐƌŝƚĞƌŝĂ͘ tŚŝůĞ ŝƚ ĐŽƵůĚ ďĞ ŶŽƚŝĐĞĚ ƚŚĂƚ ƐƚƵĚŝĞƐ ŽŶ ƐŽŵĞ
technologies were of better quality (e.g., vaccines), we believe that the main factor 
ŝŶĨůƵĞŶĐŝŶŐ ƐƚƵĚǇ ƋƵĂůŝƚǇ ŝƐ ƚŚĞ ĂƵƚŚŽƌƐ͛ ĂĨĨŝůŝĂƚŝŽŶ ĂŶĚ ƐŽƵƌĐĞ ŽĨ ƐƉŽŶƐŽƌƐŚŝƉ͘  ƐŝŵŝůĂƌ
observation of higher quality of economic studies conducted by international rather than 
local teams was made in a systematic review of economic studies in Vietnam [47].  
While it appears that medical interventions other than pharmaceuticals as well as 
studies on chronic conditions may be of higher interest for the decision makers, the 
analyzed publications tend to present more analysis related to drug treatment, especially 
vaccination, and focus more on infectious diseases than on chronic diseases.  
Despite the fact that most guidelines on economic evaluations recommend using 
the societal perspective [48], its application in CEE and former Soviet countries is limited. 
Only a few studies used a limited or not purely societal perspective as defined by the 
ISPOR task force report [49]͘ĂƚĂĂǀĂŝůĂďŝůŝƚǇĂŶĚĚĞĐŝƐŝŽŶŵĂŬĞƌƐ͛ĂĐĐĞƉƚĂŶĐĞĂƌĞƚŚĞŬĞǇ
factors in defining the perspective of the study [10] which, in the studied countries, 
majorly concern healthcare or third-party payors. 
Quality of economic evaluations 
Insufficient quality of economic evaluations is the first knock-out criterion in 
ĂƐƐĞƐƐŵĞŶƚ ŽĨ ƐƚƵĚŝĞƐ͛ ƚƌĂŶƐĨĞƌĂďŝůŝƚǇ [50] and lack of transparency in the reporting of 
health economic studies is the major concern of decision makers around the world [3, 51]. 
At the same time we observed a significant indistinctness in reporting the methodology of 
economic evaluations conducted in healthcare settings of CEE and former Soviet 
countries. This reporting approach may improve by using standardized instruments, such 
as the CHEERS statement [52].  
Absence of a clearly stated perspective of the study causes difficulties in the 
assessment of both the credibility of the study and its application in the decision making 
context. The description of the economic model used and its authorship was frequently 
lacking. Together with missing reporting on internal and external (between-model) 
validation [53], this may create difficulties for the transferability of study results. 
While costs measurement fully depends on the perspective of the analysis, both 
type of input data should be transparent, appropriately documented and available for 
readers [49].  
However, incompleteness of data, the sample size required to estimate 
population-representative costs and effects, data heterogeneity and generalizability of 
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Using Drummond's check-list for assessing economic evaluations (including 
considerations of internal and external validity of the study, such as methodology applied 
��� ���������� �������� �� �������� ���� ��� ��������� �������� ���� ������ �� ���� ��� 
��������� in more than 30% of studies: perspective stated, all relevant costs included, 
costs measured accurately in appropriate units, outcomes and costs valued credibly, and 
uncertainty addressed. Appraisal criteria such as comprehensive description of 
alternatives given, all relevant outcomes included, outcomes measured accurately in 
appropriate units, outcomes and costs adjusted for different times, incremental analysis 
���������� ��� ����������� ��������� �� ��� �������� ���������� ���� ������ �� ����� 
more than other Drummond criteria. Insufficient information on costs components and 
assessment methods frequently made it impossible to evaluate the quality of these data.  
Address of transferability in economic evaluations 
In 10 out of the 23 studies the use of a country-adapted model was clearly stated. 
The frequencies on other transferability issues ranking are presented in Table 3.2. Unit 
costs were most frequently based on local data; there was only one study which did not 
apply local unit costs. The baseline risk and resource utilization were also frequently 
assessed using local inputs, while the utility parameters were clearly identified as local in 
only one study.  
Limitations of the results regarding the use of foreign data were discussed at 
least partially in 8 studies, and 12 studies at least partially discussed the transferability of 
study results to other jurisdictions. Several studies briefly discussed the generalizability of 
the results or individual parameters (such as baseline risk, prevalence), while the studies 
of Berkhof et al. [15] and Winetsky et al. [46] generalized the received results to the other 
countries of the region (or conducted a simple transferability assessment).  
 
Discussion 
The results of this systematic review of economic evaluations conducted in CEE 
and former Soviet countries allowed us to conclude a low transparency of data reporting 
in the analyzed publications as well as insufficient consideration of inputs and results 
transferability in these studies. 
Background characteristics of economic evaluations 
We did not observe any proportional difference in the number of available 
English-language peer-review publications referenced in the international databases 
����� �� ��� ��������� ���� �� ����� �� ��� ������������ ����� the topic of the study may 
be sponsorship-driven, the number of publications submitted to international journals 
may depend on publication activity of the local research teams. This conclusion is 
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Conclusion 
Because of the limited HTA capacity, geographic transferability is an important 
alternative to following an evidence-based decision-making process in many of the CEE 
and former Soviet countries [56]. Meanwhile, countries of the CEE and former Soviet 
region require an adapted approach to addressing the use and transferability of economic 
evaluations in healthcare decision making. Because of the information (data and 
knowledge) constraints, this approach may not always correspond to the international 
guidelines on economic evaluations or practices used in HTA-experienced countries. As 
such, healthcare (or third-party payor) perspectives may be preferable to a societal one, 
and the generalizability of utilities may be considered to be appropriate, while local data 
should be used for baseline risk, unit costs, and resources consumption.  
To simplify the transferability of published studies to the other jurisdictions, 
uncertainty, the impact of influential parameters, and data transferability should be 
comprehensively addressed when reporting studies. Additionally, the transparency of 
study reporting, especially study perspective, model details, and costing methodology, 
should be improved significantly. 
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ƚƌŝĂůƐ͛ ƌĞƐƵůƚƐ ĂƌĞ ƌĞƋƵŝƌĞĚ [53], but rarely reported, in the trial-based economic 
evaluations conducted in healthcare settings of CEE and former Soviet countries. At the 
same time in countries with high data uncertainty, comprehensive probabilistic sensitivity 
assessment in modeled studies may improve the perceived quality (or reliability) of a 
study and thus the use of economic evaluations in the decision-making process [3]. 
Consideration of transferability of economic evaluations 
While economic evaluations conducted in CEE and former Soviet countries 
typically apply local costs, baseline risk and resource utilization measurement, the 
effectiveness and utilities are frequently extrapolated from other countries or 
international studies. This observation corresponds to the conclusions of other authors 
defining baseline risk, unit costs, and resource use as parameters of low transferability 
[12, 54] and is supported by the results of expert interviews  conducted on the use and 
transferability of economic evaluations to CEE and former Soviet countries (chapter 2). 
Many guidelines recommend using utility values from the jurisdiction of interest 
[10]. The evidence suggests that utilities may vary between countries [55]. Meanwhile, 
taking into account the data constraints, the decision makers from CEE and former Soviet 
countries may review generalizability of outcomes while addressing its uncertainty using 
statistical approaches.  
Moreover, we observed that the limitations of foreign data use, as well as the 
possibility of transferring the study to the other jurisdictions, are rarely described in the 
analyzed publications. Clear presentation of these parameters together with defining 
major impact factors on the results of economic evaluations and addressing data 
uncertainty will improve the transferability of studies. 
Limitations 
This study is limited to the study selection criteria: 1) English-language 
publications only; 2) studies published from 2008 onward; 3) articles with full-text 
availability. Search limitations could result in non-inclusion of some of the relevant 
ƐƚƵĚŝĞƐ͘ƌƵŵŵŽŶĚ͛ƐĐƌŝƚĞƌŝĂǁĞƌĞƵƐĞĚƚŽĂƐsess the quality of economic evaluation. This 
instrument is a general questionnaire and does not provide a total scoring of the quality of 
the assessed papers, leaving the conclusion on each article to the subjective judgment of 
the people assessing it. Because of the limited number of selected articles, the study does 
not have the statistical power to provide an assessment of relationships between different 
characteristics. 
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Introduction 
Globally, there are approximately 7.4 million cancer deaths per year, which is 
approximately 13% of deaths from all causes. Since the population of many countries 
around the world is aging, it can be expected that cancer incidence will increase [1]. 
Chronic hematologic malignancies are comparatively rare oncologic diseases. In Ukraine in 
2010 the officially-registered total morbidity rate for patients with diagnosed leukemia 
was 7.8 per 100,000 people, of which 39.3% did not live a year after diagnosis [2]. Chronic 
lymphocytic leukemia (CLL) is the most frequent form of leukemia in Western countries, 
and it accounts for approximately 30–40% of all leukemias [3,4]. It is characterized by the 
clonal proliferation and accumulation of neoplastic B lymphocytes in the blood, bone 
marrow, lymph nodes, and spleen. Although the median age of patients at diagnosis is 
higher than retirement age and so has no significant impact on state productivity loss [5], 
the economic impact of CLL is significant due to long duration and high expenses related 
to treatment, combined with low cure rates. Nevertheless, early diagnosis and effective 
t�e�t�e�t �� �e��t����i� ���i�����ies s�i�ts t�e i�di��t��s �� � ��tie�t�s �i�e e��e�t���� 
to positive values [6]. For example, in the USA for the time period 1999-2005, 5-year 
survival for leukemia was 82% (79% for CLL), although in 1975-1977 this indicator was 
close to Ukrainian data – 35% [7,8].  
In-hospital medical care to patients with CLL is generally provided in 35 
hematologic departments, based in district hospitals (16), state city hospitals (12), 
oncologic dispensaries (4), and specialized Institutes of the National Academy of Medical 
Science of Ukraine (3) [2,9]. To the latter one belong two hematologic institutes and the 
National Cancer Institute, which is a leading state institution additionally responsible for 
methodological and scientific development in this clinical area. The treatment schemes for 
the patients with CLL are based on a clinical protocol that proposes a number of treatment 
options for CLL patients and was first developed and approved under an order of the 
Ministry of Health (MOH) of Ukraine in 2010 [10]. State pharmaceutical provision for adult 
�������i� ��tie�ts is ����ted t���u�� � ��ti���� t�e�t�e�t ������� ���������� ��� the 
years 2011-2016, although governmental financing is insufficient and drug treatment is 
usually paid out of pocket by patients [11].  
��t��u�� ��� ��s � si��i�i���t i����t �� ��tie�ts� �u��it� �� �i�e �������� studies 
exploring the economic costs and burden of hematologic malignancies are relatively 
sparse in English-language publications worldwide [14,15]. Possible reasons for such a lack 
of information appear to include the low incidence rate and aged study population (over 
60 years old), which make broad, well-designed economic analyses a challenge for most 
researchers [5,16]. The limited cost reviews identified cost drivers for CLL as 
chemotherapy costs, intravenous immunoglobulin costs, transplantation costs and costs 
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Abstract 
The aim of this study is to identify the cost of treatment for chronic lymphocytic leukemia 
(CLL) in specialized hospitals in Ukraine from a health care perspective and to understand 
if patient characteristics are related to these costs. 
Cost analysis from a health care perspective was performed using retrospective data 
between 2006 and 2010 from patient-file databases of two specialized hospitals in 
Ukraine. Costs related only to CLL diagnosis (drug treatment and in-hospital expenses) 
were calculated. Uncertainty was assessed using bootstrapping and multivariate sensitivity 
analyses. Linear regression analysis was used to analyze if patients' characteristics have an 
impact on healthcare costs. Additionally one-way ANOVA (Welch test) and paired-sample 
t-test were conducted to compare mean costs of treatment between the two hospitals 
and difference in mean expenses for drugs and in-hospital stay. 
dŚĞŶƵŵďĞƌŽĨƉĂƚŝĞŶƚƐŝŶƚŚĞĚĂƚĂǁĂƐϭϰϱ͘dŚĞĂǀĞƌĂŐĞĂŶŶƵĂůĐŽƐƚĨŽƌĂƉĂƚŝĞŶƚ͛ƐĚƌƵŐ
treatment is 2,047 EUR. The cost of hospitalization was significantly lower (t=5.026; Sig 2-
tailed =0.000) and equal to 541 EUR per person, resulting in total expenditures of 2,589 
EUR. Mean total costs in the bootstrap analysis were equal to 2,584 EUR (median 2,576 
EUR, 97.5 percentile 3,223 EUR; 2.5th percentile 1,987 EUR). The regression analysis did 
not reveal a relation between sex of the patient, number of years a patient lives with the 
disease, and age at the time of hospitalization and healthcare costs, while hospital choice 
was an influential parameter (Beta=-0.260; Sig=.002). Significant difference in mean costs 
of two analyzed hospitals was also confirmed by one-way ANOVA (Welch statistics 19.222, 
p=0.000).  
Drug treatment comprises the largest portion of total costs but differences between 
hospitals exist. Because many patients in Ukraine pay out of pocket for in-hospital drugs, 
these costs are a high economic burden for CLL patients.  
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specialized hospital and are equal to 16.3EUR per patient-day (2010) [17]. Out-of-hospital 
healthcare costs were not calculated because according to the clinical protocol [10] 
treatment of CLL patients should be conducted only in hospital. The average length of 
hospital stay and drug costs were assessed by retrospective analysis of patient file data.  
To assess drug usage, daily defined doses and total amount received during the 
year were recorded. To calculate drug costs we used a step-wise approach to determine 
an average price, depending on the availability of information: tariff in governmental 
ƉƵƌĐŚĂƐĞƐ;ϮϬϭϬͿ͖ƉƌŝĐĞ͕ƌĞŐŝƐƚĞƌĞĚŝŶƚŚĞDK,͖ĂŶĚĚŝƐƚƌŝďƵƚŽƌƐ͛ƉƌŝĐĞ͘ 
Multivariate sensitivity analysis was conducted. Price deviations for sensitivity 
test of all drugs were calculated using the minimum and maximum prices from the 
available sources (hospital purchases, state registered prices, and distributors' prices).  
There are no defined general tariffs for hospital stay in Ukraine, which are relatively low in 
comparison to medical costs in the European countries and may vary from 3.4 to 19.2 EUR 
(2010) [17-19].  
All statistical analyses were performed in IBM SPSS Statistics 20 (SPSS Inc., 
Chicago, Illinois) and bootstrapping (1000 replications) was performed in Microsoft Excel 
2010. To analyze if choice of the hospital, age and sex of a patient, have an impact on total 
health care costs, logarithmic data transformation was performed on the non-normally 
distributed costs and a linear regression analysis was applied. Because of frequently 
ŵŝƐƐŝŶŐĚĂƚĂĨŽƌƚŚĞƉĂƌĂŵĞƚĞƌ͞ƐƚĂŐĞŽĨƚŚĞĚŝƐĞĂƐĞ͕͟ĂƐĂƉƌŽǆǇĨŽƌĚŝƐĞĂƐĞƉƌŽŐƌĞƐƐŝŽŶ
ǁĞ ŝŶĐůƵĚĞĚ͞ŶƵŵďĞƌŽĨǇĞĂƌƐƉĂƚŝĞŶƚ ŝƐ ůŝǀŝŶŐǁŝƚŚƚŚĞĚŝƐĞĂƐĞ͟ ŝŶ ƚŚĞ ůinear regression 
ĂŶĂůǇƐŝƐ͘ ĂƐĞĚ ŽŶ ŽŽŬ͛Ɛ ĚŝƐƚĂŶĐĞ ;Ϭ͘ϬϮϴϱϳϭͿ͕ ǁŚŝĐŚmeasures the effect of deleting a 
given observation and so allows to define data points with large residuals, we excluded six 
outliers to improve the residuals plot and model validity. Simultaneously one-way ANOVA 
(Welch test) was conducted to compare mean costs of treatment in the two hospitals 
involved (asymptotically F distributed). 
Paired-sample t-test was used to compare difference in mean expenses for drugs 
and in-hospital stay. 
 
Results 
Overall, data of 113 patients from the first hospital (State hematology institute) 
and of 32 patients from the second hospital (National Cancer Institute) were analyzed. 
Patients were aged 40 to 85 (mean age 62.9, mean age during diagnosis 60.3, s.d. 9.8). 
From the sample, 27.6% (40 patients) were newly diagnosed Due to the limited sample 
size, the distribution of patients by sex was not equal in different age groups with total 
proportion of males equal to 60.7% (88 men).  
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associated with the differential staining cytotoxicity assay with the main cost drivers 
related to the treatment chosen [16].  
The healthcare system itself, including organization of medical help to oncologic 
patients, is going through a stage of transformation, which includes implementation of a 
universal reimbursement system to begin 2016, and standardization of medical help with 
enhanced control on follow up of clinical protocols and more strict division between 
primary, secondary and tertiary levels of medical help. Taking into account that the major 
recipients of the central state budget are specialized institutions (tertiary level of help), 
the primary aim of this research was to identify the cost of treatment for CLL in specialized 
hospitals in Ukraine from a health care perspective and to understand if patient 
characteristics are related to these costs. 
 
Methods 
The study was conducted from a healthcare perspective and accounted direct 
medical costs with the aim of seeing which costs are going to be paid by the Ministry of 
Health after the health care system transformation. 
Analysis included data from databases of two specialized hospitals that are the 
�e����e�t� �� �t�te ��������� th����h the ��t����� t�e�t�e�t ������� ����������� - 
National Cancer Institute and State Institute of Hematology. These hospital databases 
were made in the programs Access and Word for the purpose of data storage and 
included all of the information available in hard copies of hospital cards; the data were 
typed into the hospital databases retrospectively by qualified personal (hospital 
assistants). Afterward, data from the two hospital databases were transferred into Excel 
and SPSS databases created for the purpose of data analysis.  
The study population included all newly-diagnosed and relapsed patients (145 in 
total) who were hospitalized during the period from 2006-2010 with the diagnosis CLL and 
whose data were recorded in the electronic database. The information derived from the 
h����t�� ���d� �e����d��� ��t�e�t�� �de�t�����t��� �������t���� ���t���ed the following 
data: sex of the patient, age during diagnosis and treatment, number of years a patient 
lives with the disease, year of treatment, therapies prescribed and duration of treatment, 
the number of hospitalizations per year and their duration. Stage of the patient's disease 
and health state on ECOG criteria were excluded from the factor list, as data on these 
parameters were frequently missing.  
Costs related only to CLL diagnosis for the last observational year were 
calculated. These costs included drug expenses and in-hospital costs. The cost of 
diagnostics, medical procedures, hotel services, and medical personnel are included into 
the integral in-hospital cost, based on data of the economic department of the National 
Cancer Institute. These costs reflect the approximation of costs for oncologic patients in a 
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As can be seen in Table 4.1, the highest cost per mg was for fludarabine, 
vincristine and rituximab. Rituximab and fludarabine (if Fludara was prescribed) had the 
highest price per average daily dose, equal to 312.03 EUR for fludarabine and 237.93 EUR 
for rituximab. As drug expenditures depend not only on cost per item, but also on total 
volume used, we present cost-items utilization and characteristics of population using it in 
Table 4.2.  
The data are presented for items that were used by more than 3% of patients. 
Cyclophosphamid, fludarabine and vincristine were prescribed to the largest percent of 
patients. Characteristics of the study population using specific cost items showed 
significant difference in the percent of males prescribed cyclophosphamide, mitoxantrone 
and chlorambucil in comparison to the other drugs. No significant difference in the 
patients' age was observed, although on average the age of patients receiving 
alemtuzumab was lower and those receiving chlorambucil was higher. From Table 4.2 also 
it may be observed that injectable form of fludarabine is prescribed significantly more 
than the oral form. 
���� �������� ������� ������ ���� �� ���������� ����� ���������� ���� ������ ����� ����
average cost of in hospital stay is equal to 542 EUR per person, resulting in total 
expenditures of 2,589 EUR. The research showed that expenses for drugs significantly 
exceeded hospitalization costs (t=5.026; Sig 2-tailed = 0.000). 
Mean total costs in the bootstrap analysis were equal to 2,584 EUR (median 
2,576, 97.5th percentile 3,223 EUR; 2.5 percentile – 1,987 EUR). Sex of the patient, number 
of years a patient lives with the disease, and age at the time of hospitalization, did not 
have a significant impact on the health care costs per patient. Hospital choice (Beta=-
0.260; Sig=.002) was a strong determinant of health care costs. One-way ANOVA also 
showed a significant difference in mean costs of two hospitals involved (Welch statistics 
19.222, p=0.000).   
The results of the multivariate sensitivity analysis showed that in the best-case 
(lowest cost) scenario the average annual spending on drug treatment of a CLL patient is 
1,659 EUR, and in the worst case scenario is 2,332 EUR. The deviation of drug costs does 
not exceed 12% on the negative side and 19% on the positive side. Annual cost of 
hospitalization ranges from 251 to 597 EUR per person and depends on the type of 
hospital at which a patient is treated.  
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Values of the cost items (drugs) and cost deviations for sensitivity test are 
presented in Table 4.1.  
 
Table 4.1 Price values of the drugs for the cost and sensitivity analyses 
Drugs* 
Base-case 
price( EUR 
per mg) 
Range used in 
sensitivity 
analysis, (EUR 
per mg) 
Source** 
Alemtuzumab (inj) 0.4500 - Tariff in governmental purchases 
2010 
Bleomycin (inj) 1.5100 1.5100-1.6300 ŝƐƚƌŝďƵƚŽƌƐ͛ƉƌŝĐĞ 
Chlorambucil 0.0080 0.0080-0.2290 Tariff in governmental purchases 
2010 
Cyclophosphamide 
(Adriablastine) 
1.0600 0.6700-1.4500 Price, registered in the MOH 
Cyclophosphamide (other 
generics) 
0.0077 0.0010-0.0120 Tariff in governmental purchases 
2010 
Dexamethasone (inj) 0.0200 0.0040-0.0840 Price, registered in the MOH 
Dexamethasone (po) 0.0002 - Price, registered in the MOH 
Doxorubicin (inj) 0.1300 0.1300-0.4400 Tariff in governmental purchases 
2010 
Etoposide phosphate (po) 0.1000 0.0980-0.1000 Price, registered in the MOH 
Fludarabine (Fludara inj.) 3.7400 3.2200-3.7400 Tariff in governmental purchases 
2010 
Fludarabine (Netran inj.) 0.7700 - Tariff in governmental purchases 
2010 
Fludarabine (Netran po.) 0.1500 - Tariff in governmental purchases 
2010 
Fludarabine (other generics) 2.7800 0.7600-3.3700 Price, registered in the MOH 
Methylprednisolone (inj) 0.1100 0.0140-0.1100 Price, registered in the MOH 
Methylprednisolone (po) 0.0260 0.0220-0.0300 Price, registered in the MOH 
Mitoxantrone (inj) 0.3800 0.3800-3.8300 Tariff in governmental purchases 
2010 
Prednisolone (inj) 0.0160 0.0130-0.0170 Price, registered in the MOH 
Prednisolone (po) 0.0072 0.0072-0.0077 Price, registered in the MOH 
Rituximab (inj) 2.0300 1.3500-2.9600 Tariff in governmental purchases 
2010 
Vincristine (inj) 3.6700 2.8600-4.0600 Tariff in governmental purchases 
2010 
Vinblastine (inj) 0.6300 0.4000-0.6300 Price, registered in the MOH 
* Trade name is indicated if the product was prescribed specifically by it 
** To value the use of the drugs from a healthcare perspective, we used a step-wise approach to determine an 
average price, depending on the availability of information: tariff in governmental purchases (2010); price 
registered in the Ministry ŽĨ,ĞĂůƚŚ͖ĚŝƐƚƌŝďƵƚŽƌƐ͛ƉƌŝĐĞ͘ 
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Discussion  
A literature review was conducted in the database PubMed to explore whether 
our results were consistent with results from studies in other countries and to understand 
if factors that impact cost of other cancer conditions are similar to those affecting CLL. The 
search was limited to a ten year period of English-language articles studying multiple-
cancer conditions. The literature review showed that the major factors influencing cost of 
ĐĂŶĐĞƌ ĐŽŶĚŝƚŝŽŶƐ ĂƌĞ ƌĞůĂƚĞĚ ƚŽƉĂƚŝĞŶƚƐ͛ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͕ ƐƵĐŚĂƐ ƐƚĂŐĞĂƚĚŝĂŐŶŽƐŝƐ ĂŶĚ
stage at treatment, degree of co-morbidity, age and gender of a patient and tumor site. 
Lal et al., Longo et al. (2006, 2007), and Yabroff et al. recorded increased costs due to 
higher stage of the disease during treatment [20-23]. Akushevich et al. in a retrospective 
analysis on oncologic patients in the USA, determined that the highest costs exist in the 
period of treatment immediately after diagnosis [24]. Yabroff et al. also recorded that 
both first and last stage of the disease at the time of treatment are associated with higher 
costs [23]. The results of the studies by Lal et al. and Kurse et al. [20,25] demonstrate a 
connection between the degree of comorbidity and treatment costs. The impact of 
patient's age on cost of cancer was significant in a number of studies, but differed in scale 
and type of impact [20-22; 24,25]. Some research described an impact of tumor site on 
total costs of the diseases [21,22,24]. Yabroff et al. showed that cost for treatment of 
localized diseases is lower, which is supported by the study of Lai et al. who note the 
highest costs of hematological malignancies among other types of cancer [23].  
Only two of the economic analyses describing an impact of factors on cost of 
treatment specifically for CLL were found. They showed a positive correlation between 
age and cost of drug treatment [26,6]. Danese et al. also concluded that male gender is 
associated with higher cost for CLL drugs treatment [26].  
Similar to the study by Stephens (2005) [16], cost of therapy was found to be the 
main driver for CLL treatment costs, significantly exceeding hospitalization costs. Despite 
previous research suggesting the major factors influencing cost of cancer conditions are 
stage at diagnosis and stage at treatment, degree of co-morbidity, age and gender, tumor 
site and type of the therapy received, our study on the Ukrainian sample from two 
specialized institutions showed only hospital choice had a significant impact on cost of 
drug treatment. A possible explanation may be risk-patient selection or difference in 
treatment practice within the hospitals. A high use of injectable forms of drugs as 
fludarabine and dexamethasone was also observed in the study. As no health technology 
assessment agency currently exists, there are no recommendations comparing injectable 
and oral forms developed in Ukraine. Nevertheless, NICE [27] recommends giving 
preference to oral form of fludarabine because of its higher efficiency. Rationality of 
injectable form of fludarabine use in CLL treatment practice may be a potential topic for 
further research in Ukraine. 
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Table 4.2 Drug utilization related to patients' population characteristics 
Drugs*  
Patients 
using the 
drug, % 
Average age 
of patients 
using this 
item (s.d.), 
years 
Males 
among 
ones who 
are using 
this drug, 
N (%) 
Prescriptions 
during the 
first year of 
treatment, N 
(%) 
Mean 
volume 
per 
patient 
(in mg) 
Alemtuzumab (inj) 
 
10.3 57.90 (9.25) 9 (60.00) 0 (0.00) 87.14 
Chlorambucil (po.) 
 
7.6 74.45 (4.61) 5 (45.50) 6 (54.5) 4.76 
Cyclophosphamide 
(inj. Adriablastine) 
 
4.8 64.29 (5.85) 6 (85.70) 4 (57.10) 7.24 
Cyclophosphamide (all 
brand names) 
 
66.2 62.95 (9.13) 59 (61.50) 29 (30.20) 2900.34 
Dexamethasone (inj) 
 
10.0 60.07 (8.71) 19 (65.50) 7 (24.10) 22.70 
Dexamethasone (po) 
 
5.4 59.20 (6.50) 3 (60.00) 1 (20.00) 4.41 
Fludarabine (Fludara 
inj.) 
 
44.4 60.56 (8.82) 36 (57.10) 13 (20.60) 377.87 
Fludarabine (po.) 
 
3.4 59.80 (8.35) 3 (60.00) 0 (0.00) 30.48 
Fludarabine inj (all 
brand names) 
 
47.6 60.65 (8.82) 40 (58.00) 13 (18.80) 411.79 
Methylprednisolone 
(po.) 
 
4.8 56.29 (10.42) 4 (57.1) 1 (14.3) 22.59 
Mitoxantrone (inj) 
 
5.5 58.12 (6.31) 7 (87.50) 0 (0.00) 4.35 
Prednisolone (inj) 
 
5.5 60.63 (10.64) 5 (62.50) 2 (25.00) 224.63 
Prednisolone (po) 
 
26.2 66.63 (8.07) 26 (68.40) 14 (36.80) 179.37 
Rituximab (inj) 
 
12.4 59.28 (6.72) 13 (72.20) 5 (27.80) 258.62 
Vincristine (inj) 31.0 64.51 (9.57) 34 (75.60) 17 (37.80) 1.66 
s.d.: standard deviation; inj. : injection ; p.o. : per os (oral) ; 
* Trade name is indicated if a product was prescribed not by generic, but by a trade name with a high frequency 
(for cyclophosphamide and fludarabine).  
80 Chapter 4
  
 
81 
 
Discussion  
A literature review was conducted in the database PubMed to explore whether 
our results were consistent with results from studies in other countries and to understand 
if factors that impact cost of other cancer conditions are similar to those affecting CLL. The 
search was limited to a ten year period of English-language articles studying multiple-
cancer conditions. The literature review showed that the major factors influencing cost of 
ĐĂŶĐĞƌ ĐŽŶĚŝƚŝŽŶƐ ĂƌĞ ƌĞůĂƚĞĚ ƚŽƉĂƚŝĞŶƚƐ͛ ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͕ ƐƵĐŚĂƐ ƐƚĂŐĞĂƚĚŝĂŐŶŽƐŝƐ ĂŶĚ
stage at treatment, degree of co-morbidity, age and gender of a patient and tumor site. 
Lal et al., Longo et al. (2006, 2007), and Yabroff et al. recorded increased costs due to 
higher stage of the disease during treatment [20-23]. Akushevich et al. in a retrospective 
analysis on oncologic patients in the USA, determined that the highest costs exist in the 
period of treatment immediately after diagnosis [24]. Yabroff et al. also recorded that 
both first and last stage of the disease at the time of treatment are associated with higher 
costs [23]. The results of the studies by Lal et al. and Kurse et al. [20,25] demonstrate a 
connection between the degree of comorbidity and treatment costs. The impact of 
patient's age on cost of cancer was significant in a number of studies, but differed in scale 
and type of impact [20-22; 24,25]. Some research described an impact of tumor site on 
total costs of the diseases [21,22,24]. Yabroff et al. showed that cost for treatment of 
localized diseases is lower, which is supported by the study of Lai et al. who note the 
highest costs of hematological malignancies among other types of cancer [23].  
Only two of the economic analyses describing an impact of factors on cost of 
treatment specifically for CLL were found. They showed a positive correlation between 
age and cost of drug treatment [26,6]. Danese et al. also concluded that male gender is 
associated with higher cost for CLL drugs treatment [26].  
Similar to the study by Stephens (2005) [16], cost of therapy was found to be the 
main driver for CLL treatment costs, significantly exceeding hospitalization costs. Despite 
previous research suggesting the major factors influencing cost of cancer conditions are 
stage at diagnosis and stage at treatment, degree of co-morbidity, age and gender, tumor 
site and type of the therapy received, our study on the Ukrainian sample from two 
specialized institutions showed only hospital choice had a significant impact on cost of 
drug treatment. A possible explanation may be risk-patient selection or difference in 
treatment practice within the hospitals. A high use of injectable forms of drugs as 
fludarabine and dexamethasone was also observed in the study. As no health technology 
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injectable form of fludarabine use in CLL treatment practice may be a potential topic for 
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Table 4.2 Drug utilization related to patients' population characteristics 
Drugs*  
Patients 
using the 
drug, % 
Average age 
of patients 
using this 
item (s.d.), 
years 
Males 
among 
ones who 
are using 
this drug, 
N (%) 
Prescriptions 
during the 
first year of 
treatment, N 
(%) 
Mean 
volume 
per 
patient 
(in mg) 
Alemtuzumab (inj) 
 
10.3 57.90 (9.25) 9 (60.00) 0 (0.00) 87.14 
Chlorambucil (po.) 
 
7.6 74.45 (4.61) 5 (45.50) 6 (54.5) 4.76 
Cyclophosphamide 
(inj. Adriablastine) 
 
4.8 64.29 (5.85) 6 (85.70) 4 (57.10) 7.24 
Cyclophosphamide (all 
brand names) 
 
66.2 62.95 (9.13) 59 (61.50) 29 (30.20) 2900.34 
Dexamethasone (inj) 
 
10.0 60.07 (8.71) 19 (65.50) 7 (24.10) 22.70 
Dexamethasone (po) 
 
5.4 59.20 (6.50) 3 (60.00) 1 (20.00) 4.41 
Fludarabine (Fludara 
inj.) 
 
44.4 60.56 (8.82) 36 (57.10) 13 (20.60) 377.87 
Fludarabine (po.) 
 
3.4 59.80 (8.35) 3 (60.00) 0 (0.00) 30.48 
Fludarabine inj (all 
brand names) 
 
47.6 60.65 (8.82) 40 (58.00) 13 (18.80) 411.79 
Methylprednisolone 
(po.) 
 
4.8 56.29 (10.42) 4 (57.1) 1 (14.3) 22.59 
Mitoxantrone (inj) 
 
5.5 58.12 (6.31) 7 (87.50) 0 (0.00) 4.35 
Prednisolone (inj) 
 
5.5 60.63 (10.64) 5 (62.50) 2 (25.00) 224.63 
Prednisolone (po) 
 
26.2 66.63 (8.07) 26 (68.40) 14 (36.80) 179.37 
Rituximab (inj) 
 
12.4 59.28 (6.72) 13 (72.20) 5 (27.80) 258.62 
Vincristine (inj) 31.0 64.51 (9.57) 34 (75.60) 17 (37.80) 1.66 
s.d.: standard deviation; inj. : injection ; p.o. : per os (oral) ; 
* Trade name is indicated if a product was prescribed not by generic, but by a trade name with a high frequency 
(for cyclophosphamide and fludarabine).  
Cost for treatment of chronic lymphocytic leukemia in specialized institutions of Ukraine 81
  
 
83 
 
We conducted a linear regression analysis on logarithmic transformed costs data 
while excluding six outůŝĞƌƐ ďĂƐŝŶŐ ŽŶ ŽŽŬ͛Ɛ ĚŝƐƚĂŶĐĞ͘ >ĞĂǀŝŶŐ ŽƵƚƐŝĚĞ ƚŚĞƐĞ Ɛŝǆ
observations might increase significance of the statistical analysis and strength of the 
relation between the independent variable (hospital choice) and dependent variable 
(healthcare costs). 
 
Conclusions 
Drug treatment comprises the largest portion of total costs, which presumably 
may be a high economic burden for a CLL patient who is the major payer of treatment 
expenses in Ukraine. Costs of drug treatment significantly depended on type of the 
hospital selected.  
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Ukraine is a country with a post-Semashko model of the healthcare system. 
Currently there is no state reimbursement system implemented in Ukraine. However, 
limited reimbursement for in-hospital treatment is provided under governmental 
programs for such diseases as AIDS, tuberculosis, diabetes, cardiovascular diseases and 
ĐĂŶĐĞƌ͘dŚĞƐĞŝŶŚŽƐƉŝƚĂůƐƚĂƚĞƉƵƌĐŚĂƐĞƐĐŽǀĞƌĨƌŽŵϳƚŽϰϬйŽĨŽŶĐŽůŽŐŝĐƉĂƚŝĞŶƚƐ͛ŶĞĞĚƐ
depending on the region and hospital type [28,29]. Major expenses on drugs are covered 
ďǇƉĂƚŝĞŶƚƐ͛ŽƵƚŽĨƉŽĐŬĞƚƉĂǇŵĞŶƚs. Thus, high cost of treatment of chronic conditions, 
such as CLL, may be a significant economic burden, especially for patients with low 
income.  
The average annual cost of drug treatment for CLL patient is 2,047 EUR, with the 
majority of costs paid out-of-pocket. From the first of December, 2011, the minimum 
annual subsistence level in Ukraine is equal to 1,155 EUR for people of working age and 
920 EUR for the retired population. This number is lower than annual costs of drug 
treatment for patients with CLL in Ukraine, according to current clinical practice in 
specialized hospitals. This may mean possible significant economic impact of the disease 
on vulnerable populations (e.g. elderly poor), taking into the account only limited 
governmental subsidy. With high costs for treatment of hematologic malignancies [15,26], 
and insufficient reimbursement level for drug treatment in Ukraine [9], treatment of CLL in 
specialized hospitals may be financially difficult for economically-unprotected patients 
because of high therapy costs.  
Implications 
Our analysis indicates that there is likely to be a significant difference in 
treatment practice of CLL within different hospitals of Ukraine resulting in a significant 
deviation in drug expenditures. Therefore, it is not clear if treatment standards are 
followed within the hospitals and if the schemes used are evidence-based and rational. 
These issues should be explored further in future studies. 
Limitations 
Retrospective analysis allowed us to make an estimation of treatment costs for 
CLL in specialized medical institutions of Ukraine and to explore its correlation with 
patient characteristics. However, our research suffered from several limitations. 
The conducted research does not allow us to assess economic burden of CLL in 
Ukraine. It is expected that costs of treatment in the current study may be higher than in 
ƚŚĞ ƌĞŐŝŽŶĂů ŽŶĐŽůŽŐǇ ĚŝƐƉĞŶƐĂƌŝĞƐ ďĞĐĂƵƐĞ ŽĨ ůĂƌŐĞƌ ƐƚĂƚĞ ƐƵďƐŝĚŝĂƌŝĞƐ ĂŶĚ ƉĂƚŝĞŶƚƐ͛
expenditures on drugs. 
Moreover, data on stage of the patient's disease and health state on ECOG 
criteria were missing and thus excluded from the factor list; however, these parameters 
may have a potential impact on CLL costs.  
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Introduction 
Infertility is a common problem in many countries. In Central and Eastern 
European and Central Asian regions, countries report high rates of abortions, while at the 
same time displaying higher levels of secondary infertility (females with previous life 
births). Additionally, the prevalence of primary infertility (females with no previous life 
births) is significantly higher in Ukraine than in other countries of the region, reaching a 
level equal to or above 3% of the female population [1].  
Despite an increasing medical demand for infertility treatments, public funding 
challenges for in vitro fertilization (IVF) exist in a number of jurisdictions. While some 
countries (such as France, Spain and Israel) provide full coverage of IVF treatments as a 
matter of policy, others either partially cover expenses (e.g. Portugal, Sweden, Turkey), or 
fail to cover it at all (e.g. India, China) [2]. Meanwhile, when coverage for IVF is absent or 
incomplete -- as exists throughout the United States – it may lead to cases where IVF 
treatments are unaffordable to couples who need it most.  
Moreover, and of particular interest from a governmental perspective, a number 
of economic studies have concluded that there are long-term financial benefits to be 
gained from creating new citizens who will eventually become future taxpayers. The cost-
efficiency of state investments in IVF is assessed by calculation of net income, usually 
expressed through taxes and other state revenues received from the working population. 
Economic evaluations revealed that there were net tax benefits of IVF financing in both 
high-income countries (e.g. USA, UK, Denmark, Sweden) [3-7] and medium-income 
countries like Brazil [8]. Net income gained from the IVF populations in all countries 
studied was positive, however the largest gain was found for the UK (£109 939), while the 
smallest gain was found for Brazil (US$ 61 428). 
While encouraging, these results may not be easily used in the decision making 
process in other countries [9], such as those of the Central and Eastern European (CEE) 
region. Besides putative differences in healthcare systems and population characteristics, 
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medical technologies. For example, in lower-income countries, costly medical technologies 
potentially may be less cost efficient than they would be in higher-income countries. 
Countries of the CEE region have, on average, a much lower Gross Domestic Product (GDP) 
than their Western European or North American counterparts; thus, the generalizability 
may be questionable for economic studies on IVF subsidies from high-income countries 
(like the USA and the UK) to lower-income jurisdictions. 
Finally, the economic impact for the population (expressed as the difference 
between state spending and economic benefits), may not be directly proportional to the 
GDP, depending more on internal policy of the country, such as tax level, social 
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Abstract 
An economic value calculation was performed to estimate the lifetime net present value 
of in-vitro fertilization (IVF) in Ukraine, Belarus, and Kazakhstan.  
Net lifetime tax revenues were used to represent governmental benefits accruing from a 
hypothetical cohort of an IVF-population born in 2009 using the methodology of 
generational accounting. Governmental expenses related to this population included 
social benefits, education and healthcare, unemployment support and pensions. Where 
available, country-specific data referencing official sources were applied.  
The average healthcare cost needed to achieve one additional birth from the 
governmental perspective varied from $2,599 in Ukraine to $5,509 in Belarus. The net 
present value from the population born using IVF was positive in all countries: for Ukraine 
($9,839), Belarus ($21,702), and Kazakhstan ($2,295). The break-even costs of drugs and 
supplies per IVF procedure is expected to be $3,870, $8,530 and $1,780, respectively. 
Probabilistic sensitivity analyses based on 5000 simulations show that the average net 
present value per person remains positive: $1,894 (s.d. $7,619), $27,925 (s.d. $12,407) 
and $17,229 (s.d. $24,637) in Ukraine, Belarus, and Kazakhstan, respectively.  
Financing IVF may represent a good investment in terms of governmental financial returns 
even in lower-income countries with state-financed healthcare systems such as Ukraine, 
Belarus and Kazakhstan.   
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Similar to Connolly et al. [4-6] and Kröger et al. [8], the following formula was 
applied for assessing the NPV of lifetime net taxes: 
 
  =∑( −�� + � ) − ��=0  
 
Where: 
Rt = sum of the governmental revenues from individuals age t 
Et = sum of the governmental expenditures from individuals age t 
r = discount rate 
T = life expectancy 
K0 = direct IVF costs.  
As NPV is used to estimate how much future returns from the investment are 
worth today, NPV > 0 represents profitable investment, NPV = 0 represents investment 
that is neither profitable nor unprofitable, and NPV < 0 represents unprofitable 
investment [7]. 
IVF costs and outcome 
Base-case scenario 
Applying IVF success rates, the costs per IVF-born cohort and cost per live birth is 
calculated. Because Belarus specific data for this parameter were not available, it was 
assumed in the base case that the success of IVF was equal in all three countries to 31.9% 
on average (success rate of IVF for 35-37-year old women based on the data of SART 
summary report on 154,412 cycles conducted during the year 2011) [10]. The percentage 
of boys born as a result of intervention was assumed to be equal to the naturally-born 
cohort and was assessed from data on sex ratios (51.70%, 51.5%, and 48.5% boys born in 
Ukraine, Belarus, and Kazakhstan, respectively) [11-13]. 
Country-specific state-registered prices were used to assess costs of drugs and 
medical supplies, while the need in quantities of the defined medical products per one IVF 
cycle was assessed from the National State reproductive program in Ukraine (and 
considered to be similar for Belarus and Kazakhstan) [14-16]. 
Despite all three countries providing universal free healthcare, country-specific 
pregnancy-related costs are unknown and, for this reason, medical care expenditures 
were accounted using costs per outpatient (during IVF procedures and pregnancy) and 
inpatient (delivery) visits by WHO-CHOICE estimates [17]. The average number of visits 
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contributions, net revenues from public enterprises, and so on. Thus, financing of IVF also 
may be cost-efficient for governments of countries with relatively low GDP per capita 
level. For example, while having universal healthcare coverage and free access to medical 
procedures for their respective populations, governments in former Soviet Union 
countries (such as Ukraine, Belarus, Kazakhstan) do not consider IVF a priority and, thus, 
provide only limited, insufficient funds for its coverage.  However, economic analysis may 
be a justification for reexamining their policies where IVF coverage is concerned. 
With the above discussion as a rationale, the present study was conducted to: (1) 
assess the economic cost and benefits of financing IVF technologies (one cycle per 
woman) in Ukraine, Belarus and Kazakhstan from the governmental perspective; (2) 
explore relations between GDP per capita and level of financial impact on the population; 
and (3) address transferability of the received results to other countries of CEE region.  
 
Methods 
Model Design 
Similar to previous studies, an economic model using the methodology of 
generational accounting was developed to estimate for Ukraine, Belarus and Kazakhstan 
whether publicly funded IVF treatments result in a financial benefit, by calculating the net 
revenue gained from a child conceived via IVF in each country [3-8]. Generational 
accounting evaluates whether there will be sufficient tax revenue in the future to pay for 
current investments into IVF programs by calculating the net present value (NPV) of 
lifetime net taxes (gross taxes minus financial expenditures of the government on 
population). Because taxation remains the main source of revenue for most states [5], 
using this applied approach provides an appropriate assessment of rationality for IVF 
investments by the governments. 
In the model we defined five stages during which populations have different 
expenses and revenues: i) prenatal; ii) early childhood (from birth until school); iii) late 
childhood (period when individual receives education including high school); iv) 
employment; and v) retirement. The prenatal stage includes costs of IVF procedures. 
During the childhood stage the cohort is a receiver of financial flows from the state that 
consists of social support, sick leave payments, medical help and education financing. 
During the employment period, the population provides revenue to the state in the form 
of tax payments, but also receives unemployment support and medical help. After 
retirement, the employment rate decreases, likewise tax contribution, but pension and 
healthcare are provided until the end of life. For each age category, state spending and 
income from population are calculated.  
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In the model, people receive healthcare services throughout their lives and 
educational services from 0 to 19 years. Average expenses of governmental support for 
unemployed were calculated using official unemployment rates among population of 
working age, coverage with financial support for unemployed, duration of unemployment 
and the amount of financial support.  
From retirement until death the population receives a pension from the 
government. Because data on disability prevalence was unavailable, no additional costs 
besides those associated with regular healthcare were accounted. 
State income 
Government revenue accrues from income tax on population of working age or 
from the aged population who continue to work and pay taxes. As no age-stratified 
income is available for the study countries, average salary and tax rates were applied for 
the entire lifetime of the cohort.  
Though governments receive additional revenue from other sources (e.g., land taxes, 
business and enterprise payments, social contributions), income taxes are argued to be 
the largest part of state revenues; therefore, the impact of population increase on state 
income was assessed as direct taxes from salaries on official employment. No country-
specific data was available bearing on a relationship between age and income, thus 
average salaries, taxes and employment rates were applied to calculate the income from 
the working-age population. Moreover, a percentage of the retired population who are 
officially employed was used to calculate additional income from this group. 
Other input parameters of the model 
Life expectancy at birth for children born in 2009 was applied [20]. All costs 
provided in the national currencies were transferred into US$ according to the National 
Banks exchange rates on November 22, 2014. Rate per 1$ was equal to 15.096 UAH 
(Ukraine), 10780.00 BYR (Belarus) and 180.87 KZT (Kazakhstan). State expenses before 
birth of the IVF cohort were adjusted to current prices (2014) using the inflation index for 
consumer prices [21]. Governmental payments and incomes were assumed to grow 
annually with the rate of annual GDP growth [22] while being discounted at 3% in the 
deterministic model. The complete list of model input parameters together with full 
reference list are provided in Appendix 5.1.  
Validity of the model 
The parameters possible for state regulation were varied in one-way sensitivity 
analysis with break-even costs calculation. Subcategory analysis for women of different 
age categories presenting variations in IVF success rates was conducted to analyze an 
impact of IVF success rate on the results of economic analysis and, moreover, to assess 
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during one IVF cycle was calculated assuming the following referrals: first appointment (1 
visit), preparation (1), initiation (1), visits during treatment with fertility medications (5 
visits), egg harvesting (1), embryo transfer (1), consultation (1). Nine monthly visits to 
gynecologists and three hospitalization days were accounted for during pregnancy and 
delivery. 
Although IVF procedures frequently result in multiple births, only one-child 
pregnancy was assumed in the base-case scenario. Moreover, while during early perinatal 
stage IVF children may require more medical assistance, in the life-duration model used 
here children conceived with IVF were considered to be comparable to those conceived 
naturally.  
Country-specific scenario 
IVF-success data and rates of multiple deliveries due to IVF were used to 
understand if these country-specific parameters have a significant impact on the results. 
The following assumptions were used in this scenario:   
1. The birth rate from IVF procedure was calculated from data on IVF success rate and 
multiple pregnancies from the study conducted by Kupka et al. [18];  
2. Because of the low incidence of triple births (1% for both Ukraine and Kazakhstan) [18] 
this parameter was accounted together with dual births  
3. Because no Belarus-specific data were available, the rate of births due to IVF was 
calculated as an average in Russia, Belarus, Kazakhstan [18];  
4. Negative health impact and higher costs associated with multiple pregnancies included 
the following: 
- Higher probability to die during neonatal period (6.4 times) [19]; 
- Higher medical costs during the first year of life (the calculated cost ratio between single 
and dual births - 3.29) [19]; 
- Doubled payments for "maternity support" because of multiple births. 
State expenses on population 
In all three analyzed countries child benefits are provided to the families of 
newborns. The first-child allowance was accounted in all of the cases, as it was considered 
that IVF is applied by childless families. It was also considered that one parent is not 
employed, thus receives monthly financial support for three years in Belarus 
($82.10/month) and Ukraine ($16.26/month) and for one year in Kazakhstan 
($214.2/month) as ensured by state policies in these countries (Estimation was made by 
the data of Labor informational resource, http://mojazarplata.by; http://mojazarplata.kz; 
mojazarplata.com.ua; accessed 16/08/2013). Basing estimates on data from accounting 
departments in three companies (two in Ukraine and one in Kazakhstan, 485 employees 
total), it was considered that mothers spend 15 sick leave days paid by the government 
annually (per child from 3 to 6 years) and 10 days per child aged 7 to 12 years.  
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Results 
 The observed cost variation for different schemes of IVF cycles applied resulted in 
a difference in average cost per cycle, with the lowest one observed in Ukraine ($732 per 
cycle) and the highest one in Belarus ($1,607 per cycle).  
 Using a similar IVF success rate, the average cost of one IVF birth from the 
governmental perspective varied from $2,599 in Ukraine to $5,509 in Belarus (see Table 
5.1).  
 
 
Figure 5.1 Projected net present value for IVF-conceived child in Ukraine, Belarus and 
Kazakhstan 
Projected lifetime net revenues from the IVF cohort are illustrated in Figure 5.1, 
where changes in NPV depending on the age of IVF cohort are observed. While in the early 
ƐƚĂŐĞƐ ŽĨ ĂŶ ŝŶĚŝǀŝĚƵĂů͛Ɛ ůŝĨĞ ŶĞƚ ŵŽŶĞƚĂƌǇ ĨůŽǁƐ ĂƌĞ ŶĞŐĂƚŝǀĞ ĨŽƌ ƚŚĞ ŐŽǀĞƌŶŵĞŶƚ --
education, health and social support are provided to the family by state without financial 
returns -- ĚƵƌŝŶŐƚŚĞǁŽƌŬŝŶŐǇĞĂƌƐ͕ƚŚĞŝŶĚŝǀŝĚƵĂů͛ƐĨŝŶĂŶĐŝĂůďĂůĂŶĐĞƚŝƉƐƉŽƐŝƚŝǀĞĨŽƌƚŚĞ
government, as state revenue is collected as tax payments and lower social expenses are 
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the possible implication of limiting financing for different groups. As drug costs are 
frequently negotiable, the impact of changes in IFV expenses on NPV was assessed. 
Additionally, one-way sensitivity analyses with 0% to 10% discounting were conducted.  
Probabilistic sensitivity analysis (PSA) on the most influential parameters with 
5000 simulations was conducted to ensure the validity of the calculation. Because the aim 
of PSA was to assess the uncertainty related to long duration of the model (cohort 
lifetime), the prenatal parameters which potentially can be controlled by the government 
(i.e., age of mother and IVF costs) were excluded from this assessment. Moreover, the IVF 
success rate was varied in the PSA to address the uncertainty of the procedure success. 
Costs included in the early-childhood period were not varied in PSA because of the low 
impact on a lifetime model and no data on deviation parameters. A number of prognostic 
factors (such as a possible tax decrease in Ukraine, prolongation of the retirement age to 
the average in OECD region for all three countries) were assessed from publicly available 
information sources describing current political trends that may affect model results. 
Because healthcare expenditures already are relatively low in the study countries, it was 
assumed they may only increase from current values or remain the same. If multiple data 
sources were available, the source providing the largest data deviation was used. The 
complete range of parameters and the distributions used in the PSA are presented in the 
Appendix 5.1. 
Table 5.1 Neonatal costs of IVFa population in Ukraine, Belarus, and Kazakhstan 
Parameter Ukraine Belarus Kazakhstan 
Drugs and 
supplies 
costs 
Option 1 IVF drugs costs per cycle (47% 
cycles), $ 
741 1,795 927 
Option 2 IVF drugs costs per cycle (43% 
cycles), $ 
538 1,129 1,243 
Option 3 IVF drugs costs per cycle (10% 
of cycles), $ 
782 1,902 905 
Medical supplies costs per cycle, $ 75 88 79 
Average drugs and supplies costs, per 1 
cycle, $ 
 
732 1,607 1,049 
Health Care expenditures per 1 IVF cycle, $ 48 58 147 
Health care pregnancy and delivery expenditures, per 1 
birth, $ 
153 287 409 
Average costs needed to receive 1 IVF birth, $ 2,599 5,509 4,157 
aIVF – in-vitro fertilization 
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the possible implication of limiting financing for different groups. As drug costs are 
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Table 5.1 Neonatal costs of IVFa population in Ukraine, Belarus, and Kazakhstan 
Parameter Ukraine Belarus Kazakhstan 
Drugs and 
supplies 
costs 
Option 1 IVF drugs costs per cycle (47% 
cycles), $ 
741 1,795 927 
Option 2 IVF drugs costs per cycle (43% 
cycles), $ 
538 1,129 1,243 
Option 3 IVF drugs costs per cycle (10% 
of cycles), $ 
782 1,902 905 
Medical supplies costs per cycle, $ 75 88 79 
Average drugs and supplies costs, per 1 
cycle, $ 
 
732 1,607 1,049 
Health Care expenditures per 1 IVF cycle, $ 48 58 147 
Health care pregnancy and delivery expenditures, per 1 
birth, $ 
153 287 409 
Average costs needed to receive 1 IVF birth, $ 2,599 5,509 4,157 
aIVF – in-vitro fertilization 
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significantly. A possible explanation of the small impact of higher-cost IVF children stems 
from the positive economic impact of the individual in general. As such, higher frequency 
of multiple births in IVF population compensates for the additional expenses related to IVF 
newborns and the higher mortality during neonatal stage. 
The PSA based on 5,000 simulations shows that the average NPV per person 
remains positive: $1,894 (s.d. $7,619), $27,925 (s.d. $12,407) and $17,229 (s.d. $24,637) in 
Ukraine, Belarus and Kazakhstan, respectively. At the same time, the ranges and standard 
deviations for Ukraine and Kazakhstan indicate that under some circumstances (meaning 
of inputs) financing of IVF can become negative for these countries. 
Table 5.3 One-ǁĂǇƐĞŶƐŝƚŝǀŝƚǇĂŶĂůǇƐŝƐ ;ŵŽƚŚĞƌƐ͛ĂŐĞ͕ /s&a drugs costs, and discounting 
rate) 
 
Scenario  
Lifetime NPVb($) 
Ukraine Belarus Kazakhstan 
 
DŽƚŚĞƌƐ͛ĂŐĞ 
NPV of IVF conceived child, mother age < 35 years 
(40.1% of success rate) 
 
10,339 
 
22,770 
 
3,061 
NPV of IVF conceived child, mother age 38-40 years 
(21.6% of success rate) 
8,673 19,212 507 
NPV of IVF conceived child, mother age 41-42 years 
(12.2% of success rate) 5,890 13,270 Negative 
NPV of IVF conceived child, mother age >42 years 
(4.2% of success rate) 
 
/s&ĚƌƵŐƐ͛ĐŽƐƚ 
Negative Negative Negative 
Cost of IVF drugs, 50% increase 8,691 19,183 650 
Cost of IVF drugs, 100% increase 7,544 16,663 Negative 
Break even cost of IVF drugs and supplies per one 
cycle, $ 3,870 8,530 1,780 
Cost of pregnancy and delivery, 50% increase 
 
Discounting rate 
9,782 21,583 2,150 
Discounting rate, 0% 10,986 Negative Negative 
Discounting rate, 5%       1,544 13,907 1,826 
Discounting rate, 10% 
 
      Negative Negative Negative 
aIVF – in-vitro fertilization; bNPV – net present value 
 
The results of one-way sensitivity analysis (Table 5.3) shows a positive NPV until 
���� �����������������������������������������������������������������������������������-
even age of the mother (age at which financing IVF remains economically beneficial for 
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paid. Advancing in age, individuals begin to provide less revenue to the state while 
simultaneously receiving increased social spending, primarily because of pension 
payments.  
Because the net revenue positions for an IVF- and a naturally-conceived child 
follow similar trajectories, where the only difference between the two is the additional 
cost of IVF investment required for conception, the graph presents the NPV for an IVF-
conceived individual only. In light of the observed difference in expenses on population in 
the three study countries, IVF may be considered an attractive economic option in 
Ukraine, Belarus and Kazakhstan with discounted NPVs of $9,839, $21,702 and $2,295, 
respectively (see Table 5.2).  
Table 5.2 Cost and income of IVFa-conceived population in Ukraine, Belarus, and 
Kazakhstan  
Scenario 
Lifetime NPVb*($) 
Ukraine Belarus Kazakhstan 
 
Expenses  
Social (maternity) support and 
sick leaves, $ 
2,976 
 
5,734 5,700 
Education, $ 4,045 6,021 7,050 
Health Care costs, $ 7,617 35,463 42,024 
Unemployment, $ 31 2.17 52,342 
Pension, $ 8,881 55,852 45,125 
Total state expenses on IVF 
population, $ 
 
26,150 106,580 104,108 
Revenue  
Revenue from population, $ 37,687 128,282 106,403 
Net income 
Net present value of IVF, $ 9,839 21,702 2,295 
Net present value of IVF in 
country-specific scenarios, $ 
8,879 21,139 2,040 
aIVF – in-vitro fertilization; bNPV – net present value; * - average per one birth. 
 
When country-specific IVF birth rates were applied in the model considering both 
IVF success rate and multiple pregnancies (Table 5.2), the results did not change 
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Meanwhile, it also may be assumed that state income from population may not be related 
ůŝŶĞĂƌůǇ ƚŽ ƚŚĞ ĐŽƵŶƚƌǇ͛Ɛ ǁĞĂůƚŚ ŝŶ ŐĞŶĞƌĂů ŝŶ ĐƌŽƐƐ-country comparisons, because of 
differences in taxation policies and government spending.  
Another interesting conclusion resulted from the probabilistic model applied, in 
which we tried to account for possible changes of the input parameters that may be 
expected during the long run of the model (lifetime of the IVF cohort). While applying the 
individual prognostic factors for each country, it appeared that the NPV in the probabilistic 
model may differ from the deterministic model, a finding explained by differences in 
economic forecast for a long time horizon. Moreover, opposite the deterministic model, 
the NPV of the IVF population may be higher in Kazakhstan than in Ukraine, if changes in 
the taxation policy (which are currently under political discussion) will be applied in the 
future. Because of the long horizon of generational accounting models we suggest that it 
is obligatory to apply PSA in order to define stability of the received results under 
conditions of possible political and economic change.  
The sensitivity analysis with the 0% discount rate has shown inaccuracy of using 
this value in a life-duration model based on generational accounting.  The assumption in 
the model that annual expenses increase proportionally to GDP makes the expenses on 
the retired population inaccurately higher than on the working population in countries 
with larger values for pensions and GDP growth. 
The generational accounting framework from the governmental perspective used 
in this model assesses costs and benefits attributed to conceiving an IVF child as an 
investment required to achieve a live birth with consequent long-term economic returns. 
This economic model was used to assess cost efficiency of state investments in countries 
with nationally-funded health services (Ukraine, Belarus, and Kazakhstan) where both 
investments (financing IVF procedures) and returns (tax received) will present a financial 
flow between two stakeholders, population and state. This model may be potentially 
applied to other countries with similar political, economic and healthcare structures, 
where major state revenues are expected to come from tax payments (such as Russia, 
Georgia, or Azerbaijan). While results of the current study showed positive economic 
balance with stability of the received results by PSA in Ukraine, Belarus and Kazakhstan, 
the transferability of the model to other countries of the region may be assessed in the 
future. 
In most western European countries a complete IVF treatment consists of a 
maximum of three IVF cycles, where treatment choices for each cycle can differ. In a cost-
ĞĨĨĞĐƚŝǀĞŶĞƐƐĂŶĂůǇƐŝƐƌĞĨůĞĐƚŝŶŐƚŚĞ͞ƌĞĂů-ǁŽƌůĚ͟situation conducted in the Netherlands, it 
was found that combining several transfer policies was not cost-effective, and so the 
single-choice treatment option should be preferred: elective single embryo transfer, 
standard treatment policy or double embryo transfer [24].  
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the government) is 38-40 years. The costs of IVF drugs and supplies impact significantly 
the results of the economic analysis. A negative NPV was obtained using a discount rate of 
10% in all three countries, as well as with a discount rate of 0% in Belarus and Kazakhstan.  
In the PSA with a fixed 0% discount rate a negative NPV was obtained for Ukraine 
and Kazakhstan ($19,962, s.d. $ 33,263 and $44,084, s.d. $89,815, respectively) and 
positive for Belarus ($24,328,s.d. $ 63,580). The instability of these results is indicated by 
the value of the standard deviation, which exceeds the average value.  
 
Discussion  
The results presented in this article show how public financing of IVF in three 
former Soviet Union countries (Belarus, Kazakhstan and Ukraine) will generate a positive 
return to the state in future tax contributions. Understanding the financial benefits from 
medical technologies not related to life-saving technologies is especially important in 
jurisdictions where financial resources are limited, such as in low- and middle-income 
countries like Ukraine, Belarus and Kazakhstan. Economic evidence in terms of cost 
minimization or budget impact techniques may be applied to rationalize financing a 
limited number of IVF cycles, or to define an intent-to-treat patient population. While in 
Belarus nearly 600 children were born via state-financed IVF treatments [23], Ukraine [16] 
and Kazakhstan together report just about 600 IVF cycles to be state financed (personal 
communication), although in Kazakhstan this number is expected to rise in 2015. The 
present research shows that financing IVF may have a positive NPV, not only in high-
income but also in lower-income countries. Based on the average cost per child conceived 
with IVF in a state clinic and using current levels of financial flows between populations 
and governments of Ukraine, Belarus and Kazakhstan, the discounted returns to state all 
were positive over the projected lifetime of an individual, with higher uncertainty of 
results for Ukraine and Kazakhstan. A higher NPV from financing IVF in Ukraine, Belarus 
and Kazakhstan can be achieved by limiting coverage of the procedure to women of 
younger age and by negotiating lower prices with IVF drug suppliers.  
In Western European countries and Brazil the discounted NPV of IVF ranged from 
$61,428 (Brazil) to $177,002 (UK; exchange rate 1 pound = US $ 1.61 on 09.09.2014), while 
in the countries of the CEE region studied here the financial returns to the state were 
significantly lower, though still positive [3-8]. However, an interesting observation from 
this study is that the NPV derived from an IVF population may not always be proportional 
to the income level of the country, expressed in GDP per capita. For example, the lowest 
financial return in the present study was observed in the country with the highest GDP per 
capita, Kazakhstan. It should be noted that GDP per capita is not always the best approach 
ĨŽƌ ĞǀĂůƵĂƚŝŶŐ ƚŚĞ ŝŶĐŽŵĞ ŽĨ Ă ĐŽƵŶƚƌǇ͛Ɛ ƉŽƉƵůĂƚŝŽŶ͕ ĂƐ ǁĞĂůƚŚ ĐĂŶ ďĞ ĚŝƐƚƌŝďƵƚĞĚ
unequally, an especially common case in countries with a developing economy. 
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cycles) has shown that the most cost-effective and least cost-effective scenarios occurred, 
respectively, with younger and older women who received three or more cycles, in the 
move from one embryo transfer to two embryo transfers [25]. Meanwhile, in the current 
study we assessed only two scenarios: a) expenses and incomes related to one birth only 
with the IVF success rate aiming at the minimum budget impact for the intervention 
financing; b) expenses and incomes related to IVF birth according to the current countries 
data on multiple births and cycle success rate. Accounting cost-efficiency of different IVF 
procedures in future studies may show increases in state benefits from IVF financing. 
Limitations 
While taxation-based income may represent a reasonably accurate means of 
estimating future economic benefits for the state, it should be noted that population also 
contributes to other financial governmental flows, such as trade and enterprise 
development, which was not accounted for in the current model. The model also did not 
account for possible emigration of people to other countries. This may particularly affect 
the results of economic studies in Belarus, where the unemployment rate is assessed by 
the number of people receiving unemployment support from the government.  
The model accounts for linear increases in spending and earning, based on 
�������� ������� ����� �� �������������� ����������� ����������� ��� ���� ����������� ������
parameters. As a consequence, the impact of unpredictable economic crises or growth 
also was not accounted for in the evaluation. Another model limitation is that the 
calculation applied average earnings in the population, ignoring the possibility of wealthier 
generations in the future. 
While the return of state investments was assessed from the narrow 
governmental perspective using only future net tax contributions, we may consider that 
with the broader assessment of net marginal contributions from individuals the net state 
benefit from IVF-conceived children will present an even more attractive economic option. 
 
Conclusion 
The results of this study may have implications for IVF reimbursement policy not 
only in Ukraine, Belarus and Kazakhstan, but in other settings with comparable 
populations and financial flows between population and governments – particularly those 
which may be considering universal coverage for fertility treatments. While income from a 
population may not be directly proportional to GDP per capita, it appears that financing 
IVF technologies collectively may represent a promising potential for state financial 
returns. 
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Appendix 5.1 Input parameters in deterministic and probabilistic models 
Parameter Country Deterministic 
value 
Minimum 
meaning 
Maximum 
meaning 
Reference 
GDP, $ Ukraine  3,615 2,985.5 7,600 1-3 
Belarus 6,480 5,820 16,000 1,3,4 
Kazakhstan  11,356 11,356 13,900 1,3 
GDP growth, % Ukraine  4.03 0.20 5.20 5,6 
Belarus 7.74 4.30 7.74 5,6 
Kazakhstan  7.46 1.2 8.9 5 
Total tax rates as % from the 
salaries 
Ukraine  55.36 33.60 55.36 7 
Belarus 47.54 42.79 52.29 8 
Kazakhstan  31.00 31.00 37.20 9 
Average monthly salary for 
males, $ 
Ukraine  379.37a 289.75 637.91  2 
Belarus 483.94 a 421.49 620.14  10,11 
Kazakhstan  779.00 b 598.85 1,564.53 12-14 
Average monthly  salary for 
females, $ 
 
Ukraine  301.73 a 230.45 507.35  2 
Belarus 384.90 a 335.22 439.22 10-12 
Kazakhstan  410.85 b 315.77 824.98 13-15 
Average monthly pension, $ Ukraine  129.24 104.84 145.72 2,16,17 
Belarus 219.94 99.32 228.44 11,12 
Kazakhstan  240.24 192.19 269.07 18 
Average monthly 
unemployment support, $ 
 
 
Ukraine  82.02 c 68.06 103.22  2,16,17 
Belarus 17.00  c 13.33 20.00 19 
Kazakhstan  119.72d 95.78 143.66 20 
  
102 
 
21. Inflation, consumer price (%). The World Bank. Available from: 
http://data.worldbank.org/indicator/FP.CPI.TOTL.ZG. [Assessed on 23 November 2014]. 
22. GDP growth (annual %) The World Bank national accounts data and OECD National 
Accounts data files. Available from: http://data.worldbank.org/indicator/NY.GDP.MKTP.KD.ZG/countries/1W-KZ-
UA-BY?display=graph. [Assessed on 31 October 2013]. 
23. [On approval of the National program of demographic safety of the Republic of Belarus for 
2011-2015]. Order of the President of the Republic of Belarus from 11 August 2011 #357. Belarus.  
24. Fiddelers AA, Dirksen CD, Dumoulin JC, van Montfoort AP, Land JA, Janssen JM, Evers 
JL, Severens JL. Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model. Human 
Reproduction. 2009; 24(7): 1648–1655. 
25. Jones CA. Doctoral Dissertation, Oxford University. ���������� ����������� ��� ������������
����������������������������������������������������������  
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a Assumption: 22.8% difference in male/female salaries according to State statistics report (Ukraine) 2; b 
Assumption: 61.9% difference in male/female salaries according to State statistics report (Kazakhstan)14;  c 
Average monthly support received for 12 months; d Average monthly support received for maximum 4 months  
;ƵŶĚĞƌƚŚĞůĂǁ͞KŶŽďůŝŐĂƚŽƌǇƐŽĐŝĂůŝŶƐƵƌĂŶĐĞ͟ŽĨƚŚĞƌĞƉƵďůŝĐŽĨ<ĂǌĂŬŚƐƚĂŶͿ͖e  Assumed that retirement age 
will not be lowered from existing.  
  
Unemployed from working 
population, % 
Ukraine  7.00 6.40 8.80 2,21 
Belarus 1.00 0.50 1.60 19,22 
Kazakhstan  5.20 5.20 6.60 14,23,24 
Retired population working, 
% 
Ukraine  15.00 13.50 18.00 2 
Belarus 22.00 19.80 26.40 12 
Kazakhstan  16.00 14.40 19.20 14 
Retire age males, years  Ukraine  60e 60 65  16, 25 
Belarus 6 e 60 65 16, 25 
Kazakhstan  63 e 63 65  25,26 
Retire age females, years Ukraine  60 e 60 65  16, 25 
Belarus 55 e 55 65 16, 25 
Kazakhstan  58 e 58 65  25,26 
State expenditures on 
education, $ 
Ukraine  247.94 191.60 253.05 2,27 
Belarus 291.60 336.96 453.60  22,28 
Kazakhstan  352.65 340.68 681.36 24,28 
State expenditures on health 
care, $ 
Ukraine  231.49 231.49 253.05 29 
Belarus 362.88 362.88 453.80 29 
Kazakhstan  488.31 488.31 794.92 29 
Fertility success rate, %   31.9 31.20 32.5 30 
Discounting, %  3.00 - - 31 
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Introduction 
Chronic hepatitis C virus (HCV) infection is a disease with a global prevalence rate of 
about 180 million individuals, and every year three to four million people are newly 
infected [1-3]. The impact of HCV on human health is evident, as 80% of acute hepatitis C 
cases transform into a chronic form and 10-20% of these cases progress to hepatocellular 
carcinoma [3].  
Currently, reliable official statistics in Ukraine are limited and mainly consist of 
data on acute HCV infection with jaundice and do not take into the account patients 
without jaundice and other clinically apparent manifestations who comprise nearly 85% of 
all morbid events [4, 5]. Ukraine is considered a country with a moderate prevalence of 
hepatitis C estimated at 1.5 to 3.5% of the population or 700,000 to 1.61 million of people 
[6]. Additionally, HCV infection rates among high risk groups in Ukraine, primary drugs 
users, homosexual males, and female sex workers, reach 40 to 60%, essentially exceeding 
the average global rate [7].  
In Ukraine as in most countries, if treatment is indicated, the standard of HCV 
treatment is a combination therapy using either pegylated interferon α-2b (Peg -α-2b) or 
α-2a (Peg -α-2a) with ribavirin. Response to therapy is measured in terms of sustained 
virological response (SVR), which is defined as undetectable HCV RNA concentrations 6 
months after completion of therapy. Successful treatment of HCV depends on the virus 
genotype. The most common and least responsive to therapy are patients who have HCV 
genotype 1 (estimated 43.7% of all HCV cases or 302,000 to 704,000 people in Ukraine) [6, 
8, 9].  
The proportion of subjects who achieve early virological response (defined as a 2 
log or greater decrease in HCV RNA levels at week 12) and also have an SVR is called a 
positive predictive value. A difference in the predictability of viral clearance between Peg -
α-2b + ribavirin and Peg -α-2a + ribavirin may cause a cost difference in treatment because 
a lower positive predictive value may result in a longer duration of therapy without 
achieving success.  
Despite a great deal of research on this topic, transferring results from previous 
studies conducted in US or Western European countries may not be possible due to 
different socio-economic systems, healthcare settings, cost parameters and their relation 
to different perspectives, as is the case for Ukraine.  
A large multicentre randomized double-blind direct comparative study 
(ClinicalTrials.gov number, NCT00081770) on treating patients who were infected with 
HCV genotype 1 with Peg -α-2b or Peg -α-2a was conducted in US on 3070 patients, 
applying treatment patterns similar to real-life clinical practice [10]. Treatment-naïve 
patients with genotype 1 without contraindications were given pegylated interferon in 
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Abstract 
Based on the pivotal trial showing no clinically relevant differences between pegylated 
interferon α-2b (Peg-α-��������α-2a (Peg-α-2a) combined with ribavirin for treatment of 
chronic hepatitis C virus (HCV) genotype 1 infection in Ukraine, a cost-minimization was 
performed  using a 1 year time horizon and both a health����������������������������������
decision tree reflects treatment pathways. Drug costs were based on drug labeling and 
adjusted to the average body mass in Ukraine. Subgroup analysis was applied to deal with 
���������������������������weight causing dose changes. A break  -   even price of Peg-α-2a 
and Peg-α-2b (based on the average dose) was calculated. Univariate sensitivity analyses 
and probabilistic sensitivity analysis were carried out to reflect decision uncertainty. For 
an average body weight, total medical costs per patient differ from $9220 for Peg-α-2b to 
$9513 for Peg-α-2a from a healthcare perspective, and from $15,212 to $15,696 from a 
patients' perspective. Sensitivity analyses show these results are robust. With average 
body weight, the break-even price of Peg-α-2b may be 7.3% higher than Peg-α-2a to have 
similar total costs. 
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pegylated interferon. We assumed that no additional medical services were received after 
treatment was discontinued or completed. Our cost analysis was conducted from both the 
health��������������������������������(parties which are frequent payers for treatment of 
HCV in the Ukrainian health care setting) with only direct medical expenses included in the 
calculation. Cost per SVR achieved was calculated since a non-significant difference in 
effect may have a meaningful difference in costs. Break-even price of Peg-α-2a and Peg-α-
2b (the point at which cost-effectiveness results were equal) was evaluated as well.  
Clinical input data 
Similar to the trial [10] in the model, virological test procedures for HCV-RNA 
were defined after the 4th, 12th, 24th, and 48th week of therapy initiation. After each 
virological test, some patients discontinued treatment with Peg -α-2b + ribavirin or Peg -α-
2a + ribavirin due to treatment failure or adverse effects (Figure 6.1).  
 
 
 
 
Figure 6.1 Decision tree comparing two strategies for genotype 1 HCV treatment 
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combination with high-dose ribavirin (on average 1000 mg per week) for 48 weeks [10-
������������������������������������HCV-RNA was measured after 4, 12, 24, and 48 weeks, 
the results of which indicated intermediate treatment success. The rates of SVR and 
tolerability did not differ significantly between the two available pegylated interferons + 
ribavirin regimens, with SVR rate of 39.8% (95% confidence interval [CI], 36.8 to 42.8) for 
standard-dose Peg -α-2b, and 40.9% (95% CI, 37.9 to 43.9%) for Peg -α-2a. Although no 
statistically significant difference in efficacy between Peg-α-2a and Peg -α-2b was reported 
[10], drugs differed in the predictability of viral clearance (positive predictive value on 
week 12 was equal to 82% and 76% for Peg -α-2b + ribavirin and Peg -α-2a + ribavirin, 
respectively) and relapse rates that may result in differences in treatment cost.  
No extensive cost analysis were conducted in the above mentioned study 
because an earlier US cost-effectiveness analysis for a hypothetical cohort of 100 HCV 
patients with mixed genotypes based on the level of positive predictive value [13] showed 
no clinically relevant difference in treatment outcome and lower cost of treatment with 
Peg -α-2b + ribavirin compared to Peg -α-2a + ribavirin. As stated above, differences in 
healthcare systems and perspectives of analysis may arouse a potential difficulty for 
transferring these US-based results (adjusting the costs and/or the cost-effectiveness 
estimate) to other countries [15]. Moreover, in routine clinical practice in Ukraine, an HCV 
genotype test is performed before treatment initiation. As treatment standards and drug 
instructions recommend different schemes for genotype 1 versus other HCV genotypes 
[16, 17], we considered that cost analysis should be also conducted separately for 
different HCV genotypes with clinical data based on a direct comparative trial.  
No studies to our knowledge have been published on the assessment of pegylated 
interferon efficiency in countries belonging to the Commonwealth of Independent States 
(CIS) region. Therefore, we aimed to study the costs of using Peg -α-2b in comparison to 
Peg -α-2a both combined with ribavirin for patients with HCV genotype 1 infection in the 
Ukrainian healthcare setting.  
 
Materials and methods 
For analysing the costs of using Peg -α-2b in comparison to Peg -α-2a both combined 
with ribavirin for patients with HCV genotype 1 infection in the Ukrainian healthcare 
setting, we used a decision analytic approach. Because no information on life-long 
treatment effects is available in the literature, a one year time horizon reflecting length of 
treatment for genotype 1 patients was defined. This relatively short time horizon makes a 
decision tree analysis the appropriate method to obtain accurate cost estimations. 
The structure of the decision tree was based on US-������ �����������
recommendations [11, 16,17]. The treatment response in the model was based on the US-
based comparative trial which assessed response at 6 months after the last dose of 
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Patients' perspective costs were defined by out of pocket payments for drugs and 
laboratory tests (antibodies to HCV, quantitative prolactin). Patient payments for drugs 
were assessed from the state registered prices with the distributors and trade margins 
established by the Order of the Cabinet of Ministers of Ukraine from 24.09.2012 (Tables 
6.1, 6.2). A test for antibodies to HCV (usually conducted once on treatment initiation) 
costs $13.77 (exchange rate 1 USD = 7.99 UAH on 01.01.2014 by the National Bank of 
Ukraine) [19].  
The costs related to ribavirin (weight dependent) were not considered in the 
model in both perspectives because due to company policies of the manufacturers of both 
drugs, ribavirin is provided free of charge by the companies when purchasing pegylated 
interferons. Because the reported adverse event profiles for both of the drugs were 
similar [10], the costs associated with adverse events were not included.  
 
Table 6.2 Decision-tree model input parameters  
Parameter, measure  
Value in 
deterministic 
model  
Source Value in  PSA  
Source 
 
 
The proportion of patients who 
completed 48 week Peg 2b, %  
 
 
47.89% 
 
[16] 
 
43.89-51.89% 
 
ClinicalTrials.gov number, 
NCT00081770 
The proportion of patients who 
completed 48 week Peg 2a, % 
 
55.26% [16] 51.51-59.41% ClinicalTrials.gov number, 
NCT00081770 
SVR Peg-2a, % 40.90% [16] 37.90-43.90% McHutchison et al., 2009 
[10] 
 
SVR, Peg-2b,% 39.80% [16] 36.80-42.80% McHutchison et al. ,2009 
[10] 
 
Average monthly salary of a 
medical worker, $1 
 
$296.00 [20] $236.80-
355.20 
20% variation from the 
data in deterministic 
model  
 
Cost of the laboratory test on 
quantitative prolactin, $1 
 
 
$84.05 [19] $47.56-
$120.53 
ŽůŬĂƌ͛ƐŝŶŝƚŝĂƚŝǀĞĨŽƌsŝƌĂů
Hepatitis patients care, 
2009 [20] 
1 Exchange rate UAH/USD is 7.99 on 01.01.2014 by National Bank of Ukraine 
 
  
112 
 
These discontinuation numbers were retrieved from the clinical trial report 
(ClinicalTrials.gov number, NCT00081770; the report was provided by MSD Outcome 
Research), excluding those patients whose follow up data were missing. This resulted in a 
difference in the number of patients continuing treatment after each virological test 
(treatment week 12 and 24). According to the trial report, a number of patients 
discontinued treatment between visits on 24th and 48th weeks (2.85% for Peg -α-2b and 
5.7% for Peg -α-2a). In the model, these patients were assumed to be in treatment for 36 
weeks on average. Drug dose selection was based on drug labeling; a dosage of the Peg -
α-2b ���������������� ��������� ���������� ��� ���� ������������������ ��� ��������� ��� �� ������
dose of 180 mcg for Peg -α-2a. The analysis was conducted using the adequate dose 
according to drug labelling (100 mcg dose for Peg -α-2b and 180 mcg for Peg -α-2a) and to 
average body weight in Ukraine (74 kg).  
 
Cost input data 
Cost analysis from the health care perspective included costs of drug treatment 
and costs of medical personnel. While costs of the pegylated interferons were determined 
from state registered prices, expenses of medical personnel services were calculated 
according to medical services norms in Ukraine (time per patient consultation equalled 12 
minutes and the number of working hours per week was 33 hours for a physician and 38.5 
hours for a nurse) [18]. 
 
Table 6.1 Cost of drug treatment: HCV genotype 1 
Regime  Drug costs (Healthcare perspective), $1 
ƌƵŐĐŽƐƚƐ;WĂƚŝĞŶƚ͛Ɛ
perspective), $2 
 
Peg-α-2a (180 mcg)  
 
264.02 
 
316.82 
Peg-α-2b (120mg)  277.20 332.64 
Peg-α-2b (50mg) 265.00 318.00 
Peg-α-2b (80mg) 268.20 321.84 
Peg-α-2b (100mg) 275.90 331.08 
Peg-α-2b (150mg) 
 283.05 339.66 
1 Prices as given on the website of the Ministry of Health of Ukraine 
(http://www.moz.gov.ua/ua/portal/register_prices_drugs/) on 01.01.14. 
2 Drugs prices with the distributors and trade margins established by the Order of Cabinet of Ministers of Ukraine 
#880 from 24.09.2012. 
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Cost analysis from the health care perspective included costs of drug treatment 
and costs of medical personnel. While costs of the pegylated interferons were determined 
from state registered prices, expenses of medical personnel services were calculated 
according to medical services norms in Ukraine (time per patient consultation equalled 12 
minutes and the number of working hours per week was 33 hours for a physician and 38.5 
hours for a nurse) [18]. 
 
Table 6.1 Cost of drug treatment: HCV genotype 1 
Regime  Drug costs (Healthcare perspective), $1 
ƌƵŐĐŽƐƚƐ;WĂƚŝĞŶƚ͛Ɛ
perspective), $2 
 
Peg-α-2a (180 mcg)  
 
264.02 
 
316.82 
Peg-α-2b (120mg)  277.20 332.64 
Peg-α-2b (50mg) 265.00 318.00 
Peg-α-2b (80mg) 268.20 321.84 
Peg-α-2b (100mg) 275.90 331.08 
Peg-α-2b (150mg) 
 283.05 339.66 
1 Prices as given on the website of the Ministry of Health of Ukraine 
(http://www.moz.gov.ua/ua/portal/register_prices_drugs/) on 01.01.14. 
2 Drugs prices with the distributors and trade margins established by the Order of Cabinet of Ministers of Ukraine 
#880 from 24.09.2012. 
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Table 6.3 Economic outcomes per patient infected with HCV genotype 1 
 
Regimen, weekly  
 
Healthcare perspective WĂƚŝĞŶƚ͛ƐƉĞƌƐƉĞĐƚŝǀĞ 
Total  
costs, $ 
Cost/SVR, 
$ 
Total 
costs, $ 
Cost/SVR, 
$ 
 
Peg-α-2a (not weight dependent,180 mcg)  
 
9513 23,202 13,969 28,539 
Peg-α-2b (expected dose consumption in 
Ukraine, average 100mcg)  
 
9220 23,165 15,212 28,352 
Peg-α-2b (mode trial dose,120mcg)  
 9264 23,276 15,283 28,482 
 
Table 6.4 Sensitivity of cost differences to uncertainty in input values (per patient) 
Parameter estimates 
Cost difference 
(Healthcare perspective), 
$ 
Cost difference 
;WĂƚŝĞŶƚ͛ƐƉĞƌƐƉĞĐƚŝǀĞͿ͕ 
$ 
 
Base-case result 
 
293 
 
360 
Patients' weight  
<40kg 657 797 
>86 kg 54 74 
Cost of medical assistance  
Maximum value 293 - 
Minimum value 293 - 
Cost of HCV laboratory test 
Maximum value - 304 
Minimum value 
 
- 312 
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Sensitivity analysis 
To reflect the uncertainty inherent in the research, univariate sensitivity analyses 
�����������������������������������������������������������������������������������������
costs. To reflect decision uncertainty, probabilistic sensitivity analysis (PSA) (1000 draws 
using Monte Carlo simulation) were carried out. In the PSA, cost of drugs and medical 
personal were varied in range ±20%, and costs of the laboratory analysis on quantitative 
prolactin were derived from the minimum to maximum price lists of the laboratories 
providing their services in Ukraine (Table 6.2) [19].  
For valuing parameters in the model from the original trial data, patients with 
missing outcomes were excluded. For instance, the confidence interval (CI) with 95% CI for 
���� ���������� �������� ��� ��������� ���� ���������� ��� ����� ����������� ���� ����
available, while the 95% CI for negative and positive 48 weeks responders was almost 
similar between both drugs compared. We assumed that the 95% CI for 48 weeks 
completers had a similar range to positive 48-weeks responders for both strategies (±4% 
Peg-α-2b and ±3.75% for Peg-α-2a). The number of 48-week completers caused changes in 
cohort drug costs, laboratory cost, and medical personal costs.  
���������������������������������������������������������������������������������
changes in doses of Peg-α-2b according to drug labelling; less than 40 kg: 50 mcg of Peg-α-
2b; 40-64 kg: 80 mcg of Peg-α-2b; 65-75 kg: 100 mcg of Peg-α-2b; 75-85 kg: 120 mcg of 
Peg-α-2b; more than 86 kg: 150 mcg of Peg-α-2b. 
 
 Results 
The results of the cost analysis are presented in the Table 6.3. Total medical costs per 
one patient (accounting the average body mass in Ukraine) varied from $9220 for Peg-α-
2b to $9513 for Peg-α-2a from a healthcare perspective, and from $15,212 for Peg-α-2b to 
$15,696 for Peg-α-��� ����� �� ���������� ������������� ���� ������ ����� ���� ��� ���� �����
population of patients with HCV genotype 1 in Ukraine varied from a minimum of $2.780 
billion (for Peg-α-2b) to $2.868 billion (for Peg-α-2a) and to a maximum of  $6.487 billion 
(for Peg-α-2b) to $6.693 billion (for Peg-α-2a) from a healthcare perspective. Using break-
even point analysis, it was defined that a price of Peg-α-2b should be 7.3% higher than 
Peg-α-2a to have equal/similar total costs. The cost per successfully treated patient, 
defined as having an SVR, was lower for Peg-α-2b in comparison to Peg-α-2a from 
patients' perspective and almost similar between treatments from a healthcare 
perspective.  
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treatment. The higher positive predictive value of Peg -α-2b may lead to cost savings as 
long as the price of Peg -α-2b is not more than 7.3% higher than Peg -α-2a. 
Treatment with pegylated interferon + ribavirin for chronic hepatitis patients is 
considered to be a standard therapy in many countries. In Ukraine, application of this 
scheme competes with interferon + ribavirin treatment (from 40 to 60% of the 
prescriptions by experts' estimates [personal communication]). As final clinical outcomes 
of HCV treatment such as virus eradication and prevention of death and progression to 
cirrhosis and hepatocellular carcinoma occur over a long period of time and are difficult to 
measure, SVR can serve as a surrogate indicator whether the treatment goal has been 
achieved [22]. Several studies indicate the association of SVR with improvements in liver 
histology, probability of developing liver decompensation, quality of life, and survival [23-
28]. While the majority of the population of Ukraine cannot afford expensive drug 
products [29], patient access to treatment with pegylated interferon plus ribavirin is 
crucial in the Ukrainian health care setting. 
The methods used here, a decision analysis using data from one pivotal trial, 
allowed us to derive essential clinical parameters for valuing the model parameters (such 
as number of patients continuing the therapy after each measurement of virological 
control). Another direct comparative trial focused on measuring SVR as an outcome of 
treatment of naïve patients with genotype 1 HCV (instead of mixed genotypes). These 
data were not included in our model as no significant clinical difference in the limited 
treatment groups (37 patients in each one) was reported [18]. Since these results are 
similar, we do not expect differences in the results of economic evaluation if these 
additional data were to be incorporated to value parameters in the model.  
While the largest comparative trial was used for clinical input data, it should be 
noted that the previous systematic review [31] provided assessment of efficacy with 
pegylated interferon treatment for patients with a mixed genotype, while no genotype-
specific comparison was conducted. Meanwhile, for treatment naïve HCV patients with 
genotype 1, there were only four studies were SVR was used as efficacy measure. Two of 
these trials, conducted by Sinha et al and Yenice et al., included a limited number of 
patients, enrolling 42 and 80, respectively [30,32]. Two studies by Rumi et al. and Ascione 
et al., both conducted in Italy (178 patients and 181 patients with genotype 1 HCV, 
respectively), reported the same probability (p=0.04) for Peg -α-2a + ribavirin to be 
clinically superior to Peg -α-2b + ribavirin [33,34]. The current cost-minimization analysis 
was based on the clinical data from the largest trial available which showed no statistically 
significant difference between treatment arms. The weighted pooled data from the three 
trials has shown almost similar SVR rates for genotype 1 patients (41.5% for Peg -α-2a + 
ribavirin and 40.2 % for Peg -α-2b + ribavirin) to the data used in the current study 
[10,33,34]. While this adjustment has no impact on the results of the current cost-
minimization study, the cost for one SVR reached remained equal for both drugs.  
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The results of univariate sensitivity analyses in genotype 1 patients are shown in 
Table 6.4. The costs of medical assistance and laboratory tests did not have a significant 
impact on total cost difference. For the subgroup analyses, the cost difference between 
Peg -α-2b and Peg -α-2a varied from 6.90% (weight less than 40 kg) to 0.56% (weight more 
than 86 kg) from a healthcare perspective, and from 6.81% (weight less than 40 kg) to 
0.63% (weight more than 86 ���� ��������������������������������������������������������
costs per SVR in accordance to the mode trial dose of Peg-α-2b [16] were slightly higher 
than using body mass-based calculation for Ukraine, though a general cost difference in 
favour of Peg-α-2b was observed. 
PSA results showed an average cost difference of 2.19 and 2.25% from the 
healthcare and patients perspectives respectively (median 3.84%, std. error = 1.37% from 
the health������ ��������������������������������������������������������������) in favour 
of Peg -α-2b + ribavirin. Mean SVR rates as a result of the PSA (40.08% for Peg -α-2b + 
ribavirin and 41.03% for Peg -α-2a + ribavirin) were similar to the deterministic data 
confirming the validity of the calculations. 
 
Discussion 
The results from this cost comparison suggest that therapy with Peg -α-2b + ribavirin 
may be less costly than Peg -α-2a + ribavirin for patients with genotype 1 HCV infection in 
cases in which no statistically significant difference in the rates of SVR achieved is assumed 
[10]. As the positive predictive value is higher for Peg -α-2b among patients with genotype 
1 with no effect on clinical outcome (SVR), it leads to a lower number of patients receiving 
treatment when successful outcome is not possible, and so to lower cost per successful 
treatment because the probability of successful treatment is equal between the 
strategies. The results of the sensitivity analyses showed that input parameters such as 
cost of medical assistance and laboratory tests do not affect the results of the base case 
analysis substantially. Because Peg -α-2b allows weight-based dosing, the subgroup 
analyses showed the economic advantage may be higher for patients with lower weight 
and lower for patients with higher weight than averag������������������������������������
weight can lead to additional cost reductions from both patients' and healthcare 
perspectives.  
Due to possible price changes for pharmaceutical products on the Ukrainian 
market as a result of negotiation policy of distributors and producers participating in state 
tender purchases (no reimbursement currently exists in Ukraine), we consider that the 
break-even price instead of the actual price should be considered to determine cost 
efficiency of the product in Ukraine. Price variation because of negotiations is a frequent 
action on the Ukrainian state pharmaceutical market, and a similar strategy was 
announced by the Ministry of Health of Ukraine in relation to access to hepatitis 
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Several economic studies on treatment of naïve patients with chronic HCV 
infection have been published in different countries [12-14, 30,31]. The most recent study 
on pegylated interferons was conducted for the US [13], applying similar methodology as 
our study, defining the cost-efficacy of Peg -α-2b + ribavirin scheme for patients with HCV 
(genotypes 1,2,3). Though the aim of the study was similar, the perspective of the US-
study was one of a managed care organization. Thus, using the transferability criteria for 
cost-effectiveness estimates as stated by the ISPOR taskforce on transferability [15], it 
may not be applicable for Ukraine, where major treatment costs for HCV treatment are 
���������� �������� ��� ���������� ��������� ���� ���������� ��� ����������� �������� ������
purchases. Despite the difference in perspectives, Malone et al. reached the similar 
conclusion, stating that treating with Peg -α-2b + ribavirin provides cost savings in 
comparison to Peg -α-2a + ribavirin because fewer patients are treated beyond 12 weeks 
when achieving SVR is unlikely [13]. The indicated study suggested that although both Peg 
-α-2a and Peg -α-2b have demonstrated similar SVR overall, for genotype 1, there is a 
significant difference in early virological response rates. Thus, using Peg -α-2a + ribavirin 
������������������������ ��������� �����������������������������������������������������
without additional health benefit over those treated with Peg -α-2b. 
A number of other economic studies compared treatment with interferons and 
pegylated interferons for genotype 1 HCV treatment-naïve patients [12,14,31], confirming 
cost-effectiveness of the latter one. A study in Spain, conducted by Buti et al. [12], also 
defined treatment with Peg -α-2b + ribavirin as the optimal strategy which includes 
adjustment to the patient's body weight for 48 weeks and good therapeutic compliance. 
Siebert et al. concluded that Peg -α-2b + ribavirin could reduce the incidence of liver 
complications, prolong life, improve quality of life, and be cost effective for the initial 
treatment of HCV in patients in Germany [30]. Sullivan et al. evaluated cost-effectiveness 
of Peg -α-2a + ribavirin versus traditional interferon, coming to the similar conclusion on 
efficiency pegylated interferons in patients in the US. In our analysis comparing two 
pegylated interferons, we observed similar results with the study of Malone et al. [11], 
though due to differences in sources of clinical outcomes (SVR rates), cost components, 
and prices, the total costs were different. Thus, the results from our study may help to 
assess costs for HCV genotype 1 treatment in Ukraine and may be more easily transferable 
to other CIS countries. 
This analysis suggests that use of Peg -α-2b + ribavirin may be preferred to Peg -
α-2a + ribavirin in treatment of genotype 1 HCV infected patients due to lower costs 
associated with treatment, given the earlier finding of comparable clinical efficacy. Use of 
Peg -α-2b + ribavirin in comparison to Peg-α-2a + ribavirin could lead to a cost reduction of 
$88 to $206 per patient if the treatment for all the cohort of genotype 1 HCV patients is 
provided. Price of Peg -α-2a would have to be lower to achieve similar efficiency to Peg -α-
2b.
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associated with treatment, given the earlier finding of comparable clinical efficacy. Use of 
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Introduction 
Hypoglycemia is a common complication of treating diabetes mellitus [1] and is 
characterized with (but not limited to) the following symptoms: sweating, palpitations, 
shaking, hunger, confusion and drowsiness [2]. Research on the daily lives of patients with 
hypoglycemia conclude that the frequency of hypoglycemic episodes is correlated with 
lower general health, greater fear and anxiety, lower health-related quality of life 
(HRQoL), higher risk of long-term complications and mortality, reduced work productivity, 
and problems performing certain daily activities [1,3-10]. Some of the major issues 
explored in past research include the frequency of hypoglycemic symptoms and their 
ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ΀ϭϭ΁͕ƉĂƚŝĞŶƚƐ͛ƵŶĚĞƌƐƚĂŶĚŝŶŐŽĨŚǇƉŽŐůǇĐĞŵŝĐƐǇŵƉƚŽŵƐĂŶĚƚŚĞŝƌƐĞǀĞƌŝƚǇ
[9,12,13], limitation on daily life because of hypoglycemia, and psychological impact of 
hypoglycemia [9,10,14]. 
Past research points to several other factors that can have an impact on how 
patients manage hypoglycemia caused by type 2 diabetes mellitus.  &ŽƌĞǆĂŵƉůĞ͕ƉĂƚŝĞŶƚ͛Ɛ
education has a direct impact on awareness and, therefore, on the severity of 
hypoglycemia [11]. sĂƌŝŽƵƐ ŝŶĨŽƌŵĂƚŝŽŶĂů ƌĞƐŽƵƌĐĞƐ ĐĂŶďĞƵƐĞĚ ĨŽƌƉĂƚŝĞŶƚƐ͛ ĂǁĂƌĞŶĞƐƐ
programs. In a number of countries, information on diabetes (including hypoglycemia) 
management is usually provided by the primary care practitioner [8,15-17]. In such cases 
patient-doctor relationships become very important for effective disease management. An 
apparent lack of concern by healthcare providers can have a negative impact on emotional 
state of patients [14,18]. 
This previous research has been conducted largely in developed countries. 
Unfortunately there is little to no research on this topic conducted in Ukraine or any other 
developing country in the Eastern Europe. It is also recognized that a number of factors, 
such as receiving insulin therapy, obesity, diabetes complications, age, sex, employment 
status, educational level, level of physical activity, and ethnicity, among others, might have 
an impact on perceived HRQoL of type 2 diabetic patients. These various factors vary from 
region to region and might be influenced by country-specific socioeconomic and lifestyle 
factors. Thus, the results from past research might not be generalizable between 
geographic regions.   
There are no studies available for Ukraine or other developing country of the 
Eastern Europe that give insight on potential impact of hypoglycemia on daily life of 
patients with type 2 diabetes. At the same time focus groups were often used in studies 
with focus on impact of hypoglyĐĞŵŝĂŽŶƉĂƚŝĞŶƚ͛ƐůŝǀĞƐ΀ϭϬ͕ϭϮ͕ϭϰ΁͘For these reasons, this 
study was undertaken to evaluate the perceived burden ŽĨ ŚǇƉŽŐůǇĐĞŵŝĂ ŽŶ ƉĂƚŝĞŶƚƐ͛
daily life in one of the developing countries, Ukraine. The primary objective of this 
qualitative study was to evaluate, through focus groups with type 2 diabetes mellitus 
patients with at least one reported case of hypoglycemia during the last year of treatment, 
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Abstract 
This study evaluates the impact of hypoglycemia on lives of Ukrainian patients with type 2 
diabetes mellitus. The secondary objective was to explore patient-physician relationships 
and attitudes of patients toward various informational resources on diabetes 
management. Three focus groups with 26 patients were conducted. Qualitative 
information was evaluated using content analysis. The results show that patients with 
type 2 diabetes mellitus in Ukraine are adapting to potential attacks of hypoglycemia, 
however, they still experience periodic manifestations of hypoglycemia that significantly 
ĂĨĨĞĐƚ ƉĂƚŝĞŶƚƐ͛ ƉƐǇĐŚŽůŽŐŝĐĂl well-being. This result is similar to observations made in 
other countries. Ukrainian patients elder than 40 years old receive information on disease 
management majorly from endocrinologists, and rarely use Internet resources on diabetes 
management. Information provision was especially important on early stage of the disease 
when patients lack information on hypoglycemia manifestations and could fail to identify 
it and manage it properly. 
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qualitative study was to evaluate, through focus groups with type 2 diabetes mellitus 
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Abstract 
This study evaluates the impact of hypoglycemia on lives of Ukrainian patients with type 2 
diabetes mellitus. The secondary objective was to explore patient-physician relationships 
and attitudes of patients toward various informational resources on diabetes 
management. Three focus groups with 26 patients were conducted. Qualitative 
information was evaluated using content analysis. The results show that patients with 
type 2 diabetes mellitus in Ukraine are adapting to potential attacks of hypoglycemia, 
however, they still experience periodic manifestations of hypoglycemia that significantly 
ĂĨĨĞĐƚ ƉĂƚŝĞŶƚƐ͛ ƉƐǇĐŚŽůŽŐŝĐĂl well-being. This result is similar to observations made in 
other countries. Ukrainian patients elder than 40 years old receive information on disease 
management majorly from endocrinologists, and rarely use Internet resources on diabetes 
management. Information provision was especially important on early stage of the disease 
when patients lack information on hypoglycemia manifestations and could fail to identify 
it and manage it properly. 
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a visual measurement aid), the actions they undertook when experiencing such 
symptoms, the impact of hypoglycemia on their work, daily activities, physical activities, 
family and social life, fear of hypoglycemia, and depression and/or other psychological 
effects/symptoms they experienced.  Additionally, patients were asked about their 
experience in communication with physicians, and source of information on disease 
management they use. Patients were encouraged to add anything they considered 
important after each of the topic and at the end of the focus groups.  
After the focus group discussion was completed, patients were asked to complete 
one generic (Questionnaire on State of Health EQ-5d-3L) and one disease specific 
(Russian-version of "Questionnaire on Low Blood Sugar Level in Adults" developed by the 
University of the Virginia in 1998) instrument assessing HRQoL that were used in the 
previous studies [7,9]. The main objective of using these instruments was to evaluate their 
acceptability and validity among Russian-speaking patient populations in Ukraine, to 
capture any missing data for patients who might have been less eager to participate in 
conversations, and to compare the results received orally and in written form.  
Data analysis 
Descriptive statistics was used to characterize the sample group in terms of 
clinical and socio-demographic characteristics. Qualitative information from the focus 
group discussions was evaluated. A content analysis was used for aspects identified by 
more than three patients in each gender group. The transcripts were analyzed by two 
researchers independently. Categories for data analysis were selected in accordance with 
the written focus group protocol as follows:  
1) Symptoms and management of hypoglycemia; 
2) Hypoglycemia as a limitation; 
3) Psychological impact of hypoglycemia. 
We grouped similar events and incidents into sub-categories, selected in 
ĂĐĐŽƌĚĂŶĐĞ ǁŝƚŚ ƚŚĞ ƉĂƌƚŝĐŝƉĂŶƚƐ͛ ƌĞƉůŝĞƐ ƵŶĚĞƌ ƐŝŵŝůĂƌ ĐĂƚĞŐŽƌŝĞƐ͕ for easier results 
presentation [10,14]. 
 
Results 
Eighteen men and fifteen women with the defined profile were contacted, from 
which twelve men and fourteen women agreed to participate in the focus groups. Table 
7.1 shows the demographic and clinical characteristics of the sample as reported by the 
patients in the written form. The difference between men and women in education and 
family status is proportional to general population [22]. From socio-economic parameters 
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the symptoms that are experienced, how they are managed, how hypoglycemia episodes 
ĐĂŶ ůŝŵŝƚƉĂƚŝĞŶƚƐ͛Ěaily life, and what is the psychological impact of hypoglycemia from 
the perspective of Ukrainian patients. A secondary objective was to explore patient-
physician relationships and attitudes of patients toward various informational resources 
on diabetes management in Ukraine. 
 
Methods 
Focus groups of patients with hypoglycemia 
We selected the focus groups method to evaluate impact of hypoglycemia on 
ƉĂƚŝĞŶƚ͛Ɛ ůŝǀĞƐ͕ ƚŽ ĂƐƐĞƐƐ ŚǇƉŽŐůǇĐĞŵŝĂ ĂǁĂƌĞŶĞƐƐ ĂŶĚŵŽƐƚ ĨƌĞƋƵĞŶƚůǇ ƵƐĞĚ ƐŽƵƌĐĞƐ ŽĨ
information for the management of diabetes mellitus 2nd type [10,12,14]. General 
principles of the focus group method [19-21] and past focus group studies conducted on 
patients with type 2 diabetes mellitus [10,12,14] were referenced for discussion guide 
design and data analysis. 
A purposive sampling strategy was applied to recruit an age-homogeneous group 
with participants older than 40 years, and having at least one reported case of 
hypoglycemia during the last year of medical observation. A total of three focus groups 
(women N =14, men N = 5 and 7) with patients from one of the largest urban cities of 
Ukraine and its surrounding were conducted. The gender division aimed to stimulate more 
open discussion among the participants and to eliminate a gender bias [12]. The focus 
group with men was conducted 2 times because of lower recruitment rate versus women. 
All focus groups were organized at independent clinical location with aim not to influence 
disclosure of information by the participants. 
All participants confirmed knowledge of Russian language as fluent. If eligible, 
potential participants were contacted by their physician to explain the purpose of the 
research with an invitation, and receive a verbal agreement to participate. Institutional 
Review Board approval was received prior to the initiation of the study. 
The majority of the participants were not acquainted with each other. Thus, an 
informal introduction session was organized for participants prior to the focus groups to 
help to open up. Before starting the focus groups, all participants were again introduced 
to the study structure and purposes, requested to read and sign an informed consent 
form, and complete a brief questionnaire on their socio-demographic and disease 
characteristics. The discussion during the focus groups was led by an experienced 
moderator with a background in life and social sciences. All sessions were audiotaped with 
permission of the participants, and after completion transcribed verbatim.  
A guide was constructed to discuss the following: symptoms patients experienced 
during hypoglycemia events and their frequency/severity (for this they were also provided 
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The majority of the participants were not acquainted with each other. Thus, an 
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help to open up. Before starting the focus groups, all participants were again introduced 
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hungry, an internal tremor begins. And then it intensifies and all your body begins . . . Both 
your arms, and feet, and weakness, and dizziness . . . ." In the written visual form men also 
indicated weakness and nervous excitation as a frequent symptom.  
All participants generally agreed that the most common action taken when 
hypoglycemia symptoms occur is the consumption of candies, fruits and sweet liquids. 
Participants also were aware of the consequences of failing to take measures at the onset 
of hypoglycemia symptoms, most frequently indicating such consequences as loss of 
consciousness and coma. 
A number of participants (5 men and 7 women) indicated that for a long time 
they did not know they were experiencing hypoglycemia manifestations: "I just did not 
pay attention in the beginning. . . " (men, 46 years); ". . . I simply did not know what was 
happening to me" (woman, 49 years). Most patients indicated that they independently 
established the connection between their feeling of sickness and low blood sugar level 
after having blood sugar measured at the moment of hypoglycemic condition. Others 
indicated that their hypoglycemic condition was detected during their hospitalization with 
a serious clinical condition. Four of six men, who took insulin, indicated that they started 
to experience hypoglycemia symptoms after initiating insulin therapy. Both men and 
women indicated that they lacked information on hypoglycemia manifestations at the 
early stage of developing diabetes mellitus and, therefore, failed to identify it and manage 
it properly. 
 
Table 7.2 Categories and sub-categories characterizing daily life for type 2 diabetes 
mellitus patients experiencing hypoglycemia 
Categories as defined in the protocol Sub-categories as defined based on the input of 
participants 
 
Symptoms and management of hypoglycemia 
 
Symptoms of hypoglycemia and their frequency 
Actions in case of event 
First time hypoglycemia was diagnosed 
Hypoglycemia as a limitation Hypoglycemia and adaptation 
Hypoglycemia and social life limitation 
Psychological impact of hypoglycemia  Depression and fear of hypoglycemia 
Actions caused by hypoglycemia fear 
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we can also note a high unemployment rate among type 2 diabetic patients. The sub-
categories ƌĞƚƌŝĞǀĞĚĨƌŽŵƚŚĞŐƌŽƵƉƐ͛ĚŝƐĐƵƐƐŝŽŶĂƌĞpresented in the Table 7.2.  
 
Table 7.1 Demographic and clinical characteristics 
Characteristic 
Men 
N = 12 
Woman 
N = 14 
Total 
N = 26 
 
Mean age (SD) 
 
47.33 (6.77) 
 
57.71 (5.54) 
 
52.92 (8.00) 
Less than 2 years history of diabetes mellitus type 2, N (%) 2 (17) 1 (8) 3 (12) 
More than 5 years history of diabetes mellitus type 2, N (%) 6 (50) 8 (58) 14 (54) 
City residents, N (%) 12 (100) 13 (93) 25 (96) 
Residing with a family, N (%) 8 (67) 13 (93) 21 (81) 
With higher education degree or above, N (%) 5 (42) 6 (43) 11 (42) 
Employed, N (%) 5 (42) 7 (50) 12 (46) 
Not working because of diabetes mellitus type 2, N (%) 7 (58) 2 (14) 9 (35) 
Household income of study participant below 375 USD/month a 10 (83) 12 (86) 22 (85) 
Self indicated as of low-income level, N (%) 9 (75) 9 (64) 18 (69) 
Using oral blood-sugar lowering medications, N (%) 6 (50) 13 (93) 19 (73) 
Constant insulin users, N (%) 
 
6 (50) 2 (14) 8 (31) 
a Exchange rate applied at 1USD /8 UAH. 
 
Category 1 Symptoms and management of hypoglycemia 
In general, patients participating in the focus groups demonstrated a high level of 
awareness of their hypoglycemia symptoms, which included: shakiness, hunger, sweating 
(both men and women), and additionally sleepiness, dizziness, moodiness/irritation, 
weakness, problems thinking, and loss of vision among women. For example, one 54-year 
old woman participant described hypoglycemia as the following: ". . . when you get or are 
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In general, patients participating in the focus groups demonstrated a high level of 
awareness of their hypoglycemia symptoms, which included: shakiness, hunger, sweating 
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old woman participant described hypoglycemia as the following: ". . . when you get or are 
Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine 127
  
 
129 
 
 
Adaptation included a decrease in the number of trips, stress prevention, regular 
food consumption, and urgent preventive actions as soon as she/he began to experience 
the symptoms of hypoglycemia. All of the participants still experience hypoglycemic 
events periodically because of physical exercise (6 women), medications (4 men), stress (4 
men and 5 women), and disruptions in the regime (7 men and 8 women). Two men and 
four women noted that hypoglycemic events happen to them more frequently during a 
certain time of the day (usually morning) or during a certain season. 
Participants indicated that hypoglycemia has no significant effect on their family 
life. However, men reported that they try to avoid irritation and family stresses, or prefer 
to stay alone. Some women indicated a feeling of discomfort in relations with their 
relatives.  
Regarding work productivity, three of the women participants indicated a 
substantial decrease in productivity because of frequent hypoglycemic events: "It is not 
just a decrease, I can't do anything" (woman, 49 years). Additionally, women tried to 
refrain from informing colleagues about the state of their health, being afraid of criticism 
and possible influence on labor relations. In large groups and social settings, the 
participants also mainly stay silent about their diabetes because they do not want to 
burden others with their health problems, or they are ashamed.  
Men tried to adapt their working day to the state of their health and 7 of them 
disclosed that they had to leave their jobs because of diabetes mellitus. Employed 
participants indicated that they needed to change their working day schedules to prevent 
hypoglycemia attacks.  
Regarding physical exercise, participants revealed that they used to limit physical 
exertion (4 men and 5 women). Driving a car was not associated with any specific problem 
(none of the women drives a car). Almost no difficulties in performing usual daily activities 
was noticed by participants, but shopping for a long period of time can be a problem for 
some of them.  
 
Answers provided by participants in the printed EQ-5D-3L Form (Table 7.4) stated 
that they have some difficulties with mobility (walking), feel moderate pain/discomfort, 
and experience anxiety/depression.  
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Category 2 Hypoglycemia as a limitation 
The majority of focus group participants (9 men and 5 women) remarked about 
adapting their rhythm, daily routine and way of life to cope with periodically occurring 
hypoglycemia attacks (Table 7.3).  
 
Table 7.3 Social, physical, and psychological impact of hypoglycemia (data based on 
focus group session only) 
 
Events reported during focus groups 
Men 
(N = 12) 
Women 
(N = 14) 
Sub- category: Hypoglycemia and social life limitation 
Decrease in work productivity 0 3 
Decrease in physical activities 4 5 
Decrease in mobility (going out, or number of long trips) 3 5 
ĚĂƉƚĂƚŝŽŶŽĨƐŽĐŝĂůĚĂŝůǇůŝĨĞ;ůŝŬĞ͚ĞĂƚŝŶŐƐĐŚĞĚƵůĞƐ͛Ϳ 6 5 
Absence of impact on driving   5 N/A 
Sub-category: Hypoglycemia and adaptation 
Some daily routine adaptation 12 13 
Awareness about the problem and readiness to help among relatives 
and close friends  7 9 
Working schedule adaptation 6 5 
Sub-category: Depression and fear of hypoglycemia 
Periodic fear or psychological discomfort  12 13 
Fear to collapse/enter coma 10 10 
Depressive states 0 7 
Fear-related change in insulin time injection  6 0 
Fear-related excessive food consumption 0 3 
Attempts to prevent hypoglycemia when feel possible onset 5 6 
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afraid each time that something can happen to you. You are going and waiting for 
something to happen. I am always afraid . . . " (woman, 52). Fear of a hypoglycemic event 
also has a significant impact on participants' behavior: it causes them to shift the time of 
insulin intake (men), eat an additional meal (women), and limit long trips (both genders) 
as presented in the Table 7.3. 
Twenty two of 26 participants (10 men and 12 women) indicated feeling a 
moderate pain/discomfort on the EQ-5D-3L. All 26 participants indicated that they feel 
anxiety and/or depression. According to the HFS Form, for men the most frequent 
manifestations of anxiety (experienced by nearly half of men) were difficulties maintaining 
control when it is necessary to bear responsibility for other people, and difficulties 
performing important tasks because of low blood sugar. For women, the most frequent 
anxiety manifestations, expressed in the HFS, were the concern that in case of attack 
there will be no meal, fruits or juice within their reach. 
Hypoglycemia reporting, awareness and sources of information  
Focus group participants revealed that they receive information about diabetes from 
different sources, but mainly from their endocrinologist. Only 7 persons of 26 indicated 
that they additionally searched for information regarding diabetes in the published lay or 
scientific literature, and only 4 participants (all men) indicated that they use Internet 
sources to research information regarding diabetes. During the discussion, 6 people also 
shared a positive impact of patients' diabetic educational programs or communication 
with other patients on information provision. Opinions about whether or not discuss the 
problem of hypoglycemia with their physician differed among study participants. 
Participants (8 men and 4 women) said that they do not completely trust their physician, 
and that it is sometimes easier for them to experiment to select the most effective 
methods for hypoglycemia prevention. An interesting difference between the gender 
groups was observed: while the majority of women indicated that their doctor is asking 
about hypoglycemia events during each visit, most of the men participants stated that 
either the physician did not have time for such questions, or the patient himself is not 
interested in information provided by the endocrinologist. Several of the men participants 
described the situation of communication with the doctor as follows: "Theoretically he 
("physician" - authors) knows everything, but practically he was not in such a situation", 
"How can you trust the physician, if the physician does not trust you. . . ", "They 
("physicians" - authors) do not particularly raise this problem, maybe, because they are 
not interested in it" (men, 49, 52, 53 years). 
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Table 7.4 Answers Provided by Participants in Printed EQ-5D-3L Form (Russian Version) 
Indicators of quality of life a 
Sex  
Total 
N (%) 
Men 
N (%) 
Women 
N (%) 
1. Mobility 
I have no problems in walking about 4 (33) 2 (14) 6 (23) 
I have some problems in walking about 8 (67) 12 (86) 20 (77) 
2. Self care  
I have no problems with  care 12 (100) 9 (64) 21 (81) 
I have some problems washing or dressing myself 0 (0) 5 (36) 5 (19) 
3. Usual activities  
I have no problems with performing my usual 
activities 6 (50) 4 (29) 10 (38) 
I have some problems with performing my usual 
activities  6 (50) 10 (71) 16 (62) 
4. Pain / Discomfort  
I have no pain or discomfort 2 (17) 2 (14) 4 (15) 
I have a moderate pain or discomfort 10 (83) 12 (86) 22 (85) 
5. Anxiety / 
Depression I am moderately anxious or depressed 
12  
(100) 
14 
(100) 
26  
(100) 
a None of focus group participants indicated the most severe state (third level) in all five categories  
 
Category 3 Psychological impact of hypoglycemia  
The fear and psychological discomfort was observed as an important aggravating 
factor of hypoglycemia among patients with type 2 diabetes mellitus (Table 7.3). During 
the discussion, everyone except one woman mentioned periodic fear or psychological 
discomfort because of hypoglycemia. Twenty participants confirmed that they had a fear 
of collapsing (because of diverse reasons). Men mainly associated the condition of 
psychological discomfort with anxiety and the inability to foresee hypoglycemic events, 
and fear of a hypoglycemia events happening at an inopportune moment or in public. 
Woman mainly connected the condition of psychological discomfort with unpredictability 
of hypoglycemia manifestations, feeling of fear, anxiety, depression, mood swings, 
irritation and permanent alertness to prevent the occurrence of hypoglycemia symptoms. 
At the same time, unlike men, women were the most afraid of losing consciousness when 
alone, without anyone nearby who would be able to rescue them: "Psychologically you are 
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afraid each time that something can happen to you. You are going and waiting for 
something to happen. I am always afraid . . . " (woman, 52). Fear of a hypoglycemic event 
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patients' well-being. Most of the participants indicated verbally that they experienced 
periodic anxiety and depression because of the possibility of hypoglycemic events, and all 
patients confirmed this in written form. While some participants (mostly men) are afraid 
that such events can happen to them in public, others (mostly women) are afraid of 
hypoglycemic events happening when they are alone and no one is available to provide 
assistance. The fear of hypoglycemia influences many patŝĞŶƚƐ͛ůŝǀĞƐďǇůŝŵŝƚŝŶŐƚŚĞŝƌƐŽĐŝĂů
activities, or causing changes in their diabetes management routines (e.g., timing of their 
food intake or insulin injection). Similar findings were observed by other researchers [24]. 
These results are in line with the findings from large-scale studies on the impact of 
hypoglycemia on quality of life. Based on a survey of 1984 participants, Marrett et al. [7] 
concluded that patients who experience severe or frequent hypoglycemic episodes report 
lower general health and greater fear of hypoglycemia compared with patients without a 
history of hypoglycemia. Hypoglycemia symptom severity was also positively associated 
with fear of hypoglycemia and lower HRQoL in another study conducted in the Asia-Pacific 
region by Sheu et al. [9]. A number of studies in Western countries (UK, France, Sweden, 
Germany) have explored the relationship of hypoglycemia with decreased HRQoL and fear 
of hypoglycemia in patients with type 2 diabetes mellitus, and have reported similar 
results [1,3-6,25,26]. Taking into account results from the previous and our study, we can 
expect that in patients with type 2 diabetes in Ukraine, there should be a similar impact of 
hypoglycemia on HRQoL, despite any socio-economic differences between the countries 
(allowing for some disparities such as gender gaps in automobile usage and other such 
habits). 
Regarding information provision on disease management, we found that 
endocrinologists are the most common source of information for type 2 diabetes patients 
in Ukraine. Primary care practitioners are not typically consulted by patients, and Internet 
resources are also rarely used. These results differ from practice in European countries or 
the USA, where general practitioners or nurses play important roles in informational 
support [8,15-17], and the level of Internet users among patients with type 2 diabetes 
reaches approximately 50% [27]. 
Despite the fact that in Ukraine, patients are consulted by specialists 
(endocrinologists) and not by primary care physician, as in some other countries [8, 15-
17], our results showed that some patients do not rely on their physician and are hesitant 
to talk to physicians about hypoglycemia, which is a common tendency of diabetic 
patients also reported in other studies [14,28]. This might result in the underreporting of 
hypoglycemia by type 2 diabetes mellitus patients in Ukraine. Underreporting of 
hypoglycemia was also shown in the study on 392 participants treated with combinations 
of oral anti-hyperglycemic agents [1]. 
Basing on retrospective experience of focus-groups participants, we also suppose 
that newly-diagnosed patients with type 2 diabetes mellitus can experience difficulties in 
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Discussion 
This study aimed to evaluate the symptoms that are experienced and the 
ŵĂŶĂŐĞŵĞŶƚŽĨŚǇƉŽŐůǇĐĞŵŝĂ͕ŚŽǁŚǇƉŽŐůǇĐĞŵŝĂĞƉŝƐŽĚĞƐŵŝŐŚƚůŝŵŝƚƉĂƚŝĞŶƚƐ͛ĚĂŝůǇůŝĨĞ͕
and what is the perceived psychological impact of hypoglycemia among Ukrainian 
patients. In general, our findings were similar to those reported in other countries. 
Relating to symptoms experienced by the patients, autonomic symptoms 
(shakiness, hunger, sweating) were named more frequently by focus groups participants 
of both genders. Neuroglycopenic symptoms (weakness, dizziness, and irritability) were 
also frequently reported by women, though we acknowledge that these symptoms can be 
related to the other health problems. We observed a difference in symptoms reporting 
between men and women, with a higher number of symptoms reported among women 
during the discussion, which is similar to the findings by Marrett et al. [7].  
Similar to the findings of other studies [14,23], it appears that Ukrainian patients 
with a long history of the disease (as perceived by patients) are adapting to hypoglycemia. 
Most of the patients were well informed about the disease symptoms, severity, and the 
actions required to treat/manage it. Focus group participants not only were able to adjust 
their nutrition schedule and level of physical activities to manage the disease, but they 
also adapted their daily activities, working schedules, and private relations to help prevent 
hypoglycemia and make it more manageable. In the majority of cases, not only family, but 
also close friends and colleagues of a patient with diabetes mellitus are well informed 
about his/her state and able to provide help in case of emergency, a result observed in 
previous research [10]. However, as observed in the study by Wu et al. [14], some 
participants in this study also preferred to conceal having diabetes at work or in large 
social settings. Others reported trying to hide not the diabetic state itself but rather the 
negative health symptoms caused by hypoglycemia, fearing that their health limitation 
might negatively affect their employment. Like the study by Dickinson and O'Reilly et al. 
[23], we conclude that family, friends and the work environment can have a significant 
positive impact on managing type 2 diabetes mellitus complications and on patients' well-
being. 
We found that "adaptation" to diabetes and associated hypoglycemic states do 
not always mean absence of negative changes in daily routine: the number of men 
indicated leaving their job because of diabetes complications, and working women 
reported a significant decrease in their work productivity because of frequent symptoms 
such as dizziness and weakness. Because of the need to be constantly alert to the 
symptoms of hypoglycemia, participants indicated that hypoglycemia events cause 
disruptions in their daily routines.  
The possibility of hypoglycemia events can lead to fear of hypoglycemia and 
hypoglycemia-related depressions, which are significant factors negatively influencing 
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to report more symptoms and higher disease severity (especially for men) when they 
answered the written form. It is possible that men were less inclined than women to share 
information openly in a group setting out of fear that it would make them appear weak 
ĂŶĚͬŽƌŝƚǁŽƵůĚůŽǁĞƌƚŚĞŝƌĞƐƚĞĞŵŝŶŽƚŚĞƌƉĂƌƚŝĐŝƉĂŶƚƐ͛ĞǇĞƐ͕ĂĨƌĞƋƵĞŶƚĨŝŶĚŝŶg in focus 
group research [19]. We believe that providing questionnaires in our study has added 
ǀĂůƵĂďůĞ ŝŶƐŝŐŚƚ ŽŶ ƉĂƚŝĞŶƚƐ͛ ĞǆƉĞƌŝĞŶĐĞ ŽĨ ŚǇƉŽŐůǇĐĞŵŝĂ͘ &ƵƚƵƌĞ ƌĞƐĞĂƌĐŚ ŵŝŐŚƚ ďĞ
designed to include a time break between these two parts if the study is repeated to 
reduce the impact of the group discussion on privately obtained information.  
Participation in the focus group 
We also observed more difficulties in arranging the men focus groups, in terms of 
involving patients in the study and finding appropriate times and dates for them to gather 
together for discussion. Although no reasons were provided, a previous hypoglycemia 
focus group study contained significantly more woman participants than men (14 versus 4, 
respectively), perhaps for similar reasons [10]. 
It is worth noting that a history of at least one episode of hypoglycemia about 
which a participant had informed his/her physician was a criterion for participation in our 
focus groups. This means that the level of awareness of our focus group participants might 
be higher than that of an ordinary diabetes patient with similar symptoms.  
 
Conclusion 
dŚĞƋƵĂůŝƚĂƚŝǀĞĂƐƐĞƐƐŵĞŶƚŽĨŚǇƉŽŐůǇĐĞŵŝĂ͛ƐŝŵƉĂĐƚŽŶƚŚĞůŝǀĞƐŽĨƉĂƚŝĞŶƚƐǁŝƚŚ
type 2 diabetes mellitus using a focus group methodology demonstrated general similarity 
between Ukrainian patients and patients in the other countries. We found serious 
negative effects of hypoglycemia on psychological and emotional states of participants, as 
ǁĞůůĂƐ ůŝŵŝƚĂƚŝŽŶŽĨƉĂƚŝĞŶƚƐ͛ ůŝǀĞƐďĞĐĂƵƐĞŽĨďŽƚŚŚǇƉŽŐůǇĐĞŵŝĂ ƐǇŵƉƚŽŵs themselves 
and the fear of experiencing them. In contrast to the findings from the other countries, 
Ukrainian patients rely on endocrinologist, as a major informational source, and almost do 
not use electronic informational resources on diabetes management. Though many of the 
participants were not satisfied with their patient-doctors communication, we conclude 
that information provision is especially important on early development of the disease 
when patients lack information on hypoglycemia manifestations and can fail to identify it 
and manage it properly. 
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managing their condition. Being not aware of hypoglycemic symptoms, newly diagnosed 
patients might not associate their poor health state with complications of diabetes 
mellitus, but rather with some other reasons, such as menopause (among women), 
cardiovascular diseases, and so forth. This leads to impaired awareness that can 
significantly decrease proper hypoglycemia management and perceived quality of life 
[11,29]. We suggest that hypoglycemia awareness programs are important on early stage 
of type 2 diabetes mellitus.  
The shared experience by the focus group participants suggests that Ukrainian 
patients experience negative feelings about their state and dissatisfaction in their 
communications with their physician, and this is similar to the findings from other studies 
[7-10,30]. We consider that provision of disease management by primary care practitioner 
(family doctor or qualified nurse) can improve level of informational support for Ukrainian 
patients because of increase in duration and frequency of consultations. 
Limitations and design considerations 
The participants were invited to take part in the focus groups by their physician. Despite 
that study was conducted by independent researchers at independent clinical location, 
the selection of participants might potentially bias intention of patients to participate in 
the research.  
 All except one of the participants were residents of the large urban city of 
Ukraine. It is possible that the difference between city and village populations (income 
and education level) can affect reported outcomes. We suspect that village residents with 
type 2 diabetes mellitus who experience hypoglycemia symptoms might be less 
knowledgeable about the symptoms and their management, and they might be less likely 
to report them to their treating physician. In addition, the level of awareness of the focus 
group participants might be higher than that of an ordinary patient with similar symptoms 
because of inclusion criteria. 
The unemployment rate among focus group participants is significantly higher 
than the average unemployment rate (14%), especially among men. Taking into account 
lower participation rate among men, we conclude that employment state has an impact 
on tendency among men to participate in the study. The majority of participants also 
indicated their family income level to be lower than average in Ukraine. Although it was 
not our research question, it might be possible that patients with type 2 diabetes in 
Ukraine experience higher economic vulnerability, an issue which can be explored in 
future work on diabetes mellitus. 
We chose to give participants the HRQoL instruments only after the focus group 
discussion to prevent patients from talking about events they could potentially have 
rather than their true personal experiences. We did observe certain difference in the 
responses provided during the discussion and in writing: EQ-5D-3L instrument allowed 
conclusion on worse health state in comparison to HFS form; the participants had a trend 
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6. Are your relatives/colleagues aware of signs of hypoglycemia, do they know how to act in this case? 
7. How frequent are hypoglycemia cases (within a year/month) in your life? How many from these 
cases you would characterize as mild/moderate/strong? 
8. How do you learn about your disease, specifics of the life with diabetes, about treatment? Which 
sources do you trust the most?  
 
Possible answers: 
From individuals From media 
endocrinologist 
nurse 
nutritionist 
pharmacist 
stomatologist 
ophthalmologist 
Other health care workers 
I myself have a medical degree and worked 
in the field of medicine 
The family, including family members with 
diabetes 
Friends, neighbors, colleagues, 
acquaintances, other patients 
Classes and workshops, support groups 
Participation in the clinical trials 
Internet (websites, search engines) 
Information from organizations (e.g., 
Diabetic Union of Ukraine) 
specialized magazines 
TV (for example, programs on health) 
Newspapers 
Booklets, brochures, etc., from clinics and 
health care workers 
Information from pharmaceutical 
companies, pharmacies, drug supplier 
Printed reports of clinical trials, laboratory 
research 
9.  How did attacks of hypoglycemia affect your daily activity? 
For example: 
- working  
- driving 
- fitness activities 
- bicycle 
- housework 
- shopping 
10. How did episodes of hypoglycemia affect your family and social life? 
- Discomfort / irritation for close people 
- Relationships with family and friends 
- Relationships with colleagues  
 
ІІІ. Questionnaire on quality of life (20 min) 
IV. Concluding remarks (10 min) 
Wrap up 
Are there any other issues that we have not discussed? What else you need to know about hypoglycemia? 
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Appendix 7.1 Guide for the Patient Focus Group on Hypoglycemia 
I. Introduction (15 min) 
 Welcome words and introduction of the moderator and participants. 
 Explanation of the general purpose of the focus group, and the way the participants were selected. 
 Discussion of the objectives and the procedure for the focus group. 
 Explanation of the presence of the recorder, and the purpose of tape recording / presence of 
observers. 
 Development of the common basic rules and principles of the discussion, such as the value of each 
opinion, the rules "to speak one at a timĞ͕ΗĂŶĚ͞ďĞƉƌĞƉĂƌĞĚƚŚĂƚƚŚĞŵŽĚĞƌĂƚŽƌŵĂǇŝŶƚĞƌƌƵƉƚƚŚĞ
ĚŝƐĐƵƐƐŝŽŶƚŽĞŶƐƵƌĞƚŚĂƚĂůůŝƐƐƵĞƐĐĂŶďĞĂĚĚƌĞƐƐĞĚ͘͟ 
 Explanation of the schedule of the meeting, breaks and location of toilets. 
 Discussion on the issue of confidentiality, signing the consent. 
 Inform the group that the information being discussed will be analyzed in general, and that the names 
of participants will not be used in the analysis of the discussion. 
 Introduction to the participants (briefly) the study protocol. 
 Filling in the questionnaire of individual data. 
  
II. Discussion (50-90 min) 
1. What comes to your mind first when you think about the hypoglycemia? How would you describe 
your state/feelings during the hypoglycemia? 
2. After providing the answers, focus-group participants receive a brief description of hypoglycemia 
symptoms (Picture) and mark all of the symptoms that they experienced. 
2.1. When did you experience these symptoms the first time? 
2.2. How frequently do you experience the symptoms described?  
2.3. How frequently theƐĞƐǇŵƉƚŽŵƐĂƌĞƐŽƐƚƌŽŶŐ͕ƚŚĂƚ͙ 
 Your working productivity decrease? 
You can't perform your work? 
You can't perform your house-hold duties?  
3. Which actions do you take when you experience the symptoms indicated above?  
3.1. Do you intake drugs to cope with hypoglycemia? If "yes", than which ones and how frequently?  
3.2. Do you increase foods consumption? If "yes", than which ones and in what amount?  
3.3. Do you increase water consumption? If "yes" than to what amount?  
3.4. Do you take any other actions? If "yes", than which ones?  
3.5. Do you report to your doctor the cases of hypoglycemia? If "yes", than how frequently (which 
exactly symptoms and in which cases you report)?  
4. Do you experience psychological discomfort due to hypoglycemia events? 
Are you afraid to get a hypoglycemia event? 
Do you feel ashamed if you get hypoglycemia event? 
How chance to have hypoglycemia influence your mental well-being? 
Describe discomfort you experience when you get hypoglycemia? 
Describe not satisfaction with yourself and/or depression you connects with possibility to get 
hypoglycemia event? 
ϱ͘ƌĞǇŽƵĂǁĂƌĞŽĨ͚ŶŽĂĐƚŝŽŶ͛ĐŽŶƐĞƋƵĞŶĐĞƐ͍tŚŝĐŚŽĨƚŚĞƉŽƐƐŝďůĞĐŽŶƐĞƋƵĞŶĐĞƐǇŽƵĐĂŶƌĞĐĂůů͍ 
In case focus-group participants are not able to reply, they are provided with a brief description of 
possible consequences  
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 I do not work due to diabetes complications 
 I do not work due to other reasons  
 
How do you access your social level? (circle one option) 
 Low-income 
 Middle income 
 High-income 
 
Estimated level of household income (per month) (circle one option) 
 < 1.000 UAH 
 1.000 – 3.000 UAH 
 3.000 – 6.000 UAH 
 6.000 – 10.000 UAH 
 ��������UAH 
 
Do you use Internet? (circle one option) 
 Yes 
 No 
 Thank you!  
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Appendix 7.2 Individual data of the focus group participant 
We ask you to fill in the short demographic profile to enable profound analysis of the results of the focus group 
discussion 
Age (years) ____________________ 
How many years have passed since you were diagnosed with diabetes? (circle one option) 
 <2 years 
 ≥2 years but <5 years 
 ≥5 years but <10 years 
 ≥�������� 
 
Which antidiabetic medication do you intake? (circle one option) 
 �������������������������������������� 
 ��������������� ������������������������������� 
 ������������������������������������������������������������ 
 Do not take therapy at all 
 
Where do you get information about the course and treatment of diabetes? (multiple answers possible, mark 
all applicable) 
 From the endocrinologist 
 From the other physician 
 From the nurse 
 Searched in the specialized literature  
 Searched online sources  
 From unknown people 
 From relatives and acquaintances  
 
Your gender  
 Male 
 Female 
 
Place of residence (circle one option) 
 Kyiv 
 Other city 
 Village 
 
Family state (circle one option) 
 Live within a family 
 Live separately 
 
Level of education (circle one option) 
 Uncompleted secondary school 
 Secondary school 
 Professional training 
 High School  
 
Are you employed? (circle one option) 
 I am working 
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discussion 
Age (years) ____________________ 
How many years have passed since you were diagnosed with diabetes? (circle one option) 
 <2 years 
 ≥2 years but <5 years 
 ≥5 years but <10 years 
 ≥�������� 
 
Which antidiabetic medication do you intake? (circle one option) 
 �������������������������������������� 
 ��������������� ������������������������������� 
 ������������������������������������������������������������ 
 Do not take therapy at all 
 
Where do you get information about the course and treatment of diabetes? (multiple answers possible, mark 
all applicable) 
 From the endocrinologist 
 From the other physician 
 From the nurse 
 Searched in the specialized literature  
 Searched online sources  
 From unknown people 
 From relatives and acquaintances  
 
Your gender  
 Male 
 Female 
 
Place of residence (circle one option) 
 Kyiv 
 Other city 
 Village 
 
Family state (circle one option) 
 Live within a family 
 Live separately 
 
Level of education (circle one option) 
 Uncompleted secondary school 
 Secondary school 
 Professional training 
 High School  
 
Are you employed? (circle one option) 
 I am working 
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Introduction 
Chronic lymphocytic leukemia (CLL) is a progressive oncological disease 
characterized by the clonal proliferation and accumulation of neoplastic B lymphocytes in 
the blood, bone marrow, lymph nodes and spleen. According to the Ukrainian National 
Cancer Register the total morbidity rate for patients with diagnosed leukemia was 7.8 per 
100,000 people [1]. No national Ukrainian statistical data on CLL prevalence are available; 
however, if we assume the same distribution as in the US exists for the four major types of 
leukemia, up to 3.7 per 100,000 people are estimated to be CLL related [2]. The clinical 
course of this disease can be highly diverse and dependent on many factors, such as stage 
of the disease by K. Rai (from 0 to IV) and J. Binet (from A to C), chromosomal 
abnormalities, or mutations of the immunoglobulin heavy variable chain gene [3-5]. 
With the exception of blood band marrow transplantation – which has significant 
limitations by age and comorbidities – CLL remains an incurable condition. According to 
the national treatment protocol in Ukraine there are a number of treatment options for 
CLL patients [5]. ����������������������� ��������������������������� ���������������������
state of CLL, monotherapies are currently available: cytotoxic drugs including alkylating 
agents (chlorambucil, cyclophosphamide and bendamustine), antimetabolites or purine 
analogues (fludarabine or cladripine), mitoxantrone (an anthracycline) and prednisolone 
(a corticosteroid), as well as a number of therapeutic chemotherapy combination schemes 
[3,5]. One of the most frequently prescribed schemes for CLL patients treated in 
specialized hospitals of Ukraine is a combination of fludarabine with cyclophosphamide 
(FC) [6]. 
Rituximab, a monoclonal antibody that targets the CD20 cell surface antigen, is 
recommended for use in combination with chemotherapy for both treatment- naive 
patients, refractory patients (those experienced treatment failure or disease progress 
within 6 month of the last treatment) or relapsed (those experienced a response to 
therapy, but progressed after 6 or more months). Despite being one of the most expensive 
drugs used in CLL treatment in Ukraine, rituximab was included in the state tender 
purchases the previous years [6,7]. As an additive to FC, rituximab has been shown to be a 
promising medical product according to clinical trial data on both previously treated and 
untreated CLL patients [4,8].  
The cost-effectiveness of FCR (combination of rituximab with FC) versus FC 
scheme in treatment of naive or refractory/relapsed patients was previously confirmed in 
Spain, the US and the UK [9-11]. In Spain the incremental cost-effectiveness ratio (ICER) 
��������������������������������� ����-year (QALY) gained for the first-line treatment and 
������������the second-line treatment over a 10-year horizon [9]. In the US study the ICER 
was $23,530 per QALY considering a third-party payer and $31,513 per QALY considering a 
societal perspective over the life-time horizon [10]. In the UK rituximab also was 
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Abstract 
The aim of this study was to assess the cost-effectiveness, from a healthcare perspective, 
of adding rituximab to fludarabine and cyclophosphamide scheme (FCR versus FC) for 
treatment-naive and refractory/relapsed Ukrainian patients with chronic lymphocytic 
leukemia (CLL).  
A decision-analytic Markov cohort model with three health states and one-month cycle 
time was developed and run within a life time horizon. Data from two multinational, 
prospective, open-l��el ����e � ����ie� �e�e ��e� �� ���e�� ���ie���� ����i��l� ��ile 
utilities were generalized from the UK data, local resource utilization and disease-
associated treatment, hospitalization, and side effect costs were applied. The alternative 
scenario was performed to assess the impact of lower life expectancy of the general 
population in Ukraine on the incremental cost-effectiveness ratio (ICER) for treatment-
naive patients. One-way, two-way, and probabilistic sensitivity analyses were conducted 
to assess the robustness of the results.  
The ICER (in US dollars) of treating CLL patients with FCR versus FC is $8,704 per quality-
adjusted life year (QALY) gained for treatment-naive patients and $11,056 for 
refractory/relapsed patients. When survival data were modified to the lower life 
expectancy of the general population in Ukraine, the ICER for treatment-naive patients 
was higher than $13,000. This value is higher than three times the current gross domestic 
product per capita in Ukraine. Sensitivity analyses have shown a high impact of rituximab 
costs and a moderate impact of differences in utilities on the ICER. Furthermore, 
probabilistic sensitivity analyses have shown that for refractory/relapsed patients the 
probability of FCR being cost-effective is higher than for treatment-naive patients and is 
close to one if the threshold is higher than $15,000. 
State coverage of rituximab treatment may be considered a cost-effective treatment for 
the Ukrainian population under conditions of economic stability, cost-effectiveness 
threshold growth, or rituximab price negotiations. 
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Binet stages A (5% in FC and 4% in FCR) or B (63% in FC and 64% in FCR). Mean age of 
patients was 61 years and74% were males. Eastern Cooperative Oncology Group (ECOG) 
performance status of 0 was reported in 58% of FC and 56% of FCR groups [4] (Eastern 
Cooperative Oncology Group (ECOG) performance status is the criteria used to assess how 
ƚŚĞĚŝƐĞĂƐĞĂĨĨĞĐƚƐĚĂŝůǇ ůŝǀŝŶŐĂďŝůŝƚŝĞƐŽĨƉĂƚŝĞŶƚƐ͕ǁŚĞƌĞ͞Ϭ͟ ŝƐĂĨƵůůǇ active person and 
͞ϱ͟ŝƐĚĞĂĚ͖see the web-site of ECOG for details: http://www.ecog.org/). 
The modeled cohort of refractory/relapsed patients was considered to be 
identical to the trial population from an international, multicenter, open-label, phase 3 
study on 552 randomly assigned (1:1) patients carried out in 88 centers in 17 countries. 
Patients who had received one prior line of therapy, such as single-agent chlorambucil (or 
combined with prednisone/prednisolone), single-agent fludarabine (or another nucleoside 
analog), or an alkylatorcontaining combination regimen, but not an alkylator/nucleoside 
analog combination were enrolled in that study. The distribution of CLL patients by 
confirmed Binet stages in this trial was the following: stage C (31% in FC and 31% in FCR), 
stage A (11% in FC and 9% in FCR), and stage B (58% in FC and 60% in FCR).Mean age of 
patients was 62 years in FC and 63 in FCR groups, 66% (FC) and 68% (FCR) were males. An 
ECOG performance status of 0 was reported in 59% of FC and 61% of FCR groups [8].  
Treatment and treatment effect 
According to trial data and national clinical guidelines [4,8], CLL patients on FCR 
scheme should receive the following doses of drugs during each cycle: fludarabine 
(25mg/m2/d), cyclophosphamide (250mg/m2/d) for 3 days, rituximab (375 mg/m2 on day 
one of the first cycle and 500 mg/m2 on day one of subsequent cycles). In the model, 
dose-per-patient was calculated using an average body surface among the Ukrainian 
population (1.86 m2). We considered that the Markov cohort population did not receive 
full courses of therapy similar to the trials population [4,8], so the final average doses of 
each drug were adjusted to the average consumed doses (by treatment adherence in 
trials) .  
Survival data 
Overall survival (OS) and progression-free survival (PFS) were retrieved from the 
ƚƌŝĂůƐ͛ƉƵďůŝĐĂƚŝons presenting Kaplan-Meier plots [4,8]. The reported observation period 
equal to 61 months for treatment-naive patients and to 57 months for previously-treated 
patient (52 months for PFS during FC treatment) was chosen [4,8]. There was no 
information available on characteristics of Ukrainian CLL patients by Binet stages and 
ECOG performance status. At the same time, by gender and age distribution Ukrainian CLL 
patients were similar to trial populations selected as clinical data sources [4,6,8]. Two 
parametric extrapolation methods were applied. A Weibull model was selected to 
incorporate monotonic hazards, while a log-logistic model was selected as an alternative 
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considered to be a cost-effective option with an ICER of £13,189 per QALY for FCR versus 
FC in the treatment of naive patient population; however its combination with other 
chemotherapy agents was not recommended by the National Institute for Health and Care 
Excellence (NICE) [11]. 
To the best of our knowledge no economic evaluation on rituximab use was 
performed in Ukraine, nor any other country of the Central and Eastern European (CEE) or 
former Soviet region. Because of differences in treatment practice, perspectives, unit 
costs (including hospitalization) and demographic characteristics (both patients and 
general population), generalizability to Ukraine of the economic evaluations mentioned 
above is not possible. While no cost-effectiveness threshold has been established in 
Ukraine, the WHO considers technologies with a threshold of less than one GDP per capita 
to be very cost-effective, and those with a threshold of less than three GDP per capita to 
be cost-effective [12]. In 2013 the GDP per capita in Ukraine was equal to US$ 3,900, 
according to data of the World Bank [13]. 
In sum, the aim of this study was to assess, from a healthcare perspective using a 
life time horizon, the cost-effectiveness of FCR compared to FC for treatment-naive and 
refractory/relapsed Ukrainian CLL patients.  
 
Methods 
Framework / Structure of the model 
Two decision-analytic Markov cohort models with the same structure were 
developed in Microsoft® Excel 2007 to assess the incremental costs and benefits 
associated with adding rituximab to the chemotherapy scheme FC. These models were run 
on two populations using data from two randomized controlled trials, one with treatment 
naive and one with refractory/relapsed patients. Three health states were defined in the 
models with a cycle time of one month: 1) stable or progression-free state; 2) disease-
progressed state; and 3) death. Assessment of the incremental costs and benefits from a 
healthcare perspective was conducted using a life-time horizon. Quality adjusted life years 
(QALYs) comprised the main outcome in both models with uniform 3% discounting for 
both costs and effects [14].  
Target population 
We considered the modeled cohort of treatment-naive patients to be identical to 
the trial population from a published prospective, open-label, phase 3 study on 817 
randomly assigned (1:1) patients carried out in 190 centers in 11 countries. Enrolled in this 
study were treatment-naive patients diagnosed with immunophenotypically confirmed 
CLL in Binet stage C (31% in FC and 31% in FCR) or those with confirmed active disease in 
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data on utilities for different cancer states were generalized to the Ukrainian population 
for whom local data was absent.  
The two trials used a multinational sample as a source of survival data for Markov 
ĐŽŚŽƌƚ>>ƉĂƚŝĞŶƚƐ΀ϰ͕ϴ΁͘ůƚŚŽƵŐŚƚŚĞƉĂƚŝĞŶƚ͛ƐĐŽƵŶƚƌǇŽĨĞŶƌŽůŵĞŶƚŝŶƚŚĞƚƌŝĂůƐǁĂƐŶŽƚ
reported, we assume that most were enrolled in countries with developed economies, 
where life-duration of the general population differs from those in Ukraine. Therefore we 
report an alternative scenario with Ukraine-specific mortality rate for non-CLL related 
causes to assess the impact of this parameter on the ICER. For this the gender- and age-
specific difference in death probability among general population in the US and Ukraine 
was calculated. For this the difference in death probabilities between US and Ukrainian 
males and females of different age was firstly calculated using states statistic data [18,19]. 
Afterwards, the death probability among the population identical to the cohort by sex and 
age characteristics was retrieved. As the next step the OS and PFS from the trial were 
added to the positive or negative coefficient of mortality difference depending on the age 
of the patient during therapy initiation. The survival analysis with Weibull extrapolation 
was performed on the received adjusted data to ensure higher reliability of the received 
results.  
Additional scenario analyses were conducted to assess the impact of survival 
analysis on cost-ĞĨĨĞĐƚŝǀĞŶĞƐƐƌĞƐƵůƚƐ͘tĞǀĂƌŝĞĚĚƵƌĂƚŝŽŶŽĨƉĂƚŝĞŶƚƐ͛ŽďƐĞƌǀĂƚŝŽŶƉĞƌŝŽĚ
in the trials and assessed impact of these changes on the results of survival analysis and 
economic evaluations. Probabilistic sensitivity analyses with 5000 runs were conducted to 
define overall uncertainty of the model. Both deterministic and probabilistic model 
parameters are presented in Table 8.1.  
 
dĂďůĞϴ͘ϭZĞƐŽƵƌĐĞƵƐĞ͕ĐŽƐƚƐ͕ĂŶĚƵƚŝůŝƚŝĞƐĂŶĚƉĂƚŝĞŶƚƐ͛ĐŚĂƌĂĐƚĞƌŝƐƚŝĐŝŶƉƵƚdata used in 
both deterministic and probabilistic models 
Parameter Deterministic value Data source  
Range 
used in 
sensitivity 
analyses  
Comments  
Resource use 
Annual number of 
hospitalization days (for 
salvage patient), days 
 
34 Analysis of the 
hospital records 
[6] 
27.2-40.8 20% variation 
from the 
average, flat 
distribution 
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to incorporate non-monotonic hazards. The model that provides the closest parametric 
estimation was selected for cohort survival assessment.   
Costs 
In line with recommendations of the ISPOR taskforce report on transferability 
[15], unit costs and resource utilization were retrieved from local sources. From the health 
care perspective, the following costs were included in the model: initial therapy costs, 
hospitalization costs, adverse events costs and salvage costs (Table 8.1). Unit drug costs 
were included in the deterministic model by the most frequently prescribed trade names 
΀ϲ΁͘ hŶŝƚ ĚƌƵŐ ƉƌŝĐĞƐ ǁĞƌĞ ƌĞƚƌŝĞǀĞĚ ĨƌŽŵ ƚŚĞ ǁĞďƐŝƚĞ ŽĨ hŬƌĂŝŶĞ͛Ɛ DŝŶŝƐƚƌy of Health 
(accessed on 06.06.2014 from http://www.moz.gov.ua/ua/portal/register_prices_drugs/). 
Costs of grades 3 and 4 adverse events reported with a frequency greater than or equal to 
5% were accounted for in the model calculations. Opinion of experts from specialized 
institutions of Ukraine and hospital records were used to define the most frequently 
prescribed treatment schemes for these conditions.  
A previously-published costing study in Ukraine was used to assess costs of 
salvage treatment [6]. Because of data obsolescence, these costs were considered to grow 
by the consumer price index for pharmaceuticals and health care for the last four years 
(5.7%). Additionally, the model took into consideration the monthly growth in costs for 
salvage treatment proportional to an average monthly consumer price index for 
pharmaceuticals and health care (0.11875%) [16]. Data of specialized hospitals in Ukraine 
were used to determine an average duration of hospitalization due to a relapse, as well as 
daily costs of hospital stay excluding pharmaceutical treatment [6]. Similar to 
pharmaceutical treatments, hospital stay unit costs were considered to grow 
proportionally to an average consumer price index for pharmaceuticals and health care. 
The exchange rate of the National Bank of Ukraine on 04.06.2014 (11,833UAH per US$) 
was used in all calculations. 
Utilities 
No country-specific utility data was available for CLL patients, nor for the general 
Ukrainian population, therefore, utilities of health states associated with CLL treatment 
(values of 0.78 for the progression-free or stable disease state and 0.68 for the progressed 
disease) were assumed generalizable from the UK [17]. 
Sensitivity analyses and data transferability 
We used sensitivity analyses to address uncertainty in the defined input 
parameters specific for Ukraine and those generalized from other populations. Using 
univariate analyses we assessed the impact of variations in rituximab costs, hospitalization 
costs, salvage treatment costs, costs of side effects, average monthly index of 
consumption prices and discount rates. Multivariate analysis was applied because the UK 
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data on utilities for different cancer states were generalized to the Ukrainian population 
for whom local data was absent.  
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to incorporate non-monotonic hazards. The model that provides the closest parametric 
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Unit costs 
 
Fludarabine costs, US$ per mg 
 
3.31 
Costs of drugs the 
most frequently 
prescribed via state 
budget [6] 
 
1.89-3.31 
Range of costs 
available on the 
state market, 
flat distribution  
Cyclophosphamide costs, US$ 
per mg 0.0022 0.0022-0.036 
Rituximab costs, US$ per mg 
 
2.24 1.76-2.24 
Hospitalization costs per day,  
US$ 16 
Cost of 
hospitalization stay 
in specialized 
hospital of Ukraine 
2010 [6,16]  
13-19 
20% costs 
variation, flat 
distribution 
Salvage therapy costs, US$ per 
month 177.06
c 
Cost of relapse 
treatment in 
specialized hospital 
of Ukraine 2010 
[6,16]  
141.64-212.47 
20% costs 
variation, flat 
distribution 
Average monthly index of 
consumption prices  0.1188% 
Calculated as 
average from the 
last 4 years  
- - 
Average body surface 
 
1.86 Average body surface in Ukraine - - 
Side effects costs      
 
Average cost per on treatment 
naïve patient (FCa), US$ 
 
74 
Average costs by 
the most 
frequently 
prescribed trade 
names (hospital 
cards analysis [6] 
ĂŶĚĞǆƉĞƌƚ͛Ɛ
opinion) 
 
64-248 Minimum and 
maximum costs 
by prices for 
each generic 
name, 
registered on 
the web-site of 
the Ministry of 
Health, flat 
distribution 
Average cost per on treatment 
naïve patient (FCRb), US$ 
106 96-335 
Average cost per on 
refractory/relapsed patient 
(FCa), US$ 
67 58-194 
Average cost per on 
refractory/relapsed patient 
(FCRb), US$ 
68 60-182 
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Refractory/relapsed patients 
 
Total dose of fludarabine 
received during 6 cycles of the 
therapy, mg 
 
202.69 
 
Trial dose adjusted 
to percentage of 
patients received 
therapy on each 
cycle and body 
surface among 
Ukrainian 
population 
 
186-279 
 
Average trial 
dose received 
by Ukrainian 
patient during 4 
to 6 cycles of 
the therapy, flat 
distribution 
Total dose of 
cyclophosphamide received 
during 6 cycles of the therapy, 
mg 
2,131.56 1,860-2,790 
Total dose of rituximab 
received during 6 cycles of the 
therapy, mg 
4,854.60 3,720-5,580 
Treatment naive patient 
 
Total dose of fludarabine 
received during 6 cycles of the 
therapy (Patients on FCa 
treatment), mg 
 
223.2 
Trial dose adjusted 
to average number 
of cycles received by 
the patients in the 
trial  and body 
surface among 
Ukrainian 
population 
 
186-279 
Average trial 
dose received 
by Ukrainian 
patient during 4 
to 6 cycles of 
the therapy, flat 
distribution 
Total dose of 
cyclophosphamide received 
during 6 cycles of the therapy 
(Patients on FCa treatment), 
mg 
2,232 1,860-2,790 
Total dose of fludarabine 
received during 6 cycles of the 
therapy (Patients on FCRb 
treatment), mg 
241.8 186-279 
Total dose of 
cyclophosphamide received 
during 6 cycles of the therapy 
Patients on FCRb treatment), 
mg 
2,418 1,860-2,790 
Total dose of rituximab 
received during 6 cycles of the 
therapy (Patients on FCRb 
treatment), mg 
 
4,231.5 3,487.5-5,347.5 
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c- Monthly salvage costs were calculated from a previous study on cost-of treatment of CLL in Ukraine by 
recalculating the annual costs to monthly costs. The received costs were assumed to grow from the time of the 
assessment on consumer price index for pharmaceuticals and health care for the last four years. Each time the 
conversion of the costs was conducted from local currency (UAH). 
 
Results 
Treatment with rituximab resulted in both a longer expected survival and a gain 
in QALYs compared to the standard therapy (Table 8.2). The gain in expected number of 
life years was 1.60 for both treatment-naive and refractory/relapsed patients treated with 
the FCR vs FC scheme in the base-case scenario. Associated costs were higher with FCR 
rather than FC treatment in the base case and all alternative scenarios (Table 8.2).  
Survival analysis: treatment naive patients  
 
Progression-free 
survival FCa 
scheme  
 
Lambda 
 
0.013576 
 
Weibull estimation 
 
 
±0.000681 
 
Weibull 
analysis, normal 
distribution 
(Beta for 
Lambda overall 
survival on FCR 
scheme) 
Gamma 0.000681 ±0.013858 
Correlation 
coefficient 
-0.99259  
Overall survival 
FCa scheme 
Lambda 0.000994 ±0.042679 
Gamma 1.511907 ±0.042679 
Correlation 
coefficient 
-0.99722  
Progression-free 
survival FCRb 
scheme 
Lambda 0.005851 ±0.000451 
Gamma 1.219618 ±0.020593 
Correlation 
coefficient 
-0.99513  
Overall survival 
FCRb scheme 
Lambda 0.000213 ±0.00014 
Gamma 1.809901 ±0.168617 
Correlation 
coefficient 
-0.99808000  
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Utilities     
 
Progression-free survival 
 
0.78 
 
[17] 
 
0.75-0.82 
 
CI, normal 
distribution [17] 
Overall survival 
 
0.68 [17] 0.64-0.72 CI, normal 
distribution [17] 
Survival analysis: refractory/relapsed patients  
 
Progression-free 
survival FCa 
scheme  
 
 
 
Lambda 
 
0.01958 
 
Weibull estimation 
 
 
±0.001381 
 
Weibull 
analysis, normal 
distribution 
Gamma 1.15346 ±0.020872 
Correlation 
coefficient 
-0.99051400  
Overall survival 
FCa scheme 
 
 
 
Lambda 0.00436 ±0.000742 
Gamma 1.24444 ±0.046098 
Correlation 
coefficient 
-0.99598300  
Progression-free 
survival FCRb 
scheme 
 
 
Lambda 0.02847 ±0.00237 
Gamma 0.95491 ±0.024185 
Correlation 
coefficient 
-0.99062300  
Overall survival 
FCRb scheme 
 
 
 
 
Lambda 0.00594 ±0.00039 
Gamma 1.09334 ±0.017784 
Correlation 
coefficient 
-0.99524000  
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Table 8.3 Univariate and multivariate sensitivity analysis: impact of costs variations on 
cost-effectiveness results 
Parameters of variation 
and values 
ICERa , treatment  
naive patients 
ICERa , treatment 
experienced patients 
US$/QALYb 
% of 
change 
from base 
ICER 
US$/QALYb 
% of 
change 
from base 
ICER 
Average monthly index 
of consumption prices 
 
 
 
 
0% 
 
$8,501 2% $10,677 4% 
0.2375% 
(doubled d) 
$8,907 -2% $11,453 -4% 
Discounting, annual 
 
 
 
 
 
 
0% $6,904 21% $8,754 21% 
5% $10,194 -17% $13,010 -18% 
10% $15,041 -73% $19,494 -76% 
Multivariate (discounting 
and average monthly 
index of consumption 
prices) 
 
 
0% $6,645 24% $8,297 25% 
Doubled d $11,184 -28% $14,440 -31% 
Rituximab costs 
 
 
 
 
 
 
50% d $4,538 48% $6,471 42% 
25% d $2,455 72% $4,173 62% 
120% d $10,371 -19% $12,903 -17% 
Hospitalization costs 
 
 
 
 
 
 
50% d $8,673 0% $10,895 2% 
25% d $8,657 1% $10,810 2% 
120% d $8,717 0% $11,133 -1% 
Salvage therapy costs 
 
 
 
 
 
50% d $8,563 2% $10,298 7% 
25% d $8,492 2% $9,914 10% 
120% d $8,761 -1% $11,372 -3% 
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The difference in QALYs gained and costs was smaller in the scenarios where 
survival analysis was conducted on the trial data with the longer follow-up (and the 
opposite). When survival data on treatment-naive patients were extrapolated to 65 
months, the incremental value of QALYs became negative. There was a smaller observed 
difference in both QALYs and costs for the FC and FCR treatment-naive population, when 
adjustment to the expected higher mortality among the general population of Ukraine 
was conducted.  
 
Table 8.2 Cost-effectiveness analysis of adding rituximab to fludarabine plus 
cyclophosphamide scheme in treatment-naive and refractory/relapsed patients 
Conditions Cost difference 
QALYa 
difference 
ICERd 
(US$/QALYa) 
Treatment naive patients   
Base-case scenario FCRb vs. FCc   US $10,827 1.24 US $8,704 
Scenario 1: Ukraine-specific mortality among general 
population 
 US $8,022 0.62 US $12,897 
    
Scenario 2: 56 months survival data  US $16,881 2.61 US $6,475 
Scenario 3: 60 months survival data  US $15,204 2.22 US $6,851 
Scenario 4: 62 months survival data  US $7,677 0.62 US $12,343 
Scenario 5: 65 months extrapolated survival data  US $4,786 -0.83 dominated 
Treatment experienced patient  
Base-case scenario FCRb vs. FCc  
 
US $13,081 1.18 US$11,065 
Scenario 1: 52 months survival data, ICERd                       (US$ 
per QALYa) 
US $ 14,660 1,53  US $9,557 
aQALY  - quality adjusted life years; bFCR – rituximab plus fludarabine and cyclophosphamide scheme; cFC - 
fludarabine and cyclophosphamide scheme; dICER- incremental cost effectiveness ratio.  
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converges to one for refractory/relapsed patients and to 0.80 for treatment-naive patients 
(Figure 8.2).  
 
 
Figure 8.1 Cost-effectiveness plane: adding rituximab to treatment of naive and 
refractory/relapsed patients 
 
Figure 8.2 Cost-effectiveness acceptability curves 
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Side effects costs (FCRc) 
 
 
 
 
 
 
50% d $8,662 
 
0% $11,036 0% 
25% d $8,640 1% $11,022 
 
0% 
120% d $8,722 0% $11,076 0% 
Utilities 0.78 - PSe 
0.88   PFSf 
 
$7,710 11% $9,744 12% 
0.58 -  PSe 
0.68 -PFSf 
 
$9,993 -15% $12,800 -16% 
0.58 - PSe  
0.88 -PFSf 
 
$7,786 11% $10,838 2% 
aICER- incremental cost effectiveness ratio; b QALY - quality adjusted life years; cFCR – rituximab plus fludarabine 
and cyclophosphamide scheme; d –from deterministic value; ePS – progression state; fPFS – progression free 
state. 
 
For every expected QALY gained, US$8,704 will be needed in the base-case 
scenario for state coverage of treatment-naive patients, which can be considered a cost-
effective option. The ICER of treating refractory/relapsed patients with the FCR scheme is 
close to the cost-effectiveness threshold within the base-case scenario (ICER US$11,056; 
threshold of three GDP per capita is US $11,700). The incremental cost-effectiveness ratio 
of FCR use for treatment-naive patients will be close to $13,000 if a higher mortality 
among the general population in Ukraine is considered in the survival analysis. This ICER 
for treatment-naive patients is above the theoretical cost-effectiveness threshold in 
Ukraine. 
As can be seen from Table 8.3, an increase in the average consumer price index 
and discount rate caused a higher ICER for both treatment-naive and refractory/relapsed 
patient populations. Similarly, multivariate analyses with zero values for both discounting 
and average monthly index of consumer prices resulted in ICERs of US$6,645 and 
US$8,297, respectively. Rituximab cost was the only cost parameter having a significant 
impact on the ICER in both populations. Changes in utilities had a moderate impact on 
cost-effectiveness results. 
The results of PSA showed a high probability for FCR treatment to be cost-
effective for both treatment-naive patients (cost difference US$13,118, s.d. US$8,079; 
QALYs difference 2.21, s.d. 1.78; ICER US$5,938) and refractory/relapsed patients (cost 
difference US$14,290, s.d. US$2,455; QALYs difference 1.68, s.d. 0.45; ICER US$8,485) with 
the threshold of US$11,000 (Figure 8.1). As the threshold value increases, the probability 
of FCR being cost-effective is higher for refractory/relapsed patients. In particular, when 
the threshold is higher than US$15,000, the probability of FCR being cost-effective 
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converges to one for refractory/relapsed patients and to 0.80 for treatment-naive patients 
(Figure 8.2).  
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Figure 8.2 Cost-effectiveness acceptability curves 
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perspectives, model durations and data extraction approaches differed. Methodological 
differences and non-generalizability of data limited transferring results of these studies to 
Ukraine. The third-party perspective is not applicable for Ukraine and, because of the 
significant number of assumptions [10], the societal perspective also is not considered. 
Additionally, the use of parametric extrapolation methods for survival analysis instead of 
raw trial data was considered important because of the high impact of survival parameters 
ŽŶƚŚĞ/Z͘tŚŝůĞŶŽƌĞůĂƚŝŽŶďĞƚǁĞĞŶƚŚĞĐŽƵŶƚƌǇ͛ƐŝŶĐŽŵĞĞǆƉƌĞƐƐĞĚďǇ'WƉĞƌĐĂƉŝƚĂ
and the cost-effectiveness of FCR in comparison to FC scheme has been shown in prior 
research [9,10,11], in our study we see a significant difference in the values of the ratios 
observed. We also note an important similarity between our study and one conducted in 
the Spanish health care setting [9]; namely, treating treatment-naive patients with FCR 
scheme appeared to be more cost-effective than for refractory/relapsed patients. 
Limitations 
As a limitation we should point out that data pertaining to the trial population 
and the mortality rate from non-CLL causes among trial populations were not available, 
thus may not correspond to the Ukrainian population. Moreover, Ukrainian costs data are 
limited and based on one study assessment.  
 
Conclusions 
State coverage of rituximab treatment may not be considered a cost-effective 
treatment option for the Ukrainian population compared to current care; however, it may 
become cost-effective under conditions of economic stability, cost-effectiveness threshold 
growth or rituximab price negotiations. Taking into account the WHO recommendations 
on cost-effectiveness thresholds and current GDP per capita in Ukraine, state coverage of 
FCR scheme for treatment-naive patients is more economically argued than that for 
refractory/relapsed patients.  
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Discussion 
Neither for treatment-naive nor for refractory patients does adding rituximab to 
the FC scheme make it a cost effective option when using a threshold of US$3,900 [13]. 
However, use of the FCR scheme can still be considered a cost-effective option when using 
the theoretical threshold of three times the GDP per capita in Ukraine. As such, we 
conclude that providing this drug should not be considered the highest priority, but should 
depend on budget availability. This conclusion is supported by the decision uncertainty 
demonstrated by the sensitivity analyses; thus, the state coverage of this drug for both 
treatment-naive and refractory/relapsed population remains a possibility to be argued. 
The Ukrainian Ministry of Health purchĂƐĞƐ ƌŝƚƵǆŝŵĂďĂŶŶƵĂůůǇ ĨŽƌ>>ƉĂƚŝĞŶƚƐ͛
needs without recommendations on its actual use. Nearly US$1.4 mln of state budget was 
spent on rituximab purchase in 2013 [7]. However, based on current evidence there is a 
higher rationality for it to be provided for the treatment naive patient population, rather 
than for refractory/relapsed patients. At the same time, if the theoretical threshold will 
become higher as a result of an improving Ukrainian economy, then coverage of 
refractory/relapsed patients is likely to become more cost-effective option than that for 
the treatment-naive population, an outcome primarily related to the higher stability of the 
results. On the other hand, in an unstable economic environment, adding rituximab to FC 
treatment of refractory/relapsed patients may not be a cost-effective option from a health 
care perspective, taking into account that any increase in the discount rate, treatment 
costs, or inflation rate (index of consumer prices) leads to an ICER estimate close or above 
the value of the theoretical threshold. Because rituximab cost was the most influential 
parameter, price negotiation may be applied to ensure that state spending on this 
treatment is rational.  
Because multinational clinical data were used for both models, we were 
concerned with how much the trial population would be representative for Ukraine. While 
published data were used to populate the models, the cohort population in both models 
was not different by gender and age characteristics from both trial population and profiles 
of CLL patient in Ukraine in terms of mean age of naive patients (60.3), age of 
refractory/relapsed patient (62.8) and the fact that 67% of patients were male [6]. 
Moreover, we considered that because of differences in age at diagnosis between 
different countries, if trial data were primarily retrieved from economically-developed 
countries, the mortality from other causes in CLL trial population may be different from 
those in Ukraine. We conclude that if such a case exists, then it is doubtful that the use of 
rituximab in CLL population in Ukraine will be cost-effective.  
As stated in the introduction, until now the cost-effectiveness of rituximab was 
assessed only in health care settings of economically more developed countries, such as 
the US [10], the UK [11], and Spain [9]. While all studies used three-stage models, the 
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Use of economic evaluations and need for transferability in CEE and former Soviet 
countries  
While scope of impact of the cost-effectiveness criterion on the decision-making 
process differs from country to country [3, 12], it appears from chapter 2 that economic 
evaluations can be an additional tool for state reimbursement decisions – even in 
countries without a formal HTA agency. While other factors (for example, budget impact) 
may be predominant in middle-income countries, comparative economic studies may be 
accepted under the following conditions: (1) The methodology is considered relevant 
(technology, comparators, population) and of high quality; (2) Experts or decision makers 
��������������������������������������������������������������������������������������������
from other jurisdictions [13]. 
Setting out to implement an HTA approach, CEE and former Soviet countries 
already are facing a number of barriers, primarily related to low HTA capacity (including 
budget, manpower and data constraints) and to the decision-making process itself. 
Although capacity building should be addressed before implementing an HTA system [14], 
some countries follow an alternative approach, using HTA without having built more 
capacity and without strict priority settings. This approach slows down the development 
of the system and may lead to incorrect decisions and, therefore, to a waste of resources.  
Figure 9.1 nicely illustrates that even though the basis for a reimbursement 
decision may not yet be clear [13], HTA capacity is a requirement for any HTA-based 
decision. At the same time, reimbursement decisions may be argued on the grounds of 
factors such as the importance of the submitted HTA report to the decision makers (thus, 
a formal or advisory role of HTA, belief in the evidence provided, educational level of the 
decision makers), health priority of the technology, budget availability, and transparency 
of the decision-making process (including rationality in the decision making, personal 
opinion and conflict of interest). Consequently, if the role of HTA in budget allocation is 
not defined, as is the case in many countries [5], low HTA capacity results in a limited 
added value of the submitted HTA reports in reimbursement decisions. As a result, the 
producers of medical technologies are not motivated to invest in budget-consuming 
submissions, especially under conditions of limited or unsecured financing.  
HTA manpower is scarce in many middle-income jurisdictions [6], and 
educational programs in HTA and economic evaluations are highly needed there (chapter 
2). It is unfortunate, however, that many countries of the study region have not the means 
to widely finance educational programs. On the other hand, in those countries that can 
afford this, we often see a brain drain from state regulatory committees to the private 
sector [17].  
Besides manpower, financial issues have a major impact on the use of economic 
evaluations and HTA development in most countries, including countries of the European 
Union [15, 17].  
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 Transferability issues are known and considered important in the countries 
studied, but have not yet gained the attention they deserve 
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 Variations in unit cost, resource use and baseline risk could have a significant 
impact on the results of economic studies, thereby rendering them non-
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Additionally, a lack of data on both costs and outcomes influences both the 
��������������������������������������������������������������������������������������
evidence (chapters 2, 3). These requirements for high–quality, unbiased submissions 
become more critical if not enough expertise is available [3], which currently seems to be 
the case in CEE and former Soviet countries (chapter 2). 
Because of the barriers indicated above, generalizability or simple transferability 
adjustments of economic evaluations may be the only way to include economic 
considerations in the decision-making process in many CEE and former Soviet countries 
(chapters 2, 3). Meanwhile, generalizing economic evaluations from neighboring countries 
is not possible, and due to significant differences in healthcare practices, system 
structures and financing, the transferability of studies between different geographic 
regions is even more limited. 
Chapter 3 makes clear that only very few transparently reported economic 
evaluations for healthcare settings of CEE and former Soviet countries have been 
published; most economic evaluations originate from North America (Canada and the 
USA) and Western and Northern Europe [17]. This seems to be the cause of a paradoxical 
situation: knowing about transferability issues, HTA-related bodies use published 
economic evidence conducted in other jurisdictions which are often not comparable with 
the own jurisdiction. 
Previous research has also addressed this limited generalizability as a result of 
variability in health and economic indicators [10, 20]. Even for economically comparable 
Western European countries, such as the UK and France, it was found difficult to 
generalize economic evaluations [21].  
Being a first knock-out criterion for transferability [6], the quality of economic 
evaluations is an issue of concern for decision makers in CEE and former Soviet countries 
(chapter 2), similar to other geographic jurisdictions [3]. Nevertheless, as described in 
chapter 3, both quality and transparency of evaluations conducted in healthcare settings 
of CEE and former Soviet countries are frequently insufficient. Furthermore, they often 
lack a stated perspective and a clear cost description and fail to fully address uncertainty. 
Additionally, piggy-backed economic studies are usually based on small, local trials rather 
than on multicenter trials, so the small sample sizes limit generalizability of the results due 
to low statistical power. Most economic evaluations conducted in the study region did not 
���������������������������������������������������������������������������������������hey define 
critical influential parameters and their threshold values. As such, the transferability of 
trial- and model-based studies to other jurisdictions is complicated [21-23].  
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ƉƌŽĐĞĚƵƌĞ;ǁŚŝĐŚ ŝƐƉƌŝŵĂƌŝůǇĚĞƉĞŶĚĞŶƚŽŶŵŽƚŚĞƌ͛ƐĂŐĞͿĂŶĚƚŚĞƉƌŽƚŽĐŽůƐĨŽůůŽǁĞĚŝŶ
the particular jurisdiction/clinic have a defining impact on the resultant net present value 
from the population born. Similarly, population mortality among the general population 
has an additional impact on the results of economic studies (chapters 5 and 8). Diversity of 
case-mix characteristics (e.g., gender distribution, age at diagnosis, body mass index) may 
affect cost-effectiveness results because of the impact of these characteristics on cohort 
life duration, higher income/costs associated with the particular gender group, or 
differences in drug doses received (chapters 5, 6, and 8). 
Relative risk reduction or treatment effect is considered to be an easily 
transferable parameter both by pharmacoeconomic guidelines [24] and by CEE 
reimbursement experts. As shown in Chapters 6 and 8 for certain disease areas, using the 
transferred treatment effect may be beneficial for economic studies conducted in the CEE 
region and former Soviet Union as an opportunity: 1) to increase power in a study and to 
assess the generalizable treatment effect; 2) to compare with a wider number of 
alternatives; 3) to avoid trial costs; and 4) to have evidence available within a shorter time 
span [20, 24, 25].  
Despite evidence of differences in utilities between populations [2, 24, 26], country-
specific utility weights are not of major interest for decision makers in CEE and former 
Soviet countries, and are rarely used in relevant published studies (chapters 2, 3). While 
transferability of utility parameters is disease specific and should be assessed on an 
individual basis, ŝŶĂƋƵĂůŝƚĂƚŝǀĞƐƚƵĚǇŽŶƚǇƉĞϮĚŝĂďĞƚĞƐƉĂƚŝĞŶƚƐ͕ƉĂƚŝĞŶƚƐ͛ƉĞƌĐĞƉƚŝŽŶŽĨ
the disease state did not differ between Ukrainian and Western-European populations 
(chapter 7).  
 
Recommendations and policy implication 
 
Box 2. Recommendations and policy implication 
 
 Address barriers related to decision making process and limited HTA capacity 
 Develop pharmacoeconomic guidelines related to the local context and 
requirements 
 Adapt a standardized approach to simplify transferability assessment process 
 Define priorities for HTA evaluations 
 Provide incentives to improve quality and transparency of economic evaluations 
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Practical application of transferability principles and transferability of input parameters 
by major data categories 
While the generalizability of economic evaluations within the CEE region and 
former Soviet Union is without validity problems, certain input parameters possess a 
different level of transferability [24]. The most difficult to transfer are costs and prices, 
baseline risk and treatment effect, in contrast to treatment adherence and utility values, 
which are considered of less importance. Costs are not considered to be generalizable 
parameters and are almost always locally adapted in published studies from this region.  
The following factors may limit the degree of cost generalization from the other 
jurisdictions: 1) the cost components of one unit differ between jurisdictions; 2) the cost 
of individual units may be different and not be proportional to the purchasing index or 
GDP per capita; 3) market differences may result in cost variations. As an example, the 
hospitalization costs in Ukraine from a state or healthcare perspective frequently include 
diagnosƚŝĐƐ͕͞ŚŽƚĞůƐĞƌǀŝĐĞƐ͕͟ĂŶĚĂĚŵŝŶŝƐƚƌĂƚŝŽŶĂŶĚŵĞĚŝĐĂůĐĂƌĞĐŽƐƚƐ͖ĂƚƚŚĞƐĂŵĞƚŝŵĞ
unit costs in most of the countries with reimbursement system are defined by diagnostic-
related groups (chapter 3). Not only cost components themselves, but also their relative 
values can differ. Chapters 4, 5, 6 and 8 demonstrate a significant difference between the 
costs of therapy and medical care (hospitalization or ambulatory visits), culminating in 
non-comparability of the results between Ukraine and high-income markets. 
While pharmaceutical markets in many Western European countries have rigid 
pricing regulations, primary out-of-pocket markets in former Soviet countries are 
frequently missing price-entry schemes for generic products. As a result, there is a 
considerable variety in drug costs (chapters 5 and 8), which, depending on the technology, 
may have an impact on the results of economic evaluations.  
Resource utilization between countries may vary for both inpatient and 
outpatient visits (chapters 4-8), dependent on parameters such as normative 
recommendations by the Ministry of Health, clinical guidelines, current clinical practice, 
and population characteristics (e.g., age/gender, education level, share of internet users 
among patients). For example, in contrast to Western European and North American 
countries, Ukrainian type 2 diabetes patients are seen by specialists (endocrinologists) and 
not by primary care specialists or nurses (chapter 6), and Ukrainian clinical guidelines on 
hematologic malignancies provide additional treatment options under conditions of 
limited availability of financing (chapter 4). Because of the impact of health economic 
indicators (chapter 1), resource utilization may be a critical parameter for both non-
comparative (chapters 4, 5) and comparative (chapter 8) economic evaluations.  
Baseline risk is a parameter that widely varies between different jurisdictions 
[2,24]. While the risk of future events of interest without treatment may vary more for 
preventive technologies, case-mix characteristics may significantly impact the results of 
economic studies. Chapter 5 makes clear the baseline risk of the success of an IVF 
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Stakeholders to involve  
^ƚĂŬĞŚŽůĚĞƌƐ͛ ŽƉŝŶŝŽŶƐ ŽŶŵĞƚŚŽĚŽůŽŐǇ ĂŶĚ ĚĂƚĂ ƚƌĂŶƐĨĞƌĂďŝůŝƚǇǁĞƌĞ ŐĂƚŚĞƌĞĚ
implicitly during group meetings or face-to-face interviews before the start of each study 
presented in Part 2. Obviously, relevant stakeholders should be involved explicitly to 
improve the quality, the transparency and the transferability, and thus to improve the use 
of economic evaluations in healthcare decision making of CEE and former Soviet countries. 
As such, policy makers should provide clear incentives to research payers/sponsors (often 
the producer of a medical technology) and researchers. Therefore, applying the CHEERS 
statement [28] is strongly recommended.  
 
Unaddressed issues and possibilities for future research 
In this work we analyzed transferability of economic evaluations and their 
components to CEE and former Soviet countries without an established centralized HTA 
agency. The following aspects, not addressed in this dissertation, may be of interest for 
future research: 
Priorities for economic evaluations conducted for healthcare settings of CEE and former 
Soviet countries 
As indicated in chapter 3, economic evaluations conducted for healthcare settings of 
CEE and former Soviet countries may be fund driven and, therefore, at risk of being 
unrelated to the priorities of decision makers. Because these priorities may be assessed 
indirectly (for example, by budget allocations), systematizing this evidence may be useful 
for future studies.  
Impact of evidence on reimbursement decisions in CEE and former Soviet countries  
The research presented in this dissertation allowed conclusions to be drawn regarding 
the use of economic evaluations in the healthcare decision making processes of CEE and 
former Soviet countries. However, the scope of impact of economic studies as well as the 
background impact of other evidence and factors is not known. 
Quality of local language publications in CEE and former Soviet countries 
To our knowledge there are no studies assessing quality of local-language publications 
with the use of quality checklists.  This may be attributed, in part, to language barriers and 
conflicts of interest.  
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Barriers to address 
Governmental bodies of countries wishing to enhance utilization of HTA in 
healthcare decision making should at least address the following barriers: 1) non-
transparency of the decision-making process and the limited value of economic 
evaluations perceived by decision makers; 2) limited capacity of HTA bodies and 
insufficient education of experts; and 3) insufficient or low quality input data and a 
��������� ������������ ��� ����������������� ����������� ����������� ��������� ����������� – 
that is primarily based on education – potentially may have a significant impact on both 
acceptability and transferability judgments. The major HTA capacity issues, such as 
��������� ���������������������������������������������� �������������������������� ��� ����
establishment of a single HTA body. 
Guidelines to develop 
Guidelines on the use of, or on performing economic evaluations for CEE and 
former Soviet countries should include limitations and approaches related to the local 
context (such as dealing with lack of data), requirements for quality and transparency 
(e.g., inputs and methods presentation, addressing uncertainty and data heterogeneity, 
threshold evaluation) and addressing of transferability. Although guidelines in many 
countries recommend using the societal perspective [27], in view of data constraints this 
approach should be reconsidered in countries of the CEE region and former Soviet Union 
which are in the process of implementing or have recently implemented single HTA 
agencies.  
Transferability to adapt 
The centralized or governmental HTA bodies of CEE and former Soviet countries 
should focus on a standardized approach for simple transferability of economic 
evaluations in order to avoid budget and manpower constraints and provide rational 
decisions. Moreover, the requirements and needs for local data should be strongly 
adjusted. When the model from the reference country is of appropriate quality and 
includes relevant study technology and comparators, and both jurisdictions have similar 
healthcare structures and disease incidence/prevalence, simple adaptation (costs, 
resource use, baseline risk) is recommended.  
Priorities to apply 
Taking into account that HTA resources are limited, HTA research priorities 
should be defined by a country payer. To define if a high-cost technology is a priority for 
HTA, reimbursement decisions from HTA-developed jurisdictions and their economic 
backgrounds can be used to filter non-efficient technologies.  
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^ƚĂŬĞŚŽůĚĞƌƐ͛ ŽƉŝŶŝŽŶƐ ŽŶŵĞƚŚŽĚŽůŽŐǇ ĂŶĚ ĚĂƚĂ ƚƌĂŶƐĨĞƌĂďŝůŝƚǇǁĞƌĞ ŐĂƚŚĞƌĞĚ
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Variations in cost-effectiveness ratios depending on country characteristics 
Differences in costs, resource use, and baseline risks in lower- and higher-income 
countries suggest possible higher ICER for expensive innovative treatments in CEE and 
former Soviet countries. However, more evidence is needed before we can draw valid 
conclusions regarding possible dependence of ICER expectations on average country 
values for the data categories. 
Difference in utility values for CEE and former Soviet countries and countries with 
frequently referenced utility sets  
As stated above, transferability of utility values is not an issue of importance for 
researchers and decision makers in CEE and former Soviet countries. At the same time, the 
failure to address variations in utilities between different populations may be attributable 
to insufficient knowledge of their values. 
 
General conclusion 
If HTA capacity – defined here as budget, knowledge, manpower and data quality 
constraints – in low and middle income countries in central and eastern Europe is limited, 
transferability and priority settings should be the major issues to be diagnosed prior to 
implementing an explicit HTA process. While it is not possible to generalize the results of 
economic evaluations, certain input parameters may be transferable between 
jurisdictions. Transferability of input data should be assessed individually for each case to 
define which parameters are important to localize. Possible variations in the values of 
model parameters should be addressed accordingly. In sum, it can be said that geographic 
transferability of economic evaluations is a necessity for CEE and former Soviet countries. 
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influential component what differs from such economically developed countries as the 
USA and Germany. 
 In chapter 5 net lifetime tax revenues of a population received via in-vitro 
fertilization (IVF) in Ukraine, Belarus, and Kazakhstan were calculated. As described in the 
chapter, financing IVF may be a positive financial return even in lower-income countries 
with state-financed healthcare systems such as Ukraine, Belarus, and Kazakhstan. Some 
������������ ����� ��� ���� ������������ ���� ������ ������ ����� ���� �������-specific and have a 
defining impact on the results of the economic analysis, and so have a limited 
generalizability. Additionally, it was noted that return of investment into IVF may not be 
directly proportional to economic indicators, as GDP per capita in the country, being 
dependent on many parameters, such as societal guarantees to population provided by 
state and taxation rates. 
Chapter 6 presents a comparative cost study of the use of pegylated interferons (Peg-
α-2b and Peg-α-2a) as a treatment for genotype 1 chronic hepatitis C. The clinical 
outcomes (���������� ���������� ��������� ���� ���������� ������-up on the therapy) were 
generalized from other populations by using data of an American multicentre randomized 
controlled trial, while in the base-case scenario the cost data were specific for the Ukraine 
population. For patients with an average body weight, a small cost saving with Peg-α-2b 
treatment is observed from both a patient and a healthcare perspective. With the 
adjustment to reflect an average body weight in Ukraine, the difference in costs per 
patient and costs per sustained virologic response in favor of Peg-α-2b was slightly higher, 
���� ���������������������� ������������������������������� 
In chapter 7 a qualitative study on the preferences and perceptions of Ukrainian type 
2 diabetes patients experiencing hypoglycemia is presented. From the results of three 
focus groups with in total 26 patients it was concluded that the adaptation of Ukrainian 
patients to potential episodes of hypoglycemia is similar to observations made in other 
countries. In contrast to some other economically developed countries, Ukrainian patients 
older than 40 years receive information on disease management majorly from 
endocrinologists, and rarely use Internet resources on diabetes management. This fact 
should be accounted in disease management studies as well as in relevant economic 
evaluations. 
Chapter 8 presents the results of a cost-effectiveness analysis of the use of rituximab 
in the treatment of CLL in previously non-treated and relapsed/refractory patients in 
Ukraine. The incremental cost-effectiveness ratio (ICER) of adding rituximab to the 
fludarabine and cyclophosphamide scheme (FCR versus FC) is $8,704 per quality-adjusted 
life year gained for treatment-naive patients and $11,056 for refractory/relapsed patients. 
The transferability of clinical outcomes, overall and progression-free survival was assessed 
by modifying the trial data to the lower life expectancy of the general population in 
Ukraine. In this case the ICER for treatment-naive patients was higher than $13,000, which 
  
176 
 
Summary 
Despite that the transferability of economic evaluations is a widely discussed 
topic, it was until recently only limitedly explored in the region of Central and Eastern 
European (CEE) and former Soviet countries.  
In part 1 of the thesis the use of economic studies in healthcare decision making 
and the current need for transferability of economic evaluation studies in the study region 
are presented. In chapter 2, presenting the results of a qualitative assessment of the 
opinion of experts, it becomes clear that economic studies are not always formally used in 
healthcare decision making in the CEE region. As stated, their acceptance depends upon 
the perspective of the study, perceived quality, the methodology used, costs source and 
assessment method, reliability of the study and population characteristics. Even though 
economic studies are not considered to be generalizable from one jurisdiction to another, 
foreign evidence still may be used for local decisions. Because similarities in healthcare 
systems and practices are considered important by the experts, along with costs and 
����t��es� ����arative economic development, perspective of the study, and disease 
epidemiology, transferability of studies within one geographic region may be simpler than 
across regions.  
Chapter 3 describes the characteristics of published economic evaluations from CEE 
and former Soviet countries, retrieved by a systematic literature search. Using 
�������d�s ��e����st �t �as ������ded t�at �te�s s��� as �e�s�e�t��e stated, relevant 
costs included, costs measured accurately in appropriate units, outcomes and costs valued 
credibly, and uncertainty addressed were the least frequently and not transparently 
addressed parameters. Even though studies frequently generalized clinical effect and 
utilities from other populations, limitations of using foreign data were rarely discussed. 
Additionally, transferability of the results was not sufficiently discussed in the published 
economic studies. The transferability of studies to other jurisdictions may be simplified if 
input uncertainty and data transferability are comprehensively addressed and the 
transparency of reporting is improved. 
�e��s��� �a�e�s� �et��d����� �e����e�e�ts a�d data a�a��a����t� a�e t�� � ���ta�t 
factors influencing the transferability of economic evaluations. In part 2 of the thesis 
basing the study design on the assessed preferences of the decision makers and on the 
data available, transferability principles are applied (chapters 4-8).  
As can be seen from chapter 4, the costs for the treatment of chronic lymphocytic 
leukemia (CLL) in Ukraine may significantly vary even between comparable specialized 
institutions. While the major costs are related to drug treatment, many patients in Ukraine 
pay out of pocket for in-hospital drugs, and so these costs become an economic burden 
for an individual patient. While drug therapy is a main driver of CLL treatment costs not 
only in Ukraine, in the structure of total CLL treatment costs medical care remains as non-
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Summary 
Despite that the transferability of economic evaluations is a widely discussed 
topic, it was until recently only limitedly explored in the region of Central and Eastern 
European (CEE) and former Soviet countries.  
In part 1 of the thesis the use of economic studies in healthcare decision making 
and the current need for transferability of economic evaluation studies in the study region 
are presented. In chapter 2, presenting the results of a qualitative assessment of the 
opinion of experts, it becomes clear that economic studies are not always formally used in 
healthcare decision making in the CEE region. As stated, their acceptance depends upon 
the perspective of the study, perceived quality, the methodology used, costs source and 
assessment method, reliability of the study and population characteristics. Even though 
economic studies are not considered to be generalizable from one jurisdiction to another, 
foreign evidence still may be used for local decisions. Because similarities in healthcare 
systems and practices are considered important by the experts, along with costs and 
����t��es� ����arative economic development, perspective of the study, and disease 
epidemiology, transferability of studies within one geographic region may be simpler than 
across regions.  
Chapter 3 describes the characteristics of published economic evaluations from CEE 
and former Soviet countries, retrieved by a systematic literature search. Using 
�������d�s ��e����st �t �as ������ded t�at �te�s s��� as �e�s�e�t��e stated, relevant 
costs included, costs measured accurately in appropriate units, outcomes and costs valued 
credibly, and uncertainty addressed were the least frequently and not transparently 
addressed parameters. Even though studies frequently generalized clinical effect and 
utilities from other populations, limitations of using foreign data were rarely discussed. 
Additionally, transferability of the results was not sufficiently discussed in the published 
economic studies. The transferability of studies to other jurisdictions may be simplified if 
input uncertainty and data transferability are comprehensively addressed and the 
transparency of reporting is improved. 
�e��s��� �a�e�s� �et��d����� �e����e�e�ts a�d data a�a��a����t� a�e t�� � ���ta�t 
factors influencing the transferability of economic evaluations. In part 2 of the thesis 
basing the study design on the assessed preferences of the decision makers and on the 
data available, transferability principles are applied (chapters 4-8).  
As can be seen from chapter 4, the costs for the treatment of chronic lymphocytic 
leukemia (CLL) in Ukraine may significantly vary even between comparable specialized 
institutions. While the major costs are related to drug treatment, many patients in Ukraine 
pay out of pocket for in-hospital drugs, and so these costs become an economic burden 
for an individual patient. While drug therapy is a main driver of CLL treatment costs not 
only in Ukraine, in the structure of total CLL treatment costs medical care remains as non-
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Nederlandse samenvatting 
Ondanks dat de transferabiliteit van economische evaluaties wereldwijd een veel 
besproken onderwerp is, was het tot kort een weinig besproken onderwerp in de regio 
van Centraal- en Oost-Europa en de voormalige Sovjet landen.  
In deel 1 van het proefschrift wordt het gebruik van economische studies voor 
besluitvorming in de gezondheidszorg en het huidig gebruik van het concept 
transferabiliteit van economische evaluaties in de regio beschreven. Hoofdstuk 2 laat de 
resultaten zien van interviews met experts uit de regio. Hieruit blijkt dat economische 
studies vaak geen formele status hebben in het besluitvormingsproces. Daarnaast bleek 
dat de acceptatie van economische studies af hangt van een aantal factoren zoals het 
perspectief van de studie, kwaliteit van de studie, gebruikte methodologie, kostenbron en 
beoordelingsmethode, betrouwbaarheid van de studie en populatiekenmerken. Hoewel 
economische studies niet als generaliseerbaar worden beschouwd, wordt buitenlandse 
data toch geregeld gebruikt voor lokale besluiten. Omdat overeenkomsten in 
zorgsystemen en behandelpraktijk, naast vergelijkbare kosten, economische ontwikkeling 
van het desbetreffende land, studieperspectief en epidemiologie van de ziekte, belangrijk 
wordt gevonden door de experts is de transferabiliteit van studies binnen een 
ŐĞŽŐƌĂĨŝƐĐŚĞƌĞŐŝŽǁĂĂƌƐĐŚŝũŶůŝũŬŵĂŬŬĞůŝũŬĞƌĚĂŶƚƵƐƐĞŶǀĞƌƐĐŚŝůůĞŶĚĞƌĞŐŝŽ͛Ɛ͘ 
Hoofdstuk 3 beschrijft de studiekenmerken van gepubliceerde Engelstalige 
economische evaluaties uit Centraal- en Oost-Europa en voormalige Sovjet landen. Met 
behulp van de checklist van Drummond et al. kon worden geconcludeerd dat items als 
perspectief, inclusie van relevante kosten, accurate meting van kosten, geloofwaardige 
waardering van uitkomsten en kosten, en beschrijving van de onzekerheid het minst vaak 
en niet transparant waren beschreven. Hoewel de studies vaak klinische effecten en 
utiliteiten uit andere landen gebruikten werden de beperkingen van het gebruik van 
buitenlandse data in slechts een beperkt aantal studies besproken. Daarnaast werd de 
transferabiliteit van de studieresultaten niet genoeg bediscussieerd in de gepubliceerde 
economische studies. De transferabiliteit van studies naar andere jurisdicties kan worden 
vereenvoudigd als de onzekerheid rondom de data en de transferabiliteit van de data 
duidelijk wordt besproken en als de transparantie van de rapportage verbeterd.  
Methodologische vereisten van beleidsmakers en de beschikbaarheid van data 
zijn twee belangrijke factoren die de transferabiliteit van economische evaluaties 
beïnvloeden. In deel 2 van het proefschrift worden de transferabiliteit principes toegepast 
in samenhang met de door beleidsmakers geprefereerde studieopzet en de 
beschikbaarheid van data (hoofdstukken 4-8).  
Zoals te zien is in hoofdstuk 4, zijn er significante verschillen in Oekraïne tussen 
de gespecialiseerde instellingen in de behandelkosten van chronische lymfatische 
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is three times higher than the current gross domestic product per capita in Ukraine. 
Sensitivity analyses have shown a high impact of rituximab costs and a moderate impact of 
differences in utilities on the ICER. Population characteristics and unit costs have a 
significant impact on the study result. 
The main findings, presented in chapter 9, suggests that the use of economic 
evaluations in healthcare decision making faces barriers related to the low health 
technology assessment (HTA) capacity. Despite that transferability of economic 
evaluations conducted in health care settings of CEE and former Soviet countries is limited 
and rarely applied; the principle of transferring data is familiar in the countries studied. 
While variations in some of the parameters, such as unit cost, resource use, and baseline 
risk cause non-ŐĞŶĞƌĂůŝǌĂďŝůŝƚǇ ŽĨ ƚŚĞ ƌĞƐƵůƚƐ͕ ĞĨĨŝĐĂĐǇ ĂŶĚ ƉĂƚŝĞŶƚƐ͛ ƉƌĞĨĞƌĞŶĐĞƐŵĂǇ ďĞ
generalizable in some cases. 
The recommendations of chapter 9 regarding improvement of the use of economic 
evaluations in healthcare decision making are the following: to address barriers related to 
decision making process and limited HTA capacity, to develop HTA and health economic 
guidelines, to standardize the approach for transferability, to define HTA priorities, and to 
provide incentives for improving the quality of studies. 
This dissertation concludes that geographic transferability of economic evaluations is 
necessary for CEE and former Soviet countries. 
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Hoofdstuk 8 laat de resultaten van een kosteneffectiviteitstudie zien naar het 
gebruik van rituximab in de behandeling van CLL bij behandelnaïeve en relapsed/refractair 
patiënten in Oekraïne. De incrementele kosteneffectiviteitsratio (ICER) van het toevoegen 
van rituximab aan een behandelschema met fludarabine en cyclofosfamide (FCR versus 
FC) is $8.704 per QALY (voor kwaliteit van leven gecorrigeerde levensjaren) voor 
behandelnaïeve patiënten en $11,056 voor relapsed/refractair patiënten. De 
transferabiliteit van de klinische uitkomsten, algehele en progressievrije overleving is 
beoordeeld door het aanpassen van de studiedata aan de lagere levensverwachting van 
de algemene bevolking in Oekraïne. In dit geval werd de ICER voor behandel-naïeve 
patiënten hoger dan $13.000, wat drie keer hoger is dan het huidige bruto binnenlands 
product per hoofd van de bevolking in Oekraïne. Gevoeligheidsanalyses laten daarnaast 
een grote impact van de kosten van rituximab op de ICER zien en een matige impact van 
verschillen in utiliteiten. Verder hebben ook populatiekenmerken en prijzen een 
significante impact op de resultaten.  
De belangrijkste resultaten, zoals te zien in hoofdstuk 9, suggereren dat voor dat 
economische evaluaties in de besluitvorming gebruikt kunnen worden een aantal 
barrières gerelateerd aan de beperkte capaciteit voor Health Technology Assessment 
(HTA) in Centraal- en Oost Europa en voormalige Sovjet landen moeten worden 
overwonnen. Ondanks dat transferabiliteit van economische evaluaties uit Centraal- en 
Oost-Europa en voormalige Sovjet landen beperkt is en amper wordt toegepast; zijn de 
principes achter transferabiliteit bekend in deze landen. Hoewel variabiliteit in parameters 
zoals prijzen, zorggebruik en baseline risico ervoor zorgen dat de resultaten niet 
generaliseerbaar zijn, zijn data gerelateerd aan efficacy en patiëntenpreferenties in 
sommige gevallen wel generaliseerbaar. De hierop volgende aanbevelingen in hoofdstuk 9 
zijn als volgt: opheffen van barrières gerelateerd aan het besluitvormingsproces en de 
beperkte HTA capaciteit; ontwikkel richtlijnen voor economische evaluaties en HTA-
studies, standaardiseer de benadering van transferabiliteit, definieer prioriteiten voor 
HTA-studies en introduceer prikkels om de kwaliteit van studies te verbeteren.  
De conclusie van dit proefschrift is de geografische transferabiliteit van 
economische evaluaties noodzakelijk is voor Centraal-en Oost-Europa en voormalige 
Sovjet landen.  
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leukemie (CLL). Het grootste deel van de kosten zijn gerelateerd aan geneesmiddelen en 
aangezien veel patiënten in Oekraïne zelf moeten betalen voor ziekenhuisgeneesmiddelen 
zijn deze kosten een financiële last voor een individuele patiënt. Niet alleen in Oekraïne 
vormen de kosten van geneesmiddelen een substantieel deel van de totale 
behandelkosten van CLL, maar in tegenstelling tot de Verenigde Staten en Duitsland zijn 
de kosten van de medische of ziekenhuiszorg in Oekraïne relatief laag.  
In hoofdstuk 5 zijn de netto levenslange belastingopbrengsten van een populatie 
geboren met behulp van in-vitro fertilisatie (IVF) in Oekraïne, Wit-Rusland en Kazakstan 
berekend. Het financieren van IVF zorgt voor een positieve financiële opbrengst zelfs in 
lagerinkomen landen met staatsgefinancierde zorgsystemen zoals in Oekraïne, Wit-
Rusland en Kazakstan. Uit de resultaten bleek dat sommige parameters zo��� ������� 
bevallingen per IVF-������� ������e����e� ���� e� ee� �e��������e � ���� �e��e� �� �e 
resultaten van de economische analyse. Daarom zijn deze parameters maar beperkt 
generaliseerbaar. Daarnaast bleek dat het investeringsrendement in IVF niet 
proportioneel gerelateerd is aan economische indicatoren zoals het bruto binnenlands 
product van een land. Dit kan verklaard worden door middel van parameters zoals sociale 
garanties van de staat aan de bevolking en de verwachte belastingopbrengsten.  
Hoofdstuk 6 bevat een vergelijkende kostenstudie naar het gebruik van pegylated 
interferon (Peg-α-2b en Peg-α-2a) voor de behandeling van genotype 1 chronische 
hepatitis C. De klinische uitkomsten (sustained virologic response/SVR en therapietrouw 
van de patiënt) zijn gegeneraliseerd vanuit de Verenigde Staten door gebruik te maken 
van een Amerikaanse gerandomiseerde multicenter studie, waarbij in de base-case 
scenario alleen de kostendata specifiek voor de Oekraïense populatie waren. Bij patiënten 
met een gemiddeld lichaamsgewicht is er vanuit zowel het patiëntenperspectief als vanuit 
het gezondheidszorgperspectief een kleine kostenbesparing te zien bij behandeling met 
Peg-α-2a. Echter als het gemiddelde lichaamsgewicht uit de studie wordt aangepast aan 
het gemiddelde in Oekraïne was het verschil in kosten per patiënt en per SVR in het 
voordeel van Peg-α-2b.  
In hoofdstuk 7 wordt een kwalitatieve studie naar de preferenties en percepties 
van Oekraïense diabetes type 2 patiënten met ervaringen met hypoglykemie 
gepresenteerd. Uit de resultaten van drie focusgroepen met in totaal 26 patiënten kan 
worden geconcludeerd dat de aanpassing van Oekraïense patiënten naar potentiële 
episodes van hypoglykemie vergelijkbaar is met gedane observaties in andere landen. In 
tegenstelling tot een aantal economisch ontwikkelde landen, krijgen Oekraïense patiënten 
ouder dan 40 jaar vooral informatie van de endocrinoloog over disease management en 
gebruiken ze amper het Internet voor het vinden van informatie. Dit resultaat moet 
worden meegenomen in disease management studies en ook in de relevante 
economische evaluaties.  
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het gemiddelde in Oekraïne was het verschil in kosten per patiënt en per SVR in het 
voordeel van Peg-α-2b.  
In hoofdstuk 7 wordt een kwalitatieve studie naar de preferenties en percepties 
van Oekraïense diabetes type 2 patiënten met ervaringen met hypoglykemie 
gepresenteerd. Uit de resultaten van drie focusgroepen met in totaal 26 patiënten kan 
worden geconcludeerd dat de aanpassing van Oekraïense patiënten naar potentiële 
episodes van hypoglykemie vergelijkbaar is met gedane observaties in andere landen. In 
tegenstelling tot een aantal economisch ontwikkelde landen, krijgen Oekraïense patiënten 
ouder dan 40 jaar vooral informatie van de endocrinoloog over disease management en 
gebruiken ze amper het Internet voor het vinden van informatie. Dit resultaat moet 
worden meegenomen in disease management studies en ook in de relevante 
economische evaluaties.  
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ˀ̖̥̖̀̚ 
ʻ̨̖̭̥̯̬́ ̦̌ ̨̯ ̸̨̯ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ -  ̨̡̨̛̹̬
̨̭̱̙̖̥̍̔̌̌́ ̯̖̥͕̌ ̨̔ ̨̦̖̦̖̔̌̏̐ ̛̬̖̥̖̦̏ ̨̦̌ ̸̛̱̣̭̌̌̽̚ ̨̡̨̯̣̽ ̸̨̨̛̬̦̖̦̦̐̌ ̏
ˉ̨̖̦̯̬̣̦̥̌̽̛ʦ̸̨̨̨̭̯̦-ʫ̨̡̨̬̪̖̜̭̥̏̨̛̬̖̦̖̐;ˉʦʫͿ̛̵̭̯̬̦̌̌̨̼̹̖̍̏̐ˁ̨̡̨̨̖̯̭̏̐
ˁ̨̀̌̚͘ 
ʦ ̸̛̭̯̌ ϭ ̨̦̦̜̔̌ ̶̛̛̛̭̭̖̬̯̔̌ ̨̡̨̪̦̌̌̚ ̨̨̛̛̭̪̣̦̖̽̏̌̚ ̸̵̡̨̨̡̛̛̦̥̖̭̾
̨̛̛̭̭̣̖̦̜̔̏̌̏̛̛̛̪̬̦̯́̛̬̖̹̖̦̜̏̵̨̨̛̛̬̬̦̖̦̔̌̏̌̚̛̭̱̺̖̭̯̱̺̏̀̌́̨̨̪̯̬̖̦̭̯̍̽
̏ ̨̨̛̛̪̖̬̖̦̭̥̭̯ ̵̛ ̨̬̖̱̣̯̯̽̌̏̚ ̏ ̨̦̦̥̔̌ ̨̛̬̖̦̖̐͘ ʦ ̣̖̐̌̏ Ϯ͕ ̪̬̖̭̯̣̺̖̜̔̌̏́̀
̬̖̱̣̯̯̼̽̌̚ ̸̡̨̖̭̯̖̦̦̜̌̏ ̶̨̡̛̖̦ ̛̥̦̖̦́ ̡̨̭̪̖̬̯͕̾̏ ̨̛̭̯̦̯̭̌̏́ ̨̨̪̦̯̦͕́ ̸̨̯
̸̡̨̨̡̛̛̦̥̖̭̖̾ ̨̛̛̭̭̣̖̦̔̏̌́ ̦̖ ̭̖̏̐̔̌ ̨̛̭̪̣̱̯̭̽̀́̚ ̴̨̨̬̥̣̦̌̽ ̏ ̛̛̛̪̬̦̯́
̛̬̖̹̖̦̜̵̨̨̛̬̬̦̖̦̔̌̏̌́̚ˉʦʫ̨̛̬̖̦̐̌͘ʶ̡̌̨̨̨̨̛̪̬̖̥̦̭̯̬̬̦͕̔̏̌̵̛̨̨̛̛̭̪̣̦̖̽̏̌̚
̛̛̭̯̌̏̚ ̨̯ ̡̛̪̖̬̭̪̖̯̼̏ ̨̛̛̭̭̣̖̦͕̔̏̌́ ̨̛̛̭̪̬̯̏́́ ̸̡̖̭̯͕̌̏̌ ̨̨̨̛̛̥̖̯̣͕̔̐
̸̨̡̨̛̛̭̯̦̏ ̯̬̯̌̌̚ ̛ ̨̨̥̖̯̔̏ ̶̨̡̛̖̦͕ ̨̛̦̖̙̦̭̯̌̔ ̨̛̛̭̭̣̖̦̔̏̌́ ̛ ̵̡̡̛̛̛̬̯̖̬̭̯̌̌
̶̨̛̛̪̪̱̣́͘ˈ̨̯́̬̖̱̣̯̯̼̽̌̚̸̡̨̨̡̨̨̛̦̥̖̭̾̐̛̦̣̌̌̌̚̦̖̸̛̭̯̯̭̌̀́̨̛̛̪̖̬̖̦̭̥̼̥̭
̨̨̦̜̔ ̨̛̛̛̯̖̬̬̯̬ ̦̌ ̬̱̱͕̔̐̀ ̨̛̦̭̯̬̦̦̼̖̌ ̨̛̛̭̭̣̖̦̔̏̌́ ̨̥̱̯̐ ̨̨̛̭̪̣̯̭̽̏̌̽́̚ ̏
̛̛̛̪̬̦̯́ ̵̨̡̣̣̦̼̌̽ ̛̬̖̹̖̦̜͘ ʿ̨̡̨̡̭̣̱͕̽ ̨̨̭̣̭̦̐̌ ̡̨̭̪̖̬̯̦̥̱̾̛̥̦̖̦͕̀ ̨̛̣̭̯̍̽̚
̛̭̭̯̖̥ ̵̨̨̛̬̬̦̖̦̔̌̏̌́̚ ̛ ̸̵̡̡̛̛̛̣̦̖̭ ̡̡̛̪̬̯̌ ̣̯̭́̏́̀́ ̛̙̦̼̥̏̌ ̛̪̬̥̖̯̬̥͕̌̌̌
̡̯̙̖͕̌ ̡̡̌ ̛ ̯̬̯̼͕̌̌̚ ̨̨̨̛̯̦̭̯̖̣̦̖̽ ̸̡̨̨̡̨̛̦̥̖̭̖̾ ̛̛̬̯̖̌̏̚ ̭̯̬̦̼͕̌ ̡̛̪̖̬̭̪̖̯̏̌
̨̛̛̭̭̣̖̦̔̏̌́ ̛ ̨̨̛̛̛̪̖̥̣̾̔̐́ ̨̛̣̖̦͕̌̍̏̌́̚ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̨̛̛̭̭̣̖̦̜̔̏̌ ̥̖̙̱̔
̛̭̯̬̦̥̌̌̨̨̨̦̔̐̴̸̨̡̨̨̛̖̬̖̭̐̐̌̐̨̛̬̖̦̐̌̨̥̙̖̯̼̯̍̽̨̪̬̺̖͕̸̖̥̥̖̙̱̔̛̬̦̼̥̌̚
̨̛̛̬̖̦̥̐̌͘ 
ʧ̣̌̏̌ ϯ ̨̛̪̭̼̖̯̏̌ ̵̡̡̛̛̛̬̯̖̬̭̯̌̌ ̵̨̡̨̛̪̱̣̦̦̼̍̏̌ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦
̛̚ ̭̯̬̦̌ˉʦʫ ̛ ̨̼̹̖̍̏̐ ˁ̨̡̨̨̖̯̭̏̐ ˁ̨͕̀̌̚ ̸̵̨̪̣̱̖̦̦̼̨̨̥̖̯̥̔ ̸̡̨̨̛̛̭̭̯̖̥̯̖̭̌̐
̨̡̛̪̭̌ ̛̣̯̖̬̯̱̬̼̌͘ ʰ̨̭̪̣̱̽́̚ ̡̨̨̦̯̬̣̦̼̜̽ ̸̪̖̬̖̖̦̽ ʪ̨̬̥̥̦͕̌̔̌ ̼̣̍ ̭̖̣̦̔̌
̨̼͕̏̏̔ ̸̨̯ ̸̡̨̖̯̖ ̸̨̨̛̦̖̦̖̍̌̚ ̡̛̪̖̬̭̪̖̯̼͕̏ ̨̨̨̨̭̦̦̦̭̯̍̏̌̽ ̨̼̬̏̍̌ ̯̬̯̌̌̚ ̛ ̵̛
̸̨̨̯̦̖ ̛̛̥̖̬̖̦̖͕̚ ̨̦̖̙̦̭̯̌̔̽ ̶̨̡̛̖̦ ̯̬̯̌̌̚ ̛ ̴̴̡̨̛̛̖̯̦̭̯͕̾̏ ̛ ̛̦̣̌̌̚
̨̨̛̛̭̥̦̯̖̣̦̭̯̽ ̸̵̨̪̣̱̖̦̦̼ ̨̬̖̱̣̯̯͕̽̌̏̚ - ̣̯̭́̏́̀́ ̛̦̥̖̦̖̖̌ ̸̨̭̯̌ ̛ ̨̡̨̯̬̼̯
̨̛̬̭̭̥̯̬̖̦̦̼̥̌ ̛̪̬̥̖̯̬̥̌̌̌͘ ˈ̨̯́ ̨̡̛̪̯̖̣̌̌̚ ̸̡̡̨̛̛̣̦̖̭̜ ̴̴̡̨̛̛̖̯̦̭̯̾̏ ̛
̨̛̛̛̱̯̣̯̬̦̭̯̌ ̸̨̭̯̌ ̨̨̛̺̣̭̍̍̌̽ ̛̚ ̵̛̬̱̔̐ ̶̨̛̪̪̱̣̜͕́ ̸̨̛̛̬̦̖̦̐̌́ ̨̨̨̛̯̦̭̯̖̣̦̽
̨̨̛̛̭̪̣̦̽̏̌́̚ ̵̨̛̦̭̯̬̦̦̼̌ ̵̦̦̼̔̌ ̏ ̵̨̛̛̭̭̣̖̦̔̏̌́ ̨̛̭̱̙̣̭̍̔̌̽ ̡̨̬̖̔͘ ʶ̨̬̥̖
̨̨̯͕̐ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̸̵̨̪̣̱̖̦̦̼ ̨̬̖̱̣̯̯̽̌̏̚ ̼̣̍̌ ̨̛̪̭̦̌̌ ̦̖ ̸̨̨̨̭̯̯̦̔̌ ̏
̵̨̡̨̛̪̱̣̦̦̼̍̏̌ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̵̨̛̛̭̭̣̖̦̔̏̌́͘ ʿ̨̨̛̖̬̖̦̭̥̭̯̽ ̨̛̛̭̭̣̖̦̜̔̏̌
̥̖̙̱̔ ̛̭̯̬̦̥̌̌ ̨̥̙̖̯ ̼̯̍̽ ̨̱̪̬̺̖̦͕̌ ̛̖̭̣ ̸̨̨̛̦̖̯̦̭̯ ̵̨̦̼̏̏̔ ̨̪̬̥̖̯̬̌̌̏ ̛
̨̨̛̛̪̖̬̖̦̭̥̭̯ ̵̦̦̼͕̔̌ ̨̨̭̖̭̯̬̦̦̖̏ ̸̱̯̖̦̼͕ ̌ ̡̯̙̖̌ ̛̖̭̣ ̸̡̨̖̯̭̯̽ ̴̶̨̛̛̛̦̬̥̌ ̏
̶̵̡̛̛̪̱̣̍̌́̱̖̯̍̔̸̱̣̱̹̖̦̌͘ 
˃̨̛̬̖̦̍̏̌́ ̶̛̣͕̵̛̛̛̪̬̦̥̺̌̀̛̬̖̹̖̦͕́ ̡̨̨̨̛̛̥̖̯̣̔̐̛̨̨̭̯̱̪̦̭̯̔̽̵̦̦̼̔̌
̣̯̭́̏́̀́̱̥̔̏́̛̙̦̼̥̏̌̴̡̨̛̯̬̥͕̌̌̛̛̛̣̺̥̏́̀̦̌̨̨̛̪̖̬̖̦̭̥̭̯̽̸̵̡̨̨̡̛̛̦̥̖̭̾
̶̨̨̡̖̦͘ ʦ ̸̛̭̯̌ Ϯ ̨̯̜̾ ̶̛̛̛̭̭̖̬̯͕̔̌ ̨̨̭̦̼̏̏̌́ ̛̜̦̔̌̚ ̨̛̛̭̭̣̖̦̜̔̏̌ ̦̌
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ˀ̖̥̖̀̚ 
ʻ̨̖̭̥̯̬́ ̦̌ ̨̯ ̸̨̯ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ -  ̨̡̨̛̹̬
̨̭̱̙̖̥̍̔̌̌́ ̯̖̥͕̌ ̨̔ ̨̦̖̦̖̔̌̏̐ ̛̬̖̥̖̦̏ ̨̦̌ ̸̛̱̣̭̌̌̽̚ ̨̡̨̯̣̽ ̸̨̨̛̬̦̖̦̦̐̌ ̏
ˉ̨̖̦̯̬̣̦̥̌̽̛ʦ̸̨̨̨̭̯̦-ʫ̨̡̨̬̪̖̜̭̥̏̨̛̬̖̦̖̐;ˉʦʫͿ̛̵̭̯̬̦̌̌̨̼̹̖̍̏̐ˁ̨̡̨̨̖̯̭̏̐
ˁ̨̀̌̚͘ 
ʦ ̸̛̭̯̌ ϭ ̨̦̦̜̔̌ ̶̛̛̛̭̭̖̬̯̔̌ ̨̡̨̪̦̌̌̚ ̨̨̛̛̭̪̣̦̖̽̏̌̚ ̸̵̡̨̨̡̛̛̦̥̖̭̾
̨̛̛̭̭̣̖̦̜̔̏̌̏̛̛̛̪̬̦̯́̛̬̖̹̖̦̜̏̵̨̨̛̛̬̬̦̖̦̔̌̏̌̚̛̭̱̺̖̭̯̱̺̏̀̌́̨̨̪̯̬̖̦̭̯̍̽
̏ ̨̨̛̛̪̖̬̖̦̭̥̭̯ ̵̛ ̨̬̖̱̣̯̯̽̌̏̚ ̏ ̨̦̦̥̔̌ ̨̛̬̖̦̖̐͘ ʦ ̣̖̐̌̏ Ϯ͕ ̪̬̖̭̯̣̺̖̜̔̌̏́̀
̬̖̱̣̯̯̼̽̌̚ ̸̡̨̖̭̯̖̦̦̜̌̏ ̶̨̡̛̖̦ ̛̥̦̖̦́ ̡̨̭̪̖̬̯͕̾̏ ̨̛̭̯̦̯̭̌̏́ ̨̨̪̦̯̦͕́ ̸̨̯
̸̡̨̨̡̛̛̦̥̖̭̖̾ ̨̛̛̭̭̣̖̦̔̏̌́ ̦̖ ̭̖̏̐̔̌ ̨̛̭̪̣̱̯̭̽̀́̚ ̴̨̨̬̥̣̦̌̽ ̏ ̛̛̛̪̬̦̯́
̛̬̖̹̖̦̜̵̨̨̛̬̬̦̖̦̔̌̏̌́̚ˉʦʫ̨̛̬̖̦̐̌͘ʶ̡̌̨̨̨̨̛̪̬̖̥̦̭̯̬̬̦͕̔̏̌̵̛̨̨̛̛̭̪̣̦̖̽̏̌̚
̛̛̭̯̌̏̚ ̨̯ ̡̛̪̖̬̭̪̖̯̼̏ ̨̛̛̭̭̣̖̦͕̔̏̌́ ̨̛̛̭̪̬̯̏́́ ̸̡̖̭̯͕̌̏̌ ̨̨̨̛̛̥̖̯̣͕̔̐
̸̨̡̨̛̛̭̯̦̏ ̯̬̯̌̌̚ ̛ ̨̨̥̖̯̔̏ ̶̨̡̛̖̦͕ ̨̛̦̖̙̦̭̯̌̔ ̨̛̛̭̭̣̖̦̔̏̌́ ̛ ̵̡̡̛̛̛̬̯̖̬̭̯̌̌
̶̨̛̛̪̪̱̣́͘ˈ̨̯́̬̖̱̣̯̯̼̽̌̚̸̡̨̨̡̨̨̛̦̥̖̭̾̐̛̦̣̌̌̌̚̦̖̸̛̭̯̯̭̌̀́̨̛̛̪̖̬̖̦̭̥̼̥̭
̨̨̦̜̔ ̨̛̛̛̯̖̬̬̯̬ ̦̌ ̬̱̱͕̔̐̀ ̨̛̦̭̯̬̦̦̼̖̌ ̨̛̛̭̭̣̖̦̔̏̌́ ̨̥̱̯̐ ̨̨̛̭̪̣̯̭̽̏̌̽́̚ ̏
̛̛̛̪̬̦̯́ ̵̨̡̣̣̦̼̌̽ ̛̬̖̹̖̦̜͘ ʿ̨̡̨̡̭̣̱͕̽ ̨̨̭̣̭̦̐̌ ̡̨̭̪̖̬̯̦̥̱̾̛̥̦̖̦͕̀ ̨̛̣̭̯̍̽̚
̛̭̭̯̖̥ ̵̨̨̛̬̬̦̖̦̔̌̏̌́̚ ̛ ̸̵̡̡̛̛̛̣̦̖̭ ̡̡̛̪̬̯̌ ̣̯̭́̏́̀́ ̛̙̦̼̥̏̌ ̛̪̬̥̖̯̬̥͕̌̌̌
̡̯̙̖͕̌ ̡̡̌ ̛ ̯̬̯̼͕̌̌̚ ̨̨̨̛̯̦̭̯̖̣̦̖̽ ̸̡̨̨̡̨̛̦̥̖̭̖̾ ̛̛̬̯̖̌̏̚ ̭̯̬̦̼͕̌ ̡̛̪̖̬̭̪̖̯̏̌
̨̛̛̭̭̣̖̦̔̏̌́ ̛ ̨̨̛̛̛̪̖̥̣̾̔̐́ ̨̛̣̖̦͕̌̍̏̌́̚ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̨̛̛̭̭̣̖̦̜̔̏̌ ̥̖̙̱̔
̛̭̯̬̦̥̌̌̨̨̨̦̔̐̴̸̨̡̨̨̛̖̬̖̭̐̐̌̐̨̛̬̖̦̐̌̨̥̙̖̯̼̯̍̽̨̪̬̺̖͕̸̖̥̥̖̙̱̔̛̬̦̼̥̌̚
̨̛̛̬̖̦̥̐̌͘ 
ʧ̣̌̏̌ ϯ ̨̛̪̭̼̖̯̏̌ ̵̡̡̛̛̛̬̯̖̬̭̯̌̌ ̵̨̡̨̛̪̱̣̦̦̼̍̏̌ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦
̛̚ ̭̯̬̦̌ˉʦʫ ̛ ̨̼̹̖̍̏̐ ˁ̨̡̨̨̖̯̭̏̐ ˁ̨͕̀̌̚ ̸̵̨̪̣̱̖̦̦̼̨̨̥̖̯̥̔ ̸̡̨̨̛̛̭̭̯̖̥̯̖̭̌̐
̨̡̛̪̭̌ ̛̣̯̖̬̯̱̬̼̌͘ ʰ̨̭̪̣̱̽́̚ ̡̨̨̦̯̬̣̦̼̜̽ ̸̪̖̬̖̖̦̽ ʪ̨̬̥̥̦͕̌̔̌ ̼̣̍ ̭̖̣̦̔̌
̨̼͕̏̏̔ ̸̨̯ ̸̡̨̖̯̖ ̸̨̨̛̦̖̦̖̍̌̚ ̡̛̪̖̬̭̪̖̯̼͕̏ ̨̨̨̨̭̦̦̦̭̯̍̏̌̽ ̨̼̬̏̍̌ ̯̬̯̌̌̚ ̛ ̵̛
̸̨̨̯̦̖ ̛̛̥̖̬̖̦̖͕̚ ̨̦̖̙̦̭̯̌̔̽ ̶̨̡̛̖̦ ̯̬̯̌̌̚ ̛ ̴̴̡̨̛̛̖̯̦̭̯͕̾̏ ̛ ̛̦̣̌̌̚
̨̨̛̛̭̥̦̯̖̣̦̭̯̽ ̸̵̨̪̣̱̖̦̦̼ ̨̬̖̱̣̯̯͕̽̌̏̚ - ̣̯̭́̏́̀́ ̛̦̥̖̦̖̖̌ ̸̨̭̯̌ ̛ ̨̡̨̯̬̼̯
̨̛̬̭̭̥̯̬̖̦̦̼̥̌ ̛̪̬̥̖̯̬̥̌̌̌͘ ˈ̨̯́ ̨̡̛̪̯̖̣̌̌̚ ̸̡̡̨̛̛̣̦̖̭̜ ̴̴̡̨̛̛̖̯̦̭̯̾̏ ̛
̨̛̛̛̱̯̣̯̬̦̭̯̌ ̸̨̭̯̌ ̨̨̛̺̣̭̍̍̌̽ ̛̚ ̵̛̬̱̔̐ ̶̨̛̪̪̱̣̜͕́ ̸̨̛̛̬̦̖̦̐̌́ ̨̨̨̛̯̦̭̯̖̣̦̽
̨̨̛̛̭̪̣̦̽̏̌́̚ ̵̨̛̦̭̯̬̦̦̼̌ ̵̦̦̼̔̌ ̏ ̵̨̛̛̭̭̣̖̦̔̏̌́ ̨̛̭̱̙̣̭̍̔̌̽ ̡̨̬̖̔͘ ʶ̨̬̥̖
̨̨̯͕̐ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̸̵̨̪̣̱̖̦̦̼ ̨̬̖̱̣̯̯̽̌̏̚ ̼̣̍̌ ̨̛̪̭̦̌̌ ̦̖ ̸̨̨̨̭̯̯̦̔̌ ̏
̵̨̡̨̛̪̱̣̦̦̼̍̏̌ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̵̨̛̛̭̭̣̖̦̔̏̌́͘ ʿ̨̨̛̖̬̖̦̭̥̭̯̽ ̨̛̛̭̭̣̖̦̜̔̏̌
̥̖̙̱̔ ̛̭̯̬̦̥̌̌ ̨̥̙̖̯ ̼̯̍̽ ̨̱̪̬̺̖̦͕̌ ̛̖̭̣ ̸̨̨̛̦̖̯̦̭̯ ̵̨̦̼̏̏̔ ̨̪̬̥̖̯̬̌̌̏ ̛
̨̨̛̛̪̖̬̖̦̭̥̭̯ ̵̦̦̼͕̔̌ ̨̨̭̖̭̯̬̦̦̖̏ ̸̱̯̖̦̼͕ ̌ ̡̯̙̖̌ ̛̖̭̣ ̸̡̨̖̯̭̯̽ ̴̶̨̛̛̛̦̬̥̌ ̏
̶̵̡̛̛̪̱̣̍̌́̱̖̯̍̔̸̱̣̱̹̖̦̌͘ 
˃̨̛̬̖̦̍̏̌́ ̶̛̣͕̵̛̛̛̪̬̦̥̺̌̀̛̬̖̹̖̦͕́ ̡̨̨̨̛̛̥̖̯̣̔̐̛̨̨̭̯̱̪̦̭̯̔̽̵̦̦̼̔̌
̣̯̭́̏́̀́̱̥̔̏́̛̙̦̼̥̏̌̴̡̨̛̯̬̥͕̌̌̛̛̛̣̺̥̏́̀̦̌̨̨̛̪̖̬̖̦̭̥̭̯̽̸̵̡̨̨̡̛̛̦̥̖̭̾
̶̨̨̡̖̦͘ ʦ ̸̛̭̯̌ Ϯ ̨̯̜̾ ̶̛̛̛̭̭̖̬̯͕̔̌ ̨̨̭̦̼̏̏̌́ ̛̜̦̔̌̚ ̨̛̛̭̭̣̖̦̜̔̏̌ ̦̌
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ʶ̡̌ ̨̡̨̪̦̌̌̚ ̏ ̨̦̦̜̔̌ ̶̛̛̛̭̭̖̬̯͕̔̌ ̴̸̨̡̛̖̬̖̭̐̐̌̌́ ̨̨̛̪̖̬̖̦̭̥̭̯̽
̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ ̣̖̯̭́̏́́ ̵̨̨̨̛̦̖̥̭̯̍̔̽̀ ̣̔́ ˉʦʫ ̛ ̭̯̬̦̌ ̨̼̹̖̍̏̐
ˁ̨̡̨̨̖̯̭̏̐ˁ̨̀̌̚͘ 
  
  
184 
 
̨̡̛̛̛̛̪̣̖̥̐̐ ̣̖̯̭́̏́́ ̡̨̛̣̜̍̚ ̡ ̬̖̱̣̯̯̥͕̽̌̌̚ ̸̨̪̣̱̖̦̦̼̥ ̏ ̵̛̬̱̔̐ ̵̭̯̬̦̌̌͘ ʦ
̸̨̛̛̯̣̖̨̯̵̛̬̱̔̐̸̡̨̨̡̛̛̦̥̖̭̾̵̛̬̯̼̌̏̚̭̯̬̦͕̌̡̡̛̛̱̬̦̭̖̌̶̛̪̖̦̯̼̌̭̯̬̹̖̌ϰϬ̣̖̯
̸̨̪̣̱̯̌̀ ̴̶̨̛̛̦̬̥̌̀ ̨ ̡̨̨̦̯̬̣̖ ̨̛̣̖̦̌̍̏̌́̚ ̏ ̨̛̣̹̦̭̯̖̍̽̏ ̸̭̣̱̖̌̏ ̨̯
̨̡̨̨̨̛̦̬̦̣̾̔̐̏ ̛ ̡̨̬̖̔ ̨̛̭̪̣̱̯̽̀̚ ̶̨̛̛̛̭̪̖̣̬̦̦̼̖̌̏̌̚ ʰ̦̯̖̬̦̖̯ ̬̖̭̱̬̭̼͘ ˑ̛̯
̦̦̼̖̔̌ ̨̣̙̦̼̔ ̼̯̍̽ ̛̪̬̦̯̼́ ̨̏ ̛̛̦̥̦̖̏̌ ̏ ̵̨̛̛̭̭̣̖̦̔̏̌́ ̨̪ ̡̨̨̦̯̬̣̀
̨̛̣̖̦͕̌̍̏̌́̚̌̡̯̙̖̌̏̵̨̨̛̭̯̖̯̭̯̱̺̏̏̀̸̵̡̨̨̡̛̛̦̥̖̭̾̵̨̛̛̭̭̣̖̦̔̏̌́͘ 
ʧ̣̌̏̌ϴ̪̬̖̭̯̣̖̯̔̌̏́̬̖̱̣̯̯̼̽̌̚̛̦̣̌̌̌̚ ̯̬̯̼̌̌̚ - ̴̴̡̨̛̖̯̦̭̯̾̏̽̛̛̪̬̥̖̦̖̦́
̡̛̛̬̯̱̭̥̌̍̌̏̸̛̛̣̖̖̦ˈʸʸ̱̵̡̡̛̛̱̬̦̭̌̶̨̛̪̖̦̯̌̏̬̦̖̖̌̦̖̸̵̨̛̪̣̱̹̌̏̛̯̖̬̪̌̀̛
̶̨̛̪̖̦̯̌̏ ̖̍̚ ̨̯̖̯̏̌ ̦̌ ̛̯̖̬̪̌̀ ͬ ̭ ̶̛̛̛̬̖̥̔̏̌͘ ʽ̨̛̯̦̭̯̖̣̦̽̌́ ̸̨̨̦̔̍̌̏̌́
̴̴̨̨̡̨̛̛̭̯̥̭̯̖̯̦̭̯̽ͬ̾̏̽ (ICERͿ ̡̛̛̬̯̱̭̥̌̍̌ ̏ ̵̭̖̥̥̖ ̭ ̴̨̛̣̱̱̬̦̥̔̌̍ ̛
̶̴̴̡̨̨̨̛̛̣̭̥̥̌̔ ;ˇˉˀ ̨̛̪̬̯̏ ˇˉͿ ̨̭̭̯̣̖̯̌̏́ Ψϴ͕ϳϬϰ ̌̚ ̨̛̦̔ ̨̐̔ ̛̛̙̦̚
̨̛̛̭̯̦̬̯̬̦̦̼̜̌̔̌̏̌̚ ̭ ̸̡̨̖̭̯̥̌̏ ̣̔́ ̶̨̛̪̖̦̯̌̏ ̬̦̖̖̌ ̦̖ ̸̵̨̛̪̣̱̹̌̏ ̛̯̖̬̪̌̀ ̛
Ψϭϭ͕Ϭϱϲ ̣̔́ ̶̨̛̪̖̦̯̌̏ ̖̍̚ ̨̯̖̯̏̌ ̦̌ ̛̯̖̬̪̌̀ ͬ ̭ ̶̛̛̛̬̖̥̔̏̌͘ ʿ̨̨̛̖̬̖̦̭̥̭̯̽
̸̵̡̡̛̛̛̣̦̖̭ ̨̬̖̱̣̯̯̽̌̏̚ ̼̣̍̌ ̶̨̖̦̖̦̌ ̪̱̯̖̥ ̛̛̥̖̦̖̦́̚ ̵̦̦̼̔̌ ̸̡̡̨̨̛̛̣̦̖̭̐
̨̛̛̭̭̣̖̦̔̏̌́ ;̨̺̖̜̍ ̨̛̛̼̙̖̥̭̯̏̏̌ ̛ ̨̛̛̼̙̖̥̭̯̏̏̌ ̖̍̚ ̨̪̬̬̖̭̭̐̌Ϳ ̦̌ ̨̣̖̖̍
̡̛̦̱̀̚ ̨̛̙̖̥̱̔̌̀ ̨̨̨̛̪̬̣̙̯̖̣̦̭̯̔̽̽ ̛̛̙̦̚ ̛̭̬̖̔ ̛̦̭̖̣̖̦̌́ ˄̡̛̬̦̼̌͘ ʦ ̨̯̥̾
̸̭̣̱̖̌ ICER ̣̔́̶̨̛̪̖̦̯͕̌̏̬̦̖̖̌̦̖̸̵̨̛̪̣̱̹̌̏ ̛̯̖̬̪͕̌̀̨̛̭̭̯̣̌̏̨̣̖̖̍Ψϭϯ͕ϬϬϬ͕
̸̨̯̏̛̯̬̬̌̌̚̼̹̖̏̌̚ʦʦʿ̦̌̱̹̱̔̛̦̭̖̣̖̦̌́̏˄̡̛̬̦̖̌͘ʤ̛̦̣̌̚̸̨̛̛̱̭̯̯̖̣̦̭̯̏̏̽
̨̡̪̣̌̌̚ ̸̨̛̦̯̖̣̦̖̌̽̚ ̛̛̣̦̖̏́ ̨̨̛̛̭̯̥̭̯ ̡̛̛̬̯̱̭̥̌̍̌ ̛ ̨̨̪̭̬̖̭̯̖̦̦̖̔̏ ̛̛̣̦̖̏́
̶̛̬̦̼̌̚̏̵̨̡̪̯̖̣̌̌́̚̨̛̛̛̱̯̣̯̬̦̭̯̌̦̌̸̛̦̖̦̖̌̚ICER͘ˈ̡̡̛̛̛̬̯̖̬̭̯̌̌̛̦̭̖̣̖̦̌́̛
̨̨̛̭̯̥̭̯̽ ̵̨̯̖̣̦̼̔̽ ̵̨̦̼̏̏̔ ̨̪̬̥̖̯̬̌̌̏ ̨̭̱̺̖̭̯̖̦̦̏ ̛̣̯̏́̀ ̦̌ ̬̖̱̣̯̯̼̽̌̚
̨̛̛̭̭̣̖̦̔̏̌́͘ 
ʽ̨̭̦̦̼̖̏ ̬̖̱̣̯̯̼͕̽̌̚ ̪̬̖̭̯̣̖̦̦̼̖̔̌̏ ̏ ̣̖̐̌̏ ϵ͕ ̨̪̬̖̪̣̯͕̔̌̐̌̀ ̸̨̯
̨̨̛̛̭̪̣̦̖̽̏̌̚ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ ̏ ̛̛̛̪̬̦̯́ ̛̬̖̹̖̦̜ ̏ ̵̨̨̛̛̬̬̦̖̦̔̌̏̌̚
̡̛̭̯̣̖̯̭̌̏̌́ ̭ ̨̬̖̬̥̍̌̽ ̡̨̛̦̜̚ ̨̡̨̪̬̪̱̭̦̜ ̨̨̨̛̭̪̭̦̭̯̍ ̶̨̡̛̖̦ ̶̵̡̛̛̛̥̖̦̭̔
̵̨̨̛̯̖̦̣̜̐ ;ʽʺ˃Ϳ͘ ʻ̖ ̨̭̥̯̬́ ̦̌ ̨̯ ̸̨̯ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦͕
̵̨̨̛̪̬̥̼̏̔ ̏ ̵̡̭̯̬̱̯̱̬̌ ̵̨̨̛̬̬̦̖̦̔̌̏̌́̚ ˉʦʫ ̛ ̵̭̯̬̦̌̌ ̨̼̹̖̍̏̐ ˁ̨̡̨̨̖̯̭̏̐
ˁ̨͕̀̌̚̸̨̛̬̦̖̦̐̌̌̛̡̨̬̖̔̛̪̬̥̖̦̖̯̭͕́́̶̛̛̪̬̦̪̼̨̨̛̛̪̖̬̖̦̭̥̭̯̵̦̦̼̔̌̛̖̭̯̦̼̏̚
̏ ̵̨̛̭̭̣̖̦̦̼̔̏̌ ̵̭̯̬̦̌̌͘ ˈ̨̯́ ̶̛̛̛̬̏̌̌ ̵̡̨̨̦̖̯̬̼ ̨̪̬̥̖̯̬͕̌̌̏ ̵̡̛̯̌ ̡̡̌
̨̨̛̭̯̥̭̯͕̽ ̨̨̛̛̭̪̣̦̖̽̏̌̚ ̨̬̖̭̱̬̭̏ ̛ ̨̼̜̍̌̏̚ ̡̛̬̭ ̨̭̯̔̌̀̚ ̦̖ ̨̨̛̪̖̬̖̦̭̥̭̯̽
̨̬̖̱̣̯̯͕̽̌̏̚ ̸̡̡̛̛̣̦̖̭̌́ ̴̴̡̨̛̖̯̦̭̯̾̏̽ ̛ ̸̨̛̪̬̖̪̯̖̦̔́ ̶̨̛̪̖̦̯̌̏ ;̛̦̪̬̥̖̬͕̌
̨̛̭̣̖̦̖̔̏̌̛̬̖̙̥̱̛̛̯̖̬̪̌Ϳ̨̥̱̯̐̨̨̺̯̭̍̍̌̽́̏̵̡̨̨̦̖̯̬̼̸̵̭̣̱̌́͘ 
ˁ̛̣̖̱̺̖̔̀ ̶̡̨̛̛̬̖̥̖̦̔̌ ̸̨̨̦̖̦̼̍̌̚ ̏ ̬̖̣̖̌̔̚ ϵ ̨̨̨̛̯̦̭̯̖̣̦̽ ̸̛̱̣̱̹̖̦́
̨̨̛̛̭̪̣̦̽̏̌́̚ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ ̏ ̛̛̛̪̬̦̯́ ̛̬̖̹̖̦̜ ̏ ̵̨̨̛̛̬̬̦̖̦̔̌̏̌͗̚
̸̱̖̭̯̽ ̬̖̬̼͕̍̌̽ ̭̦̦̼̖̏́̌̚ ̭ ̶̨̨̪̬̖̭̭̥ ̛̛̪̬̦̯́́ ̛̬̖̹̖̦̜ ̛ ̸̨̨̛̬̦̖̦̦̜̐̌
̨̡̨̪̬̪̱̭̦̜ ̨̨̨̭̪̭̦̭̯̍̽̀ ʽʺ˃͕ ̨̬̬̯̯̌̌̍̌̽̚ ̡̨̨̬̱̭̯̏̔̏̌ ̨̪ ̸̡̨̨̡̛̛̦̥̖̭̥̾
̶̨̡̖̦̥̌ ̛ ʽʺ˃͕ ̨̛̛̭̯̦̬̯̬̯̌̔̌̏̌̽̚ ̵̨̨̪̔̔ ̡ ̨̨̛̛̪̖̬̖̦̭̥̭̯  ̸̡̨̨̡̨̨̛̦̥̖̭̾̐
̛̦̣͕̌̌̌̚ ̨̛̪̬̖̖̣̯̔̽ ̨̛̛̪̬̬̯̖̯̼ ʽʺ˃͕ ̨̛̪̬̖̭̯̯̔̌̏̽ ̛̭̯̥̱̣̼ ̸̛̱̣̱̹̖̦́ ̸̡̖̭̯̌̏̌
̨̛̛̭̭̣̖̦̜̔̏̌͘ 
184 Summaries
  
 
185 
 
ʶ̡̌ ̨̡̨̪̦̌̌̚ ̏ ̨̦̦̜̔̌ ̶̛̛̛̭̭̖̬̯͕̔̌ ̴̸̨̡̛̖̬̖̭̐̐̌̌́ ̨̨̛̪̖̬̖̦̭̥̭̯̽
̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ ̣̖̯̭́̏́́ ̵̨̨̨̛̦̖̥̭̯̍̔̽̀ ̣̔́ ˉʦʫ ̛ ̭̯̬̦̌ ̨̼̹̖̍̏̐
ˁ̨̡̨̨̖̯̭̏̐ˁ̨̀̌̚͘ 
  
  
184 
 
̨̡̛̛̛̛̪̣̖̥̐̐ ̣̖̯̭́̏́́ ̡̨̛̣̜̍̚ ̡ ̬̖̱̣̯̯̥͕̽̌̌̚ ̸̨̪̣̱̖̦̦̼̥ ̏ ̵̛̬̱̔̐ ̵̭̯̬̦̌̌͘ ʦ
̸̨̛̛̯̣̖̨̯̵̛̬̱̔̐̸̡̨̨̡̛̛̦̥̖̭̾̵̛̬̯̼̌̏̚̭̯̬̦͕̌̡̡̛̛̱̬̦̭̖̌̶̛̪̖̦̯̼̌̭̯̬̹̖̌ϰϬ̣̖̯
̸̨̪̣̱̯̌̀ ̴̶̨̛̛̦̬̥̌̀ ̨ ̡̨̨̦̯̬̣̖ ̨̛̣̖̦̌̍̏̌́̚ ̏ ̨̛̣̹̦̭̯̖̍̽̏ ̸̭̣̱̖̌̏ ̨̯
̨̡̨̨̨̛̦̬̦̣̾̔̐̏ ̛ ̡̨̬̖̔ ̨̛̭̪̣̱̯̽̀̚ ̶̨̛̛̛̭̪̖̣̬̦̦̼̖̌̏̌̚ ʰ̦̯̖̬̦̖̯ ̬̖̭̱̬̭̼͘ ˑ̛̯
̦̦̼̖̔̌ ̨̣̙̦̼̔ ̼̯̍̽ ̛̪̬̦̯̼́ ̨̏ ̛̛̦̥̦̖̏̌ ̏ ̵̨̛̛̭̭̣̖̦̔̏̌́ ̨̪ ̡̨̨̦̯̬̣̀
̨̛̣̖̦͕̌̍̏̌́̚̌̡̯̙̖̌̏̵̨̨̛̭̯̖̯̭̯̱̺̏̏̀̸̵̡̨̨̡̛̛̦̥̖̭̾̵̨̛̛̭̭̣̖̦̔̏̌́͘ 
ʧ̣̌̏̌ϴ̪̬̖̭̯̣̖̯̔̌̏́̬̖̱̣̯̯̼̽̌̚̛̦̣̌̌̌̚ ̯̬̯̼̌̌̚ - ̴̴̡̨̛̖̯̦̭̯̾̏̽̛̛̪̬̥̖̦̖̦́
̡̛̛̬̯̱̭̥̌̍̌̏̸̛̛̣̖̖̦ˈʸʸ̱̵̡̡̛̛̱̬̦̭̌̶̨̛̪̖̦̯̌̏̬̦̖̖̌̦̖̸̵̨̛̪̣̱̹̌̏̛̯̖̬̪̌̀̛
̶̨̛̪̖̦̯̌̏ ̖̍̚ ̨̯̖̯̏̌ ̦̌ ̛̯̖̬̪̌̀ ͬ ̭ ̶̛̛̛̬̖̥̔̏̌͘ ʽ̨̛̯̦̭̯̖̣̦̽̌́ ̸̨̨̦̔̍̌̏̌́
̴̴̨̨̡̨̛̛̭̯̥̭̯̖̯̦̭̯̽ͬ̾̏̽ (ICERͿ ̡̛̛̬̯̱̭̥̌̍̌ ̏ ̵̭̖̥̥̖ ̭ ̴̨̛̣̱̱̬̦̥̔̌̍ ̛
̶̴̴̡̨̨̨̛̛̣̭̥̥̌̔ ;ˇˉˀ ̨̛̪̬̯̏ ˇˉͿ ̨̭̭̯̣̖̯̌̏́ Ψϴ͕ϳϬϰ ̌̚ ̨̛̦̔ ̨̐̔ ̛̛̙̦̚
̨̛̛̭̯̦̬̯̬̦̦̼̜̌̔̌̏̌̚ ̭ ̸̡̨̖̭̯̥̌̏ ̣̔́ ̶̨̛̪̖̦̯̌̏ ̬̦̖̖̌ ̦̖ ̸̵̨̛̪̣̱̹̌̏ ̛̯̖̬̪̌̀ ̛
Ψϭϭ͕Ϭϱϲ ̣̔́ ̶̨̛̪̖̦̯̌̏ ̖̍̚ ̨̯̖̯̏̌ ̦̌ ̛̯̖̬̪̌̀ ͬ ̭ ̶̛̛̛̬̖̥̔̏̌͘ ʿ̨̨̛̖̬̖̦̭̥̭̯̽
̸̵̡̡̛̛̛̣̦̖̭ ̨̬̖̱̣̯̯̽̌̏̚ ̼̣̍̌ ̶̨̖̦̖̦̌ ̪̱̯̖̥ ̛̛̥̖̦̖̦́̚ ̵̦̦̼̔̌ ̸̡̡̨̨̛̛̣̦̖̭̐
̨̛̛̭̭̣̖̦̔̏̌́ ;̨̺̖̜̍ ̨̛̛̼̙̖̥̭̯̏̏̌ ̛ ̨̛̛̼̙̖̥̭̯̏̏̌ ̖̍̚ ̨̪̬̬̖̭̭̐̌Ϳ ̦̌ ̨̣̖̖̍
̡̛̦̱̀̚ ̨̛̙̖̥̱̔̌̀ ̨̨̨̛̪̬̣̙̯̖̣̦̭̯̔̽̽ ̛̛̙̦̚ ̛̭̬̖̔ ̛̦̭̖̣̖̦̌́ ˄̡̛̬̦̼̌͘ ʦ ̨̯̥̾
̸̭̣̱̖̌ ICER ̣̔́̶̨̛̪̖̦̯͕̌̏̬̦̖̖̌̦̖̸̵̨̛̪̣̱̹̌̏ ̛̯̖̬̪͕̌̀̨̛̭̭̯̣̌̏̨̣̖̖̍Ψϭϯ͕ϬϬϬ͕
̸̨̯̏̛̯̬̬̌̌̚̼̹̖̏̌̚ʦʦʿ̦̌̱̹̱̔̛̦̭̖̣̖̦̌́̏˄̡̛̬̦̖̌͘ʤ̛̦̣̌̚̸̨̛̛̱̭̯̯̖̣̦̭̯̏̏̽
̨̡̪̣̌̌̚ ̸̨̛̦̯̖̣̦̖̌̽̚ ̛̛̣̦̖̏́ ̨̨̛̛̭̯̥̭̯ ̡̛̛̬̯̱̭̥̌̍̌ ̛ ̨̨̪̭̬̖̭̯̖̦̦̖̔̏ ̛̛̣̦̖̏́
̶̛̬̦̼̌̚̏̵̨̡̪̯̖̣̌̌́̚̨̛̛̛̱̯̣̯̬̦̭̯̌̦̌̸̛̦̖̦̖̌̚ICER͘ˈ̡̡̛̛̛̬̯̖̬̭̯̌̌̛̦̭̖̣̖̦̌́̛
̨̨̛̭̯̥̭̯̽ ̵̨̯̖̣̦̼̔̽ ̵̨̦̼̏̏̔ ̨̪̬̥̖̯̬̌̌̏ ̨̭̱̺̖̭̯̖̦̦̏ ̛̣̯̏́̀ ̦̌ ̬̖̱̣̯̯̼̽̌̚
̨̛̛̭̭̣̖̦̔̏̌́͘ 
ʽ̨̭̦̦̼̖̏ ̬̖̱̣̯̯̼͕̽̌̚ ̪̬̖̭̯̣̖̦̦̼̖̔̌̏ ̏ ̣̖̐̌̏ ϵ͕ ̨̪̬̖̪̣̯͕̔̌̐̌̀ ̸̨̯
̨̨̛̛̭̪̣̦̖̽̏̌̚ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ ̏ ̛̛̛̪̬̦̯́ ̛̬̖̹̖̦̜ ̏ ̵̨̨̛̛̬̬̦̖̦̔̌̏̌̚
̡̛̭̯̣̖̯̭̌̏̌́ ̭ ̨̬̖̬̥̍̌̽ ̡̨̛̦̜̚ ̨̡̨̪̬̪̱̭̦̜ ̨̨̨̛̭̪̭̦̭̯̍ ̶̨̡̛̖̦ ̶̵̡̛̛̛̥̖̦̭̔
̵̨̨̛̯̖̦̣̜̐ ;ʽʺ˃Ϳ͘ ʻ̖ ̨̭̥̯̬́ ̦̌ ̨̯ ̸̨̯ ̨̨̛̪̖̬̖̦̭̥̭̯̽ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦͕
̵̨̨̛̪̬̥̼̏̔ ̏ ̵̡̭̯̬̱̯̱̬̌ ̵̨̨̛̬̬̦̖̦̔̌̏̌́̚ ˉʦʫ ̛ ̵̭̯̬̦̌̌ ̨̼̹̖̍̏̐ ˁ̨̡̨̨̖̯̭̏̐
ˁ̨͕̀̌̚̸̨̛̬̦̖̦̐̌̌̛̡̨̬̖̔̛̪̬̥̖̦̖̯̭͕́́̶̛̛̪̬̦̪̼̨̨̛̛̪̖̬̖̦̭̥̭̯̵̦̦̼̔̌̛̖̭̯̦̼̏̚
̏ ̵̨̛̭̭̣̖̦̦̼̔̏̌ ̵̭̯̬̦̌̌͘ ˈ̨̯́ ̶̛̛̛̬̏̌̌ ̵̡̨̨̦̖̯̬̼ ̨̪̬̥̖̯̬͕̌̌̏ ̵̡̛̯̌ ̡̡̌
̨̨̛̭̯̥̭̯͕̽ ̨̨̛̛̭̪̣̦̖̽̏̌̚ ̨̬̖̭̱̬̭̏ ̛ ̨̼̜̍̌̏̚ ̡̛̬̭ ̨̭̯̔̌̀̚ ̦̖ ̨̨̛̪̖̬̖̦̭̥̭̯̽
̨̬̖̱̣̯̯͕̽̌̏̚ ̸̡̡̛̛̣̦̖̭̌́ ̴̴̡̨̛̖̯̦̭̯̾̏̽ ̛ ̸̨̛̪̬̖̪̯̖̦̔́ ̶̨̛̪̖̦̯̌̏ ;̛̦̪̬̥̖̬͕̌
̨̛̭̣̖̦̖̔̏̌̛̬̖̙̥̱̛̛̯̖̬̪̌Ϳ̨̥̱̯̐̨̨̺̯̭̍̍̌̽́̏̵̡̨̨̦̖̯̬̼̸̵̭̣̱̌́͘ 
ˁ̛̣̖̱̺̖̔̀ ̶̡̨̛̛̬̖̥̖̦̔̌ ̸̨̨̦̖̦̼̍̌̚ ̏ ̬̖̣̖̌̔̚ ϵ ̨̨̨̛̯̦̭̯̖̣̦̽ ̸̛̱̣̱̹̖̦́
̨̨̛̛̭̪̣̦̽̏̌́̚ ̸̵̡̨̨̡̛̛̦̥̖̭̾ ̶̨̨̡̖̦ ̏ ̛̛̛̪̬̦̯́ ̛̬̖̹̖̦̜ ̏ ̵̨̨̛̛̬̬̦̖̦̔̌̏̌͗̚
̸̱̖̭̯̽ ̬̖̬̼͕̍̌̽ ̭̦̦̼̖̏́̌̚ ̭ ̶̨̨̪̬̖̭̭̥ ̛̛̪̬̦̯́́ ̛̬̖̹̖̦̜ ̛ ̸̨̨̛̬̦̖̦̦̜̐̌
̨̡̨̪̬̪̱̭̦̜ ̨̨̨̭̪̭̦̭̯̍̽̀ ʽʺ˃͕ ̨̬̬̯̯̌̌̍̌̽̚ ̡̨̨̬̱̭̯̏̔̏̌ ̨̪ ̸̡̨̨̡̛̛̦̥̖̭̥̾
̶̨̡̖̦̥̌ ̛ ʽʺ˃͕ ̨̛̛̭̯̦̬̯̬̯̌̔̌̏̌̽̚ ̵̨̨̪̔̔ ̡ ̨̨̛̛̪̖̬̖̦̭̥̭̯  ̸̡̨̨̡̨̨̛̦̥̖̭̾̐
̛̦̣͕̌̌̌̚ ̨̛̪̬̖̖̣̯̔̽ ̨̛̛̪̬̬̯̖̯̼ ʽʺ˃͕ ̨̛̪̬̖̭̯̯̔̌̏̽ ̛̭̯̥̱̣̼ ̸̛̱̣̱̹̖̦́ ̸̡̖̭̯̌̏̌
̨̛̛̭̭̣̖̦̜̔̏̌͘ 
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ˁ̛̛̯̭̣̜̥̞̭̯̚ 
�� ��������� �� ������ ����������� ������� у ������������� ����������� 
������� �� ������ ���у �� ���� ��������� ���� �������� у �����������у �� ������-
������������у ������� ����� �� ������� ���������� ����������� ����у� 
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����у����� �� ���������� ����������� �� ������ ����������у����� ��������� у 
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���о�������� � ������о� �о ������������ о�������� � ����� �о����������� �� ������� 
��� ����� ��о�о����о �о�������� ������ ���������� �������� ������ �� �о��� 
о�������� ���о�����  �о�о �о���о�� ����о������� ��������о ��� 
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ˁ̛̛̯̭̣̜̥̞̭̯̚ 
�� ��������� �� ������ ����������� ������� у ������������� ����������� 
������� �� ������ ���у �� ���� ��������� ���� �������� у �����������у �� ������-
������������у ������� ����� �� ������� ���������� ����������� ����у� 
� ������� � ����� ���������� �������� ������������ ����������� ���������� 
у ��������� �� ��� у ������� ��������� � ����� ���у��� ������� у �� �������������� � 
����� �� � ���� ������������ ���у������ ������� ������ ���������� �у���� ���� 
����у����� �� ���������� ����������� �� ������ ����������у����� ��������� у 
��� � ����� ��������� �� ��� у ������� ��������� �� �у�� ����������������� ����� 
����������� ���������� �� �� ���� �������� ��� ����������� ������������ ������ 
������������ ������������ �� �у�� ������������ ������ ������ �� ������� ������� 
�у����������� ���������� ���������� ����������� �� ������������� ���у������  
���� ���у������ ������������ ������у �� ���������� ������������ � ������ 
��������� �� ���у� �������� ����������� ���у�� ����������у������ у ��������� 
��������� �� ���� ������у��� ��� ������ ���������� �у���� �������� ������ ������� 
�������� �� ��������� ������� � ��������� ������������ ��� ���� �� � ��������� 
��������� ����������� �������� ������� ����������� ����������� �� ������������� 
������������� ������������� ���������� ��� �������� ������ ������������� ������у 
���� �у�� ������ �� ��� ��� ������� ���������� 
����� � ����у� �������������� ��у���������� ����������� ������ � ��� �� 
����� ���������� ����������� ����у� ��������� у ����� ����� ������� 
�������������� ���у�у �������у��� ����������у��� ����������� ������� 
���������� �у�� �������� ��������� �� ����� ���������� ������������ 
������������ �����у ������� �������� �����у ������ у ����������� ��������� 
������������� ������ ������ �� ������������� �� ������ �у��������� ��������� 
���у�������� - � ������� ����� �� �������� �������������� ������������  
���� � ������������ ��������� ���������� �����у �� у������������ ����� 
у������������� � ����� ���у������ ��������� �������� ������������ ��������� 
����� ������������ ������ �� ���� � ������������� ��������� ���у������� �� 
��������� ������������ у ��у���������� ����������� ������������� ������������� 
����������� ���������� ��� �������� ���� �у�� ��������� ���� �������������� 
������� ���������� ������ � ����������� � ����� ���� �������� ������������� 
����������� �� ���у������� ���������� у �у��������� �у�� ���������� 
������ ����� �� ��������� �� ����� �� ����������� �� ����у������ ����� � 
����� ��������� ���������� �� ��������� �� ������������� ����������� ������� � 
������� � ���� ����������� ������у��� ��� ������ ������у ���������� �у��у ����� �� 
��������� �� ����� �� ����у������ ������ ���� �у�� ����������� �������� 
������������� ������ �-8). 
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̨̡̨̨̛̖̦̬̦̣̞͕̔̐̏ ̯̌ ̡̨̬̞̔ ̡̨̨̛̛̬̭̯̱̯̏̏̀̽ ̶̨̭̪̖̞̣̞̦̞̌̏̌̚ ʳ̦̯̖̬̦̖̯ ̛̬̖̭̱̬̭͘ ˉ̞ ̦̞̔̌
̥̯̌̀̽̛̱̯̍̛̪̬̜̦̯̞́̨̔̛̱̏̌̐̱̵̨̭̣̞̙̖̦̦̔̔́ ̞̚̡̨̨̦̯̬̣̀̵̨̬̦̦͕̌̏̀̏̌́̚̌ ̡̨̯̙̌̱
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̯̖̬̪̞͕̌̀̨̌̍̨̺̦̖̥̯̌̀̽̨̞̪̞̞̏̔̏̔̦̌̨̪̪̖̬̖̦̔̀̯̖̬̪̞̌̀ͬ̚̶̛̛̛̬̖̥̔̏̌͘ʦ̨̞̦̭̦̔̌
̨̡̨̯̔̔̌̏̌ ̬̯̞̭̯̏̌̽ ̴̡̛̖̖̯̦̞̭̯ͬ̏̽ ̡̛̛̬̯̱̭̥̱̌̍ ;ICERͿ ̱ ̵̭̖̥̞ ̚ ̴̨̣̱̬̞̦̥̔̌̌̍ ̯̌
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̨̭̣̞̙̖̦̦̔̔́;̣̦̖̌̐̌̽̚̛̛̙̦̦̏̏̌́̯̌̛̛̙̦̦̏̏̌́̖̍̚̨̪̬̬̖̭̱̦̦̐̏̌́̵̨̬̦̦̌̏̀̏̌́̚Ϳ̞̚
̵̬̱̦̦̥̏̌̏̌́ ̞̣̹̍̽ ̡̨̛̦̟̽̚ ̸̨̡̨̛̱̦̟̏̌ ̨̨̨̪̬̙̱̦̭̯̞̔̏̏̌ ̛̙̯̯́ ̭̖̬̖̔ ̦̭̖̣̖̦̦̌́ 
˄̡̛̬̟̦̌͘ 
ʦ̶̨̥̱̽ ̡̛̪̱̏̌̔ ICER ̣̔́ ̶̪̞̦̯̞͕̌̿̏̨̺ ̬̦̞̹̖̌ ̦̖ ̨̛̛̯̬̥̱̣̏̌ ̯̖̬̪̞͕̌̀ ̡̭̣̣̌̌
Ψϭϯ͕ϬϬϬ͕̨̺̱̛̯̬̛̬̌̚̞̣̹̖̍̽̌̚ ̸̛̞̭̦̱̜̀ʦʦʿ̦̌̱̹̱̔̦̭̖̣̖̦̦̌́̏˄̡̬̟̦̞̌͘ʤ̦̣̞̌̚
̸̨̛̱̯̣̭̯̞̏ ̬̖̱̣̯̯̞̽̌̏̚ ̨̡̪̌̌̏̚ ̛̭̱̯̯̜̿̏ ̛̪̣̏̏ ̨̬̯̭̯̞̏̌ ̡̛̛̬̯̱̭̥̱̌̍ ̯̌
̨̨̡̨̛̪̭̖̬̖̦̜̔̏̌ ̛̪̣̏̏ ̶̛̬̞̦̞̚ ̱ ̸̵̦̖̦̦̌́̚ ̨̛̱̯̣̞̯̬̦̭̯̞̌ ̦̌ ̸̦̖̦̦̌́̚ ICER. 
ˈ̡̡̛̛̛̬̯̖̬̭̯̌̌̦̭̖̣̖̦̦̌́̯̌̬̯̞̭̯̏̌̽̨̭̱̯̯̿̏̛̪̣̯̏̏̌̀̽̦̌̛̬̖̱̣̯̯̽̌̚̨̭̣̞̙̖̦̦̔̔́͘ 
ʽ̨̭̦̦̞̏ ̛̬̖̱̣̯̯͕̽̌̚ ̪̬̖̭̯̣̖̦̞̔̌̏ ̱ ̣̞̐̌̏ ϵ͕ ̨̡̪̱̯͕̌̀̽̚ ̨̺ ̡̨̛̛̬̭̯̦̦̏̌́
̸̵̡̨̨̛̖̦̥̞̦̶̨̨̡̞̦̱̛̪̬̜̦̯̯̞́̬̞̹̖̦̽̱̵̨̨̨̬̦̞̨̨̬̔̏͛́̚̡̛̯̯̭̌̿̽́̚̚̛̬̬̥͕̍̌͛̿̌̨̺
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̴̡̛̖̖̯̦̞̭̯̏̽̯̌̨̨̱̪̦̦̔̍̌́ ̶̪̞̦̯̞̌̿̏;̡̛̦̪̬̣͕̌̌̔̭̣̞̱̦̦̔̏̌́̛̬̖̙̥̱̯̖̬̪̞̟̌Ϳ̨̥̙̱̯̽
̛̱̣̦̯̭̌̐̌̽̀̏̌̽̚̱̵̡̛̖̔́̵̡̛̪̏̌̔̌͘ 
ʻ̭̯̱̪̦̞̌ ̶̡̨̬̖̥̖̦̞̟̔̌ ̨̱̣̍ ̸̨̨̨̦̖̦̍̌̚ ̱ ̣̞̐̌̏ ϵ ̨̨̨̭̯̭̦̏ ̨̡̪̬̺̖̦̦̌́
̡̨̛̛̬̭̯̦̦̏̌́ ̸̵̡̨̨̛̖̦̥̞̦ ̶̨̨̡̞̦ ̱ ̛̪̬̜̦̯̯̞́ ̬̞̹̖̦̽ ̱ ̵̨̨̨̬̦̞ ̨̨̬̔̏͛́͗̚ ̛̛̪̬̜̦̯́
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